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Abstract
Two neurotransmitters, ACh and ATP, initiate nerve-mediated contractions in detrusor 
smooth muscle from guinea-pigs and humans with bladder over-activity; whereas only 
ACh has a role in muscle from stable human bladders. Both Acetylcholine and ATP are 
rapidly broken down, by acetylcholinesterases and ectonucleotidases respectively. The 
activity of ectonucleotidase has been shown to be reduced in the unstable human detrusor 
compared to stable. The reduced activity may contribute to the development of the 
purinergic component of the unstable human detrusor contraction.
In vitro muscle strip experiments showed that apyrase significantly reduced the force of 
EFS contractions in guinea pig and over active human detrusor. Tension in guinea-pig 
was reduced to 81.5 ±1 4.5 % of control and by 87.5 ± 7.5 % in overactive human. 
Apyrase had no effect in stable human detrusor. In guinea-pig detrusor the 
ectonucleotidase inhibitor ARL 67156 significantly increased the force of EFS 
contractions.
The ectonucleotidase activity was investigated by measuring the degradation of a number 
of concentrations of ATP by detrusor samples. The ATP degradation rate in guinea pig 
and human detrusor was significantly reduced by the presence of ARL 67156. The ARL 
67156 sensitive fraction which represented the ectonucleotidase activity solely was not 
significantly different between the stable and overactive detrusor groups.
RNA extracted from human detrusor samples was used in gene expression assays to 
investigate the presence of four members of the ectonuleotidase family. ENTPDase 1, 2, 
3, and 5 was present in all 18 human detrusor samples. There was significantly less 
ENTPDase 1 and 3 in over active detrusor samples compared to those that were stable. 
There was no difference in the levels of ENTPDase 2 and 5 between the two detrusor 
groups.
Novel ATP sensitive biosensors were used to measure the real time release of ATP from 
guinea pig detrusor over the frequency range 1-20 Hz. The ATP signal reached a 
maximal response at a lower frequency compared to tension. The ATP signal kl/2, 
4.41 ±3.02 HZ, was significantly lower than that of the tension generated, 12.0±2.59 Hz. 
In the presence of 1 pM atropine the frequency dependence of the ATP signal and tension 
is comparable. There was no significant difference between the kl/2 of the ATP signal, 
7.29 ± 3.5 Hz, and that of tension, 3.12 ± 1.6 Hz.
The apyrase experiments show a correlation between the effect of apyrase on nerve- 
mediated contractions in human and guinea-pig detrusor and the proportion of atropine 
resistance. This is consistent with the hypothesis that ATP contributes to nerve-mediated 
contractions in guinea-pig and over-active human bladders by incomplete breakdown 
prior to its activation of detrusor smooth muscle. This was corroborated by an 
enhancement of contraction strength in guinea-pig tissue by ARL 67156, which would 
have reduced further ATP breakdown. The reduced ATP breakdown may be linked to the 
difference in the levels of ENTPDase 1 and 3 between stable and overactive detrusor.
The use of ATP sensitive biosensors show it is possible to measure the real time release 
of ATP from detrusor. The ATP release is frequency dependent and there is evidence to 
suggest that there is preferential release at lower stimulation frequencies.
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1.0 Introduction
The function of the lower urinary tract is both to store and periodically release (void) 
urine. During the storage phase, as the bladder fills with urine produced by the kidneys 
(up to 500ml) the bladder pressure (intravesical pressure) must remain relatively low and 
the outflow resistance high. For optimal emptying the bladder must be capable of force 
generation to initiate and maintain the flow of urine sufficient to overcome the now 
reduced outflow resistance. For normal storage and voiding to occur all components of 
the lower urinary tract including the detrusor, bladder neck, urethral sphincter and pelvic 
floor have to be coordinated.
1.1 STRUCTURE AND FUNCTION OF THE BLADDER
1.1.1 Structure
The bladder is a hollow organ which varies in shape, size and position. The wall of the 
bladder is composed of three main layers: the adventitial; the muscle; and the epithelial 
layers. The structure of the bladder is shown in Figure 1.1.
The serosa is the outermost layer surrounding the bladder and consists mainly of soft 
connective tissue. It is involved in maintaining the position of the bladder.
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The muscle layer consists of the detrusor, the trigone and the bladder neck. The smooth 
muscle of the detrusor in the dome of the bladder comprises smooth muscle bundles 
which vary in size and orientation. In humans the bundles can be a few millimetres in 
diameter and may contain several smaller bundles (Zimmerman, 1996). The bundles 
form an integrated meshwork which, upon contraction, will cause a reduction in all 
dimensions of the bladder lumen. The trigone is a triangular region between the ureteric 
orifices and the internal urinary meatus. It has a number of differences in its musculature 
compared to the rest of the bladder with smaller muscle bundles and a greater amount of 
connective tissue.
The internal epithelial layer, known as the urothelium, is a dynamic membrane which 
provides a barrier between the urine within the bladder lumen and the muscle layer. The 
urothelium consists of three cell layers, the basal layer attached to a basement membrane, 
the intermediate layer and the superficial apical layer. The cells within the superficial 
layer are termed ‘’umbrella cells” as they are large hexagonal cells. The urothelium not 
only acts as a barrier protecting underlying tissue but also exhibits specialised sensory 
and signalling properties. Studies have shown that the urothelium has the ability to 
respond to thermal, mechanical and chemical stimuli and express sensor molecules. 
These molecules include receptors for bradykinin (Chopra et al, 2005), purines (Lee et 
al, 2000), noradrenaline (Birder et al 1998), acetylcholine (Beckel et al, 2002), 
amiloride/mechano-sensitive Na+ channels and a number of TRP channels (Birder et al, 
2001). Urothelial cells release a number of chemical mediators for instance NO, 
acetylcholine, ATP and substance P. For example, it was shown in rabbits that ATP is
20
released in response to an increase in vesical pressure (Ferguson et al., 1997). Upon 
release ATP is thought to activate P2 X3 receptors located on afferent nerves which may 
therefore provide a sensory mechanism to initiate a micturition reflex.
Pelvic floor
Ureteric
orifices
Urethral 
smooth muscle
Urethral skeletal 
muscle
Detrusor,
dome
Trigone
Bladder neck
Figure 1.1 The structural components o f the lower urinary tract (courtesy of Professor 
C. Fry)
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1.1.2 Innervation of the bladder
Micturition is an autonomic reflex, however release of urine is regulated by voluntary 
control of neural mechanisms. It involves co-ordination between the bladder and the 
outlet structures including bladder neck, urethra and sphincter. The bladder must contract 
raising pressure whilst the outlet relaxes.
The co-ordination of these structures is controlled by three sets of peripheral nerves:
1 ) sacral parasympathetic (pelvic nerves)
2 ) thoracolumbar sympathetic (hypogastric nerves and sympathetic chain)
3) sacral somatic nerves (pudendal nerves)
There is a substantial degree of overlap and interaction between these pathways.
1.1.3 Efferent pathways
The major excitatory input to the bladder is provided by the parasympathetic efferent 
neurons that originate in the sacral parasympathetic nucleus (SPN). The neuronal cell 
bodies are located in the intermediolateral grey matter of the lumbosacral spinal cord 
(S2-S4). Preganglionic neurons exit the spinal cord and travel in the pelvic nerves to a 
pelvic plexus where they synapse with cholinergic postganglionic neurons which 
innervate the bladder and the urethra. Parasympathetic ganglion cells provide an 
excitatory input to bladder smooth muscle by release of acetylcholine and ATP and an
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inhibitory input to urethral smooth muscle by release of nitric oxide (NO). This results in 
contraction of the detrusor and relaxation of the urethra during voiding.
The efferent sympathetic pathways arise from the interomediolateral cell column and 
nucleus intercalatus of the thoracolumbar spinal cord, T 1 1-L2 . The preganglionic neurons 
pass to the sympathetic chain ganglia (SCG) and then via splanchnic nerves to the 
paravertebral inferior mesenteric ganglia. Post-ganglionic neurons from the SCG pass to 
the bladder via the pelvic nerves and the fibres from the inferior mesenteric ganglia travel 
in the hypogastric nerves (de Groat, 2006). Sympathetic post-ganglionic nerves release 
noradrenaline to provide an excitatory input to smooth muscle of the urethra and bladder 
base resulting in contraction via ai, and relaxation of detrusor via p3 -adrenoceptors 
(Furuta et al, 2006). Sympathetic neurons also cause inhibition and facilitation input to 
parasympathetic ganglia (de Groat, 1998). The culmination of efferent sympathetic 
innervation is contraction of the bladder neck and sphincter and at the same time 
inhibition of detrusor contraction during filling.
The external urethral sphincter (rhabdosphincter) and the pelvic floor muscles are 
innervated by the efferent somatic pathways. They originate from Onuf s nucleus which 
is located in the anterior horn cells of the S 2 - S 4  sacral spinal cord. The axons exit the 
spinal cord in the pudendal nerve (Chai and Steers 1996). The sphincter muscles are 
excited by the release of acetylcholine which stimulate postjunctional nicotinic receptors 
(de Groat, 2006) resulting in contraction.
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Figure 1.2 Schematic of efferent pathways to the bladder. Signals to void are sent from 
the pontine micturirtion centre to inhibit the activity o f the somatic pathway to relax the 
urethral muscle. There is also release of the inhibition on the parasympathetic motor 
nuclei to increase the contractile activity o f the bladder
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1.1.4 Afferent Pathways
The afferent pathways provide a sensory input in the control of the bladder and sphincter 
and provide an ongoing signal during the filling phase. The distension and volume of the 
bladder as well as amplitude of contraction are monitored.
Afferent activity is conveyed to the central nervous system by three sets of nerves. Those 
afferent axons passing in the pelvic nerve to the sacral spinal cord are small myelinated 
(A-8) and unmyelinated (C) fibres. They convey information about muscle tension and 
bladder volume as well as nociception (Sugaya, 2005) from the serosa, detrusor and 
urothelium of the bladder and urethra. Studies in cats have shown that A-8 afferents 
respond in a graded manner to passive distension and active contraction of the bladder 
(Habler et al, 1993). The C-fibre afferents respond to a number of substances including 
neurotoxins, capsaicin, NO and ATP (de Groat, 2006). Unmyelinated C-fibre afferents 
do not normally respond to mechanical stimuli. Release of ATP by stretching the 
urothelium is postulated to activate P2X receptors on afferents located close by which 
relay the sensation of bladder filling. P2 X3 knock-out mice studies showed a role for 
urothelially-released ATP via the receptors on a subpopulation of pelvic afferent fibres 
(Vlaskovska et al, 2001). Also, in the rat when ATP was applied to afferent nerves on the 
surface of the bladder the firing induced by bladder distension was enhanced and the 
threshold for electrical stimulation of A-8 and C-fibre afferents was reduced (Yu & de 
Groat, 2004).
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Figure 1.3 Schematic o f afferent pathways from the bladder. Afferent fibres run from the 
bladder to the spinal cord, transmitting the signal to the peri-aaueductal grey and higher 
centres o f the brain
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1.2 INCONTINENCE AND OVERACTIVITY
1.2.1 Overactive bladder and detrusor overactivity
There are two terms used by the International Continence Society (ICS) to describe lower 
urinary tract dysfunction, overactive bladder syndrome (OAB) and detrusor overactivity. 
The first is a symptom syndrome without a definitive cause and the second describes the 
involuntary detrusor contractions diagnosed by urodynamics.
Symptomatic OAB as defined by the ICS is urgency with or without incontinence, 
usually with frequency and nocturia (Abrams, 2003). The symptoms must be exhibited 
without pathological or metabolic disorders, such as bladder infection or cancer, which 
may otherwise cause the symptoms (Wein and Rackley, 2006). Urgency is described by 
the ICS as the complaint of a sudden compelling desire to void which is difficult to defer. 
Around one-third of patients with OAB experience involuntary leakage of urine (UI) 
(Milsom, et al, 2001).
Detrusor overactivity is a urodynamic observation characterised by involuntary 
contractions during the filling phase which may be involuntary or provoked (Abrams et 
al 2002). Urodynamics is the technique used to investigate bladder dysfunction. 
Observations are made of the bladder during filling, natural or artificial, and the pressure 
and flow of urine during voiding. This is done by measuring two different pressures, 
intravesical and abdominal. Intravesical pressure is the pressure within the bladder
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measured by insertion of a catheter. Abdominal pressure is measured with a rectal or 
vaginal catheter, and is the estimated pressure surrounding the bladder. Detrusor pressure 
is described as the component of intravesicular pressure that is created by the force of the 
bladder wall. It is obtained by subtracting abdominal pressure from the intravesical 
pressure. Normal detrusor function is when there is little or no change in pressure 
associated with filling, with no involuntary contractions. When there are involuntary 
detrusor contractions that are spontaneous or provoked, detrusor function is considered to 
be overactive.
Detrusor overactivity can be divided by cause into idiopathic and neurogenic detrusor 
overactive groups. Neurogenic detrusor overactivity describes patients where there is a 
relevant neurological condition for example spinal cord injury, multiple sclerosis, 
Parkinson’s disease and stroke. Idiopathic detrusor overactivity is when there is no 
defined cause.
7.2.2 Prevalence and manasement
Patients who suffer with bladder overactivity experience a wide range of symptoms 
including, urgency, frequency, nocturia and incontinence. The incidence of bladder 
overactivity has been evaluated in studies in both Europe and in the United States. The 
studies reported similar findings, that prevalence is high within the general population 
(Wein and Rackley, 2006). The European study indicated that 16.6% of people over 40 
had a least one symptom of OAB with 36% experiencing urge incontinence (Milsom, et
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al, 2001). The incidence of OAB also increases with advancing age, with detrusor 
overactivity being the most common cause of incontinence in the elderly (Wagg and 
Cohen, 2002). All symptoms of OAB significantly affect the patients’ quality of life, 
6 6 % of those with symptoms in the Milsom study reported effects on their daily lives.
There are a number of treatments for bladder overactivity ranging from changes of 
lifestyle, bladder training, pharmacotherapy and surgery. There are currently three 
classes of drugs used in treatment; antimuscarinics, antispasmodics and mixed 
antimuscarinics/antispasmodics (Newgreen, 1998). The most widely used treatment in 
the UK is antimuscarinics (Wagg and Cohen, 2002), for example oxybutynin, tolterodine 
and trospium chloride (Hashim and Abrams, 2004). However, there are a number of side- 
effects associated with these drugs due to the low selectivity for muscarinic receptors in 
the bladder. The side-effects, including dry mouth, constipation and blurred vision result 
in the agents’ poor tolerance. More recently developed antimuscarinics such as 
darafenacin and solifenacin succinate are selective M3 receptor antagonists and may 
reduce the incidence of dry mouth.
Research into the use of intravesical botulinum toxin as a treatment for spontaneous 
contractions is ongoing. One action of the toxin is believed to inhibit the exocytosis of 
synaptic vesicles therefore inhibiting the release of Ach from the neuromuscular junction 
(Haferkamp et al, 2004). Clinical studies have shown the effectiveness of the treatment. 
Kuo, (2004) reported 73.3% success, with improvements in symptoms, in patients with 
detrusor overactivity refractory to anticholinergics.
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1.2.3 Pathophysiology
The normal function of the bladder during the filling phase is to store increasing volumes 
of urine whilst maintaining a low intravesical pressure. However in OAB involuntary 
contractions occur, resulting in uninhabitable rises of pressure. As the function of the 
LUT involves complex coordination of muscular and nervous activity there are numerous 
stages at which changes could cause OAB: a number of hypothesis exist as to their cause.
One hypothesis is that the basis for bladder overactivity is myogenic, that changes in the 
normal compliant detrusor smooth muscle compromise normal function (Turner and 
Brading, 1997). To be compliant the smooth muscle must be able to stretch and rearrange 
to enable increasing volumes at low pressures, and also to contract synchronously to 
cause complete emptying. Outflow obstruction can compromise function as it causes 
increased intravesical pressure leading to hypertrophy of the bladder and individual 
detrusor cells, reduced blood flow and partial denervation (Fry and Wu, 1998). 
Numerous changes have been observed in the detrusor from overactive bladders from 
humans and animal models, for example some overactive bladders have abnormal 
spontaneous mechanical acitivity and some show supersensitvity to muscarinic agonists 
and high extracellular potassium solution (Brading, 1997). Physical changes to the 
detrusor have been observed with light and electron microscopy, including increased 
deposition of elastin and collegen. The theory is that all of these changes lead to 
increased excitability and increased ability of activity to spread between cells (Brading,
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1997) resulting in “micromotions” of the detrusor and rises in intravesical pressure 
associated with OAB (Wein and Rackly, 2006).
The functions of the lower urinary tract depend on neural circuits located in the brain, 
spinal cord and peripheral ganglia. Thus, changes or damage to any of these pathways 
may lead to OAB. Diseases and injuries such as those described on page 10 are all causes 
of neurogenic OAB. The changes that occur as a result include reduction in peripheral or 
central inhibition, enhancement of excitatory transmission in the micturition pathway, 
increased primary afferent input from the lower urinary tract and emergence of bladder 
reflexes resistant to central inhibition (de Groat, 1997).
A recently developed hypothesis proposed by Gillespie, (2004) is the autonomous 
bladder hypothesis; that is, OAB is a consequence of inappropriate activation or 
modulation of phasic activity. Experiments were performed on whole guinea-pig 
bladders, and showed that during induced phasic activity by a, p-methylene ATP and 
substance P there was a rise in intravesical pressure and an increased frequency of phasic 
activity. It was proposed that phasic activity consists of transient rises of intravesical 
pressure during the filling phase that is not generated through the same mechanisms that 
activate the detrusor in micturition, implying that there is a second mechanism within the 
bladder wall.
Ferguson et al, (1997) showed that hydrostatic pressure changes of the rabbit urinary 
bladder resulted in ATP release from the basal-lateral surface. They proposed that ATP
31
plays a sensory role in normal micturition, where urothelial-derived ATP stimulates sub 
urothelial afferents. In some bladder pathologies including interstitial cystitis (Sun et al, 
2001; Birder et al, 2003) this stretch activated release of ATP has been shown to be 
increased. The stretch induced ATP release has also been shown to be increased in 
ageing bladders (Yoshida et al, 2004). It is proposed that the ATP release is mediated by 
amiloride sensitive epithelial Na+ channels (ENaC) (Du et al, 2007).
Other hypotheses involve the role of the urothelium in sensory functions and release of 
Ach, both from the urothelium and nerves. The urothelium releases neurotransmitters in 
response to stretch and other stimuli. Yoshida et al, 2004, showed that basal release of 
Ach from the detrusor was mainly from the urothelium as release was not TTX-sensitive 
and was significantly reduced when the urothelium was removed. The release of Ach has 
also been shown to increase with age-related changes (de Groat, 2004) and muscarinic- 
receptor functions can change in bladder disorders. These factors can alter the 
excitability of bladder afferent nerves acutely and chronically which may be important in 
bladder overactivity.
As described above there are a number of hypotheses as to the cause of OAB including 
myogenic or neurogenic changes, alterations in phasic activity, changes in the role of 
urothelium and altered release of ATP. This thesis will investigate the role of nerve 
released ATP in detrusor contraction and the contribution of this to OAB.
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1.3 DETRUSOR SMOOTH MUSCLE CONTRACTION
There are a number of properties of detrusor smooth muscle that are important in the 
normal function of the urinary bladder. As the bladder fills, the myocytes must rearrange 
and stretch to allow increases in bladder volume and at the same time maintain a low 
intravesical pressure. During micturition force generation and shortening must be 
initiated comparatively quickly and contraction needs to be synchronised (Andersson, 
2004). Based on the contractile behaviour of detrusor smooth muscle, it is described as 
phasic smooth muscle and is due to its twitch-type contractions that are initiated by 
excitatory nerves.
1.3.1 Contractile proteins
As with other muscles, contraction of detrusor smooth muscle is due to interaction of the 
contractile proteins actin and myosin. There are three types of filament present in smooth 
muscle cells, thick, intermediate and thin filaments. The thick filaments consist of 
myosin; two a-helical heavy chains, from the myosin II family, that contain ATP- 
hydrolytic and actin binding sites (Zimmerman et al, 1996, Amer et al, 2003) and two 
pairs of myosin lights chains. The intermediate filaments are composed of desmin and 
vimentin which may not be directly involved in the contractile process but form the 
cytoskeleton of the cell, maintaining cell shape and distributing forces (Andersson and 
Amer, 2004; Zimmermann, 1996). The thin filaments consist of actin monomers of 
which there are four different isoforms, and tropomyosin which may aid binding of
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myosin heads to actin. The ratio of actin to myosin is about 15:1 in smooth muscle, 
compared to 2:1 in striated muscle (Anderson and Amer, 2004). Contraction of the cell 
occurs when force is generated through the interaction of the actin and myosin filaments, 
cross-bridges form between the filaments making them slide past each other in an ATP- 
driven process.
1.3.2 Contraction and relaxation
Contraction of detrusor smooth muscle cells depends upon an increase in the 
concentration of intracellular calcium, [Ca2+]i. Upon stimulation increased free Ca2+ 
binds to the calcium-binding protein calmodulin to form a Ca2+-calmodulin complex, 
which then binds and activates myosin light chain kinase (MLCK). The activated MLCK 
phosphorylates serine-19 on the 20 kD regulatory subunit light chain found on the 
myosin head which is necessary for the cross-bridge to bind to actin. The phosphorylated 
myosin undergoes repeated cycles of actin-mediated ATP hydrolysis (Andersson and 
Amers, 2004) resulting in cell contraction.
The mechanisms involved in relaxation include a decrease of intracellular Ca2+ which 
would dissociate the Ca2+-calmodulin complex and prevent activation of MLCK. Ca2+ 
levels fall through reuptake into the SR via Ca2+/Mg2+-ATPase pumps, or removal from 
the cell by secondary active transport via Na+/Ca2+ exchange (Wu and Fry, 2001).
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There is also increased activity of the myosin light chain phosphatase (MLCP). 
Activation of MLCP causes dephosphorylation of the myosin light chain head preventing 
cross-bridge formation. However, increased cell sensitivity to Ca2+ can be induced by the 
inhibition of MLCP activity, through phosphorylation of the MLCP myosin-binding 
subunit. Phosphorylation occurs by a Rho-associated kinase which is activated by Rho, a 
GTPase of the Ras family (Symons, 1996). The smooth muscle specific protein inhibitor, 
CPI-17, when phosphorylated by protein kinase C (PKC), can also inhibit MLCP activity 
and increase Ca2+ sensitivity (Eto et al, 1999).
MLCK can be phosphorylated which decreases its affinity for the Ca2+-calmodulin 
complex and decreases the Ca2+ sensitivity of the contractile system, reducing 
contraction. The cAMP-dependent kinase, protein kinase A (PKA) phosphorylates 
MLCK and can explain how cyclic nucleotides can depress contraction in this tissue 
(Andersson and Amers, 2004).
1.3.3 Calcium stores 
2+The Ca that initiates contraction comes from two main sources, the extracellular space 
via Ca2+ channels and intracellular stores, the sarcoplasmic reticulum (SR). Studies using 
low doses of thapsigargin, an inhibitor of the sarcoplasmic reticulum Ca2+ pump, have 
shown detrusor contraction is dependent on Ca2+ release from the SR (Masters et al,
1999). Ca2+ release from the SR is through activation of inositol trisphosphate receptors
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(IP3) and by Ca2+-induced Ca2+-release via ryanodine receptors. A mechanism for 
replenishing the Ca2+ store was proposed by Fry et al, (2004). Following release of Ca2+, 
the increase in [Ca2+]i was associated with a brief membrane hyperpolarisation, as Ca2+- 
dependent K+ channels are activated. This limited further entry of Ca2+ by reducing the 
open-probability of Ca2+ channels, and was followed by a transient fall of [Ca2+]i below 
the resting level. The reduction of [Ca2+]i , via the mechanisms mentioned above, 
reduced K+ channel activity which depolorised the cell. This subsequently increased the 
Ca2+ channel open probability and resulted in an increase in Ca2+ entry, thus replenishing 
Ca2+ levels.
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1.4 INITIATION OF CONTRACTION BY NEUROTRANSMITTER RELEASE
Parasympathetic nerve stimulation of the bladders of several mammalian species has 
been shown to be composed of a cholinergic component and a non-adrenergic, non- 
cholinergic component. The cholinergic component can be demonstrated in animals 
through enhancement of contraction with anticholinesterases and reduction of contraction 
with cholinergic blockers such as atropine. In animals there is an atropine-resistant 
component of contraction, albeit to different extents, 58% of rabbit contraction and 22% 
of pig contraction is resistant to atropine (Sibley, 1984). Contraction is not effected by 
adrenergic or nicotinic antagonists. The non-adrenergic, non-cholinergic component of 
detrusor contraction was first proposed to be the nucleotide ATP by Bumstock in 1972. 
Evidence has since grown to support this; the response of rat and guinea pig bladder to 
exogenous ATP mimics that of nerve stimulation and quinidine can block the response of 
both exogenous and nerve released ATP (Bumstock et al 1972). TTX-sensitive nerve 
stimulated release of ATP was measured in the superfusate surrounding guinea-pig 
bladder (Bumstock, 1978) and the atropine-sensitive component of contraction could be 
abolished by desensitising P2X receptors (Hoyle et al, 1989). The criteria required for 
ATP to be a neurotransmitter, including presence in nerve terminals, release during 
stimulation and enzymatic breakdown, have thus been demonstrated.
Unlike most animal species humans and old world monkeys show no purinergic 
component to detrusor contraction. A lack of atropine-resistant contraction has been 
demonstrated in human bladder (Sibley, 1984, Sjogren et al, 1985, Palea et al, 1993). It
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is believed that conditioning of humans and monkeys to micturate only when it is 
socially acceptable has eliminated the purinergic component of contraction. Other 
animals may need to void rapidly and as ATP activation of P2X receptors results in a 
rapid increase in intracellular Ca2+ and contraction compared to muscarinic activation 
they may have retained this mechanism of micturition. However atropine-resistance of 
nerve mediated-contraction has been observed in human detrusor from patients with 
various disorders including interstial cystitis (Palea et al, 1993), overactive bladder 
(Sjogren et al, 1985) and overactive and obstructed bladder (Bayliss et al, 1999). The 
degree of atropine-resistance varies for different patients and different disorders, with the 
atropine-resistant component as large as 35% of the contraction (Sibley, 1984). The 
atropine resistant component has also been demonstrated to be positively correlated to an 
increase of age (Yoshida et al, 2001).
ATP is co-released from nerves to activate P2X receptors (see section 1.6.2) on the 
detrusor smooth muscle to initiate contraction. ATP is then rapidly and sequentially 
degraded in the synapse by ectonucleotidases to adenosine which is taken back up into 
the neuron for re-synthesis. There are therefore a number of stages at which alterations 
could occur and enable a purinergic component of detrusor contraction to emerge.
Sympathetic nerves within the bladder release noradrenaline (NA) to activate adrenergic 
receptors within the bladder particularly in the trigone region and urethra (Andersson, 
1993). p3 -adrenoceptors (Takeda et al, 1999) in the smooth muscle when activated by
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NA relax the bladder, but a 1 -adrenoceptors in the bladder outlet contract the muscle in 
this region to keep the bladder outlet closed during filling (de Groat et al, 1999). Their 
combined action thus aids filling and storage, a-adrenoceptors on peripheral nerves have 
been shown to facilitate the release of Ach and ATP in the rat bladder (de Groat and 
Yoshimura, 2001).
The role of each of these major transmitter classes; muscarinic (Ach), purinergic (ATP) 
and adrenergic, will each be discussed in more detail in following sections.
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1.5 MUSCARINIC AND ADRENERGIC RECEPTORS AND DETRUSOR
CONTRACTION
In many species there are two main neurotransmitters, Acetylcholine and ATP, released 
from the embedded parasympathetic motor nerves that stimulate detrusor smooth muscle 
to contract. With human detrusor, contractions are most importantly mediated by 
cholinergic mechanisms, however a purinergic component has been observed in some 
bladder pathologies (Bayliss et al, 1999).
1.5.1 Muscarinic Receptors
Muscarinic receptors on detrusor smooth muscle are stimulated by Ach released from 
post-ganglionic parasympathetic motor nerves. Five genes encode separate muscarinic 
receptor glycoprotein subtypes, mi-ms, for which most have been pharmacologically 
characterised1 (Malcolm et al, 1998). Muscarinic receptors have seven transmembrane 
regions and are G-protein coupled, although the subtypes and second messenger 
pathways differ, mi, m3 and ms subtypes are coupled to Gq/n and activate phospholipase 
C (PLC) to up-regulate I P 3  production, whereas, m2 and nu are coupled to Gj/ 0  and inhibit 
the activity of adenylyl cyclase (Andersson and Yoshida, 2003).
1 ‘m’ indicates muscarinic receptors identified by molecular biochemistry, ‘M’ by pharmacology.
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The mRNAs for the five subtypes of muscarinic receptor have been identified in human 
bladder (Sigala et al, 2002), with m2 and m3 prevalent, m2 and m3 subtypes are present 
on detrusor smooth muscle cells, the predominant receptor being m2 . However, 
pharmacological experiments using subtype-selective agonists and antagonists have 
shown that contractile responses are attributed to M3 receptor activation (Schneider et al, 
2004, Chess-Williams et al 2001). The stimulation of M3 receptors by muscarinic 
agonists generates inositol trisphosphate ( I P 3 )  and diacylglycerol after PLC activation. 
I P 3  activates receptors on the SR to release Ca2+ and raise the intracellular [Ca2+]. A 
small Ca2+ influx may also accompany this process, possibly through L-type Ca2+ 
channels or non-selective cation channels (Inoue and Brading, 1990).
Studies have shown that L-type Ca2+ channels are involved in the contractile process 
following muscarinic stimulation. Nifedipine inhibition of L-type channels attenuated 
carbachol-induced contractions in rat detrusor (Schneider et al 2004a) and human 
detrusor (Schneider et al 2004b), as did diltiazem in rabbit detrusor (Damaser et al,
1997). In guinea-pig tissue muscarinic-dependent contractions were reduced by caffeine 
and nifedipine indicating both intracellular store release of Ca2+ and influx through L- 
type Ca2+ channels are required (Hashianti et al, 2000). A role for L-type Ca2+ channels 
in replenishing intracellular Ca-stores after muscarinic activation (Fry et al, 2004) has 
been discussed above (section 1.3.3)
The role of M2 receptors is less clear, but it may be indirectly involved in the contractile 
process particularly at lower agonist concentration (Hashianti et al, 2000). Ach
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stimulation of these receptors can attenuate adenylyl cyclase activity, which would 
reduce the amount of cellular cAMP, opposing relaxation. There is some evidence to 
suggest that in some disease states M2 receptors contribute more directly to bladder 
contraction. For example, Braverman et al (1998) have shown that in the denervated rat 
bladder M2 receptors contribute to contraction. In obstructed, hypertrophied rat bladders 
there was an increase in M2, and a decrease in M3 receptor density. Similar results 
showing M2-mediated contraction of neurogenic human bladder were observed by 
Pontari et al (2004).
Rho-kinase has also been implicated in contraction following muscarinic stimulation 
both in animal and human bladder by increasing the sensitivity to Ca2+ of the contractile 
machinery. In rabbit detrusor, bethanechol-induced contractions were almost abolished 
by a combination of Rho-kinase and non-selective cation channel inhibitors (Jezior et al,
2001). Rho-kinase inhibitors also reduced carbachol-induced contractions in rat bladder 
(Fleischmann et al 2004) and concentration-dependently attenuated contractions in 
human bladder (Schneider et al 2004b).
Muscarinic receptors are also found presynaptically and can be involved in regulation of 
neurotransmitter release. Pre-synaptic Mi receptors are facilitatory and M4  inhibitory to 
neuromuscular function. In the rat bladder, continuous electrical field stimulation 
enhanced the release of Ach via Mi receptors, using PKC second messenger systems and 
L- and N-type Ca2+ channel function (Somogyi et al, 2003). A presynaptic Mi 
facilitatory mechanism has also been observed in human detrusor (Tobin and Sjogren,
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1995). The inhibitory effects of M4  receptors were shown in human detrusor where Ach 
acts as a negative feedback modulator to reduce further Ach release (D’Agostino et al, 
2000). Experiments have shown that in the spinal cord-transected rat the pre-synaptic Mi 
receptor facilitatory mechanism is replaced by a facilitatory M3 receptor mechanism 
(Somogyi et al, 2003).
Muscarinic receptors are also located on the urothelium, the mRNA for all five subtypes 
have been identified in human tissue (Tyagi et al, 2006). Saturation curves for [3H]- 
QNB, a non-specific muscarinic ligand, binding showed a greater muscarinic receptor 
density in the urothelium compared to the detrusor smooth muscle (Hawthorn et al,
2000). The roles of muscarinic receptors in the urothelium are not fully understood. 
However M2 receptors have been shown to induce the release of a diffusible factor that is 
able to reduce contraction of the detrusor (Chess-Williams, 2002).
1.5.2 Adrenergic receptors
There are three major classes of adrenergic receptors, ai, 012 and p -  receptors. The 
classes are further subdivided: ai receptors into aiA, a iB, am and an; 0.2 receptors into 
a2A; and a2B and the p receptors are divided into Pi, p2 and p3. They all have seven 
transmembrane domains and are G-protein coupled although each group activates 
different signalling pathways. The ai receptors increase phospholipase C activity, a 2
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receptors decrease the activity of adenylate cyclase, whilst the (3 receptors stimulate 
adenylate cyclase activity leading to elevation of cAMP (Docherty 1998).
Adrenergic receptors are mainly found in the bladder neck and trigone regions of the 
bladder. In the human bladder there is an overall low expression of the ai receptors with 
only aiA and diD being expressed with two-thirds being diD (Malloy et al, 1998). The 
expression is slightly different in the rat as there is greater expression of a iA compared to 
ciiD and very little a iB (Hampel et al, 2002). The role of these receptors in the bladder is 
still to be fully determined. A study showed there is no response from the detrusor with 
application of concentrations of the a-agonist phenylepherine up to 10 pM (Nomiya and 
Yamagauchi, 2003). They also showed that expression levels of a receptors were not 
changed in patients with obstructed bladders and that obstruction did not significantly 
alter the response to phenylepherine. However de Groat and Yoshimura (2001) have 
shown that ai activation promoted the closure of the bladder outlet. Furthermore a 
receptors on peripheral nerves have been demonstrated to facilitate the release of both 
Ach and ATP in the rat bladder.
All three subtypes of p adrenoceptors are expressed in human and animal detrusor and 
the predominant subtype is p3 (Fujimura et al, 1999). Isoprenaline, noradrenaline and 
adrenaline produce a concentration-dependent relaxation of human detrusor (Igawa et al,
1998) and the p3 receptor has been implicated in detrusor relaxation (Yamaguchi, 2002). 
Activation of this receptor subtype in animal models increases bladder capacity and has 
been suggested to play a role in the storage phase in human bladder (Takeda et al, 1999).
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1.6 ATP AND PURINE RECEPTORS IN DETRUSOR SMOOTH MUSCLE
1.6.1 ATP as a neurotransmitter
ATP has long been known as a ubiquitous intracellular source of energy but it was in 
1929 that the potent extracellular effects of adenosine nucleotides and adenosine were 
reported in guinea pig (Drury and Szent-Gyorgyi, 1929). It was sometime later that 
Bumstock first posed the questions is ATP a neurotransmitter; and do some nerves 
release more than one neurotransmitter (Bumstock 1972, Bumstock 1976). Since the 
seventies evidence has grown to show that co-transmission is the rule rather than the 
exception (Sneddon et al 1996) and that ATP can be co-released within the central and 
peripheral nervous systems with a number of substances including noradrenaline (NA), 
acetylcholine (Ach), neuropeptide Y (NPY), nitric oxide (NO), and vasoactive 
polypeptide (VIP) (Bumstcok 1999).
In nerve terminals ATP has been shown to be present individually and co-packaged with 
Ach and NA in all types of synaptic vesicles (Sperlagh and Vizi 1996; Bodin and 
Bumstock, 2001; Zimmermann and Whittaker, 1977). Although variable storage ratios 
have been observed in different systems there is always less ATP than NA or Ach 
(Sperlagh and Vizi 1996) and it is likely this would be tme in the bladder. The 
neurotransmitter ratios can change and vesicle composition within a nerve terminal may 
be heterogeneous. Electrical stimulation can affect the yield and composition of synaptic 
vesicles (Zimmermann and Whittaker, 1974) and cocaine was shown to decrease
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preferentially the ATP content of noradrenergic vesicles in rat tail artery (Palaty, 1991). 
In the bladder the fluorescent marker quinacrine, which complexes with ATP, was 
positive in numerous intermural neurones in the guinea pig-bladder (Crowe et al, 1986). 
As the composition of synaptic vesicles can change it may be possible that in some 
bladder pathologies where atropine-resistance is observed the ATP content increases in 
co-packaged vesicles. Alternatively more individual ATP vesicles could be exocytosed 
resulting in more prominent ATP-induced contractions.
Functional studies and measurement of neuronal-stimulated overflow of ATP with 
luciferin-luciferase assays have confirmed the release of ATP with Ach from motor 
nerves terminals in a number of tissues (Vizi et al, 2000; Silinsky and Redman, 1996). In 
the bladder TTX-sensitive nerve-stimulated release of ATP has also been measured 
(Bumstock et al 1978) and there is some evidence to suggest the ATP is co-released from 
the same nerves as Ach (MacKenzie et al, 1982). In sympathetic nerves differential co­
transmission of ATP and NA has been observed suggesting that the two transmitters are 
from separate populations of exocytotic vesicles (Todorov et al 1996). This study, 
together with a second, showed a biphasic contraction in guinea-pig vas deferens, with 
ATP mediating the initial twitch phase and NA the tonic phase, showing either release 
was not simultaneous, or that there were different pathways in contractile activation. The 
twitch contraction with stimulation up to 8  Hz was mediated by ATP, but above 8  Hz NA 
contributed to the twitch by enhancing postjuctional actions of ATP (Todorov et al
1999). The release of ATP has been shown to be dependent on stimulation frequency in 
nerves that mediated contraction of other smooth muscles (Silinsky and Redman, 1996).
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Co-transmission of ATP and NA in rabbit ear artery showed that ATP action was more 
prominent at lower stimulation frequencies and that as the frequency increased, the ATP 
contribution decreased and NA increased (Kennedy et al 1986). Similar findings were 
made in rat superior cervical ganglia where a greater proportion of ATP was released at 
lower frequencies compared to Ach (Vizi et al 1997). The same may be true in bladders 
where atropine suppresses high frequency responses by 25%, but at low frequencies 
atropine has little effect whereas ABMA has a maximum action (Brading and Williams, 
1990).
The release of both co-transmitters can be auto-regulated by both transmitters and this 
pre-junctional control can be dependent upon stimulation frequency and relative amounts 
of the co-transmitters (Sneddon et al, 1996). There are numerous prejunctional receptors 
for transmitters such as Ach, NA and also for ATP and its breakdown products, 
particularly adenosine. However the particular receptors, and the mechanism whereby 
they regulate co-transmitter release is still being investigated in different tissues. When 
ATP and NA are co-released in the guinea-pig vas deferens activation of p adrenoceptors 
located presynaptically caused an enhancement of NA release but a reduction of ATP 
release (Gongalves et al, 1996). However at low stimulation frequencies NA release has 
been shown to be inhibited by NA acting on prejunctional (X2 receptors in the same tissue 
but this auto-inhibition is overridden at higher frequencies (Todorov et al, 1999). 
Adenosine and an Al selective receptor agonist, 2-chloro-N6-cyclopentyl-adenosine 
(CPA) reduced the overflow of stimulated ATP release in the guinea-pig vas deferens 
(Driessen et al, 1994). Adenosine has also been shown to act on PI receptors to reduce
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the strength of nerve-mediated contractions in both guinea-pig and human detrusor 
(Ikeda et al, 2003) and may therefore also reduce Ach release. As ATP is rapidly 
degraded to adenosine following release from the nerve terminal the role of ATP in some 
tissues may be an inhibitory one.
Co-transmission has been described as a way of controlling the content of a 
neurochemical message by varying the proportions of participating neurotransmitters 
(Mayer and Baldi 1994). Why ATP is co-released in human detrusor but does not 
activate contraction directly may be due to evolutionary changes in that humans no 
longer need to mark territory and for social reasons need to control voiding at particular 
times. ATP release may not have been eliminated but may now play a more pre­
junctional modulatory role in co-transmission. Any changes in the modulation due to 
altered storage or proportional release, or receptor presynaptic expression, as discussed 
above, could alter transmitter release and therefore contraction, specifically atropine- 
resistant contraction.
1.6.2 Purinergic receptors and the bladder
Purinergic receptors were first divided into two major classes: PI receptors which are 
selective for adenosine, and P2 receptors which are selective for nucleotides. 
Distinguishing and characterising different classes and subtypes of the purinergic 
receptors has however been inhibited by the lack of selective agonists and antagonists.
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There are four distinct subtypes of PI receptors that have been characterised so far, Al, 
A2a, A2b and A3. They have seven transmembrane domains and are G-protein coupled 
to modulate adenylate cyclase activity and therefore the intracellular levels of cAMP 
(Windsheif, 1996). Al and A3 receptors inhibit adenylate cyclase activity whilst A2a and 
A2b activate its activity (Ralevic & Bumstock, 1998). In the bladder, all the PI-subtypes 
are expressed, with the A2b subtype more highly expressed than the others (Dixon et al.,
1996). All four subtypes are expressed in bladder urothelium with Al localised to the 
apical membrane and the others are located on the basolateral membrane of umbrella 
cells as well as on plasma membranes of the underlying cell layers (Yu et al, 2006). 
Adenosine has been shown to modulate the contractile properties of detrusor smooth 
muscle in rats, guinea-pigs and humans by reducing the force of contractions elicited by 
agonist and field-stimulation when pre-treated with adenosine (King et al., 1997, Ikeda et 
al, 2003). Adenosine-mediated membrane hyperpolarization and subsequent relaxation 
has been demonstrated, in the guinea-pig bladder, to invlove a A2A receptor linked to 
K At p  channel activation via increased adenylate cyclase activity (Gopalakrishnan et al,
2002). The reduction of contraction may also be due to activation of Al receptors present 
on motor nerves which may inhibit further neurotransmitter release (Fry et al, 2004). It 
has been proposed that a further role of PI receptors in the urothelium is to modulate 
exocytosis in umbrella cells (Yu et al, 2006).
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The second major class of purinergic receptor, P2, was divided into P2X and P2Y based 
initially on pharmacological evidence in 1985 (Bumstock and Kennedy, 1985). 
Following this numerous other P2 receptors were demonstrated and named including P2 Z, 
P2t and P211. Due to the increasing number of P2 receptors and their random naming; the 
nomenclature was rationalised by dividing them it into two major groups termed P2X 
and P2Y (Abbracchio and Bumstock, 1994, Fredholm et al, 1994). P2X describes those 
receptors that are ligand-gated non-specific cation channels and P2Y describes those that 
are G-protein coupled. Unlike P2Y receptors, most P2X receptors are desensitised by a, 
(3-methyleneATP.
Currently seven P2X receptors subtypes have been cloned and characterised, they are 
termed P2Xi to P2 X7 . Each subunit has two transmembrane domains separated by an 
extracellular domain of approximately 280 amino acids (North, 2006) which contains the 
putative ATP binding site (Gever et al, 2006). Channels can form as multimers of several 
subunits, evidence suggests that they form homomeric and heteromeric trimers (Stoop et 
al, 1999) and possibly in a “head to tail” arrangement (Jiang et al, 2003). The 
heteromeric trimers that have been identified and characterised are P2 X2/3 , P2 X 1/5 , P2 X2 /6  
and P2 X4 /6 . The characteristics of the receptor depend on the subtype combination.
RT-PCR studies have shown that in human detrusor smooth muscle tissue the subtypes 
of P2X receptor are present in the order P2Xi »  P2 X4  > P2 X7 »  P2 X5 »  P2 X2 »  
P2 X3 = P2X6 = 0 (O’Reilly et al, 2001a). However this gives no indication of the relative 
importance of each receptor, just the expression magnitude and does not account for the
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relative content of muscle and nerve. In cat detrusor smooth muscle P2 X4 , P2X5 and 
P2X6 were not detected (Birder et al, 2004). The most abundant P2 receptor in human 
detrusor, the P2X}, has been cloned and localised to chromosome 17 (O’Reilly et al, 
2001a, Longhurst et al, 1996). The role of the P2Xi channel in detrusor is to mediate the 
purinergic component of smooth muscle contraction. Nerve-mediated contraction of the 
bladder in mice lacking the P2Xi receptor was reduced by -50-70% (Vial & Evans 
2000).
Activation of P2X receptors by ATP generates an inward, depolarising current in 
detrusor muscle carried by Ca2+ and Na+ (Kennedy, 2000). Depolarisation is sufficient to 
activate L-type Ca2+ channels to generate an action potential and Ca2+ influx to initiate 
contraction (Inoue and Brading, 1991). The influx of Ca2+ may lead to further increases 
of [Ca2+k due to Ca2+ induced Ca2+ release from intracellular stores.
There are also several subtypes of the P 2 Y  receptor category. P 2 Y  receptors are seven 
transmembrane domain G-protein coupled receptors with binding sites being identified 
on the 6th and 7th domains (Bumstock, 1997). There are currently eight mammalian P 2 Y  
receptors, P 2 Y i ,  P 2 Y 2 ,  P 2 Y 4 ,  P2Y6, P 2 Y n ; P 2 Y i 2 ,  P 2 Y i 3  and P 2 Y u .  There are also three 
non-mammalian, p2 y3 , p2yg, and p2y and also a number of orphan receptors that remain 
to be fully characterised. Activation of a P 2 Y  receptor is coupled to a variety of second 
messenger systems. For example, P 2 Y i ,  P 2 Y 2 , P 2 Y 4> P 2 Y 6 are coupled to phospholipid 
turnover and intracellular Ca2+ mobilization via I P 3 generation. P 2 Y n  activates
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phospholipase C and adenylate cyclase and P2Yi2 inhibits adenylate cyclase activity (Sak 
and Web, 2002).
P2Y receptors were not identified in cat detrusor (Birder et al, 2004) but similar studies 
have not been performed on human tissue. P2Y receptors, although not a specific 
subtype, have been implemented in relaxation of smooth muscle in mouse and rat bladder 
(Boland et al, 1993; Bolego et al, 1995). Studies in the marmoset detrusor suggest P2Y 
mediated relaxation that may occur through activation of cAMP-dependent PKA activity 
(McMurray et al, 1998).
One study looking at the expression of P2 receptors in urothelium has shown that all P2X 
receptors are present in cat bladder urothelium in the basal and apical layers, although 
staining was more intense for P2X3, and P2Yi, P2Y2, and P2 Y4  (Birder et al, 2004). The 
P2 X3 receptor has been detected in human urothelium (Sun and Chai, 2004). The study 
suggested ATP acted via urothelial P2 X3 receptors to transmit pain signals to the CNS 
and showed that the receptor was upregulated upon stretch of the urothelium. The role of 
all the P2 receptors in urothelium is unknown however it is likely that they play a part in 
the sensory functions of the urothelium. Some changes have been observed in bladder 
urothelium P2 receptors from humans and cats with interstitial cystitis (IC). Birder et al 
(2004) have shown that there was a significant reduction of P2Xi and P2 Y2 receptors in 
cats with IC compared to normal. In human patients with IC increases in P2 X2 and P2 X3 
have been observed compared to samples from control patients (Tempest et al, 2004, Sun 
et al, 2004). Studies with P2 X3 receptor knockout mice have shown enlarged bladder
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capacity and reduced frequency of micturition (Cockayne et al, 2000) again consistant 
with a role for these receptors in transducing the sensation of bladder fullness.
The presence of P2 receptors on nerves within the bladder has also been investigated in 
humans and cats. Studies (Moore et al, 2001, Ray et al, 2003) have looked at the relative 
abundance of the P2X receptors that were co-localised with synaptic vesicles on 
parasympathetic nerves. They showed that all subtypes could be identified, although 
P2 X4 , P2X 6 and P2 X7 were less abundant, present in only 6  - 18% of varicosities. 
Changes in the presence of P2X receptors in the sensory nerves were observed in patients 
with urge incontinence and sensory urgency. Urge incontinence was associated with a 
complete absence of P2 X3 and P2Xs receptors (Moore et al, 2001) whilst in patients with 
sensory urgency all P2X receptor subtypes were reduced to 0.5 - 5% of that in control 
patients (Ray et al, 2003). It is likely that the loss of P2X receptors may impair both 
detrusor distension and contraction.
There is also evidence to suggest there are two further groups of purinergic receptors, P3 
and P4. The P3-like receptor has been demonstrated through radio-labelling studies and 
has an affinity for adenine nucleosides and nucleotides (Yoshioka et al, 2001). The P4 
receptor has affinity only for diadenosine polyphoshates (Pintor et al, 2000). Their 
physiological functions remain unclear at present.
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1.6.3 ATP, contractile activation and bladder pathologies
Once ATP is released into the neuromuscular junction it is activates purinergic receptors 
located on the detrusor smooth muscle as described previously. P2Xi receptors are the 
predominant subtype within the bladder and the primary receptor through which 
atropine-resistant contractions are mediated. Any change in purinergic receptor levels 
particularly the P2Xi receptor may affect the proportion of the purinergic component of 
contraction especially in overactive bladders. Changes to the expression of purinergic 
receptors throughout pathological bladders have been shown although they vary 
according to location (in the bladder) and the disorder. With detrusor from patients with 
symptomatic outlet obstruction the amount of P2Xi receptor per smooth muscle cell was 
shown to be higher compared to control bladders (O’Reilly et al, 2001b) which would 
aid purnergic contraction. In contrast, in female idiopathic overactive bladders the P2Xi 
receptors were significantly reduced although P2 X2 was elevated and the authors 
suggested a P2Xi/2 receptor may be involved (O’Reilly et al, 2001a).
Changes to presynaptic receptor expression may also play a role in atropine-resistance as 
they may modulate the release of ATP and/or Ach. Presynaptic changes that have been 
observed include a reduction in P2X3 and P2X5 in human patients with idiopathic 
overactivity (Moore et al, 2001) and a significant loss of all P2X receptors in patients 
with sensory urgency (Ray et al, 2003). The receptor expression evidence for emergence 
of atropine-resistant contraction is however not conclusive and the significance of the 
findings remains unclear.
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Another explanation for the emergence of atropine-resistant contractions observed in 
pathological bladder is that there is a relative change to the sensitivity of the purinergic 
receptors to ATP and cholinergic receptors to Ach compared to normal bladders. This 
possibility was investigated by measuring ATP and carbachol induced intracellular Ca2+ 
transients in isolated detrusor smooth muscle cells from stable and overactive human 
bladders. The ATP and Ach half-maximal concentrations ( E C 5 0 )  and the magnitude of 
the Ca2+ transients were equivalent in the detrusor from the stable and overactive 
bladders (Wu et al, 1999). Results from this study suggested that atropine-resistance in 
overactive bladders cannot be attributed to changes in the sensitivity of the receptors, 
even though it has been shown by others that there are changes in P2X receptor 
expression (O’Reilly et al, 2001 a,b).
1.6.4 ATP breakdown
Both Ach and ATP released from the nerve terminal are rapidly inactivated via 
enzymatic breakdown by acetylcholinesterases and ectonucleotidases respectively. The 
breakdown products can also act pre- or postsynaptically to alter contraction and 
transmitter release before they are taken back up into nerve for re-synthesis.
Ectonucleotidases sequentially degrade ATP to adenosine 5’-diphosphate (ADP), 
adenosine monophosphate (AMP), adenosine and inosine. Breakdown to ADP is the 
most important step in inactivation as ADP is less active at P2 receptors (Westfall et al,
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1997). The enzymes are located on cell membrane surfaces and there is evidence in 
sympathetic nerves that a soluble enzyme is also released upon stimulation (Todorov et 
al, 1997). Ectonucleotidase activity is dependent on Mg2+ or Ca2+ ions and is optimal at 
pH 7.5 (Kennedy et al 1996) therefore any changes to the neuromuscular junction 
environment will effect ATP breakdown.
These enzymes are insensitive to inhibitors of other types of ATPases including ouabain, 
oligomycin, sodium azide and p-nitrophenyl phosphate. A number of substances have 
been shown to inhibit the action of ectonucleotidases including suramin and PPADS, 
however their action is not specific and may not be suitable when investigating the 
effects the enzymes have on ATP mediated contractions. A more specific 
ectonucleotidase inhibitor has been developed, ARL 67156 (6-N,N-dethyl-P,y- 
dibromomethylene-D-ATP), it is an ATP analogue and its structure is illustrated in Figure 
1.4. The effect of ARL 67156 was first demonstrated in rabbit tracheal epithelium where 
secretions mediated by UTP but not ATP-y-S were potentiated and in human blood cells 
where it inhibited [y32P]-ATP dephosphorylation in a concentration-dependent manner 
(Crack et al, 1995). In the guinea-pig bladder exogenous ATP-mediated, but not ABMA- 
mediated, contractions are increased in the presence of ARL 67156 (Westfall et al,
1997). Peak nerve-stimulated contractions in bladder were increased as were those in the 
presence of atropine (Westfall et al, 1997) showing that ARL 67156 enhanced the 
purinergic component of detrusor contraction by inhibiting ectonucleotidase activity. 
Ectonucleotidase activity has been shown to be reduced in human detrusor from some 
pathological bladders (Harvey et al, 2002). Human detrusor from bladders of certain 
pathologies (in particular obstructed bladders), and unlike stable bladders, generate
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atropine-resistant contractions which may result from reduced enzyme activity. Reduced 
ATP breakdown may allow ATP greater access to the P2X receptors on the detrusor 
smooth muscle and produce atropine-resistant contractions.
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Figure 1.4 Structure of A) ATP and B) the ecto-nucleotidase inhibitor ARL 67156.
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In conclusion, ATP has been established as a co-transmitter at numerous nerve-smooth 
muscle junctions. The presence of atropine-resistant contractions in animal and human 
detrusor may be attributed to activation via nerve-mediated ATP release and they may 
play a role in pathological bladder overactivity. The reason for the emergence of 
atropine-resistant contractions in human pathology may be a result of reduced 
extracellular breakdown, altered release or altered receptor sensitivity and it is a major 
objective of this thesis to gain insight into the cause of these contractions. The remaining 
sections of the Introduction will describe in more detail the routes whereby ATP 
hydrolysis is brought about and the methods available to measure extracellular ATP.
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Scheme 1.1 Schematic indicating possible reasons for the emergence of atropine 
resistant contraction in pathological human bladder overactivity. 1) altered release o f 
ATP, 2) reduced extracellular ATP breakdown by ectonucleotidases. 3) increased 
sensitivity o f the smooth muscle receptors to ATP.
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1.7 ECTONUCLEOTIDASES
Extracellular nucleotides including ATP, ADP, UTP, UDP and diadenosine 
polyphosphates, can be hydrolysed by a variety of enzymes. There are several families of 
enzymes that can contribute to the hydrolysis of nucleotides in the extracellular space 
(Zimmermann 2001). The families include the ectonucleoside triphoshate 
diphosphohydrolayse (E-NTPDase) family, the ectonucleoside pyrophosphatase 
/phosphodiesterase (E-NPP) family and the alkaline phosphatases. The nucleoside-5’- 
monophoshpates are hydrolysed by ecto-5’nucleotidase. The enzymes have overlapping 
substrate specificity and tissue distributions. They are present in many tissues including 
smooth, cardiac and skeletal muscle, liver, kidney, pancreas, urinary bladder and 
neurones (Kennedy et al 1996, Plesner, 1995 and Hourani and Chown, 1989). The 
enzymes are located on membrane of cells or in a soluble form in fluids. It is the E- 
NTPDase family that is inhibited by ARL 67156 and considered to play a major role in 
the breakdown of ATP to AMP in the neuromuscular junction.
60
r- >>nn Alkaline Ecto-5 -
E-NTPDases E-NPPs Phosphatases Nucleotidase
COOH
COOH
COOH
NTPDasd NTPDasc5 
NTP0as«2 NTPDase6 
NTPDase3
NPE1
NPP2
NPP3
Ktdney/bone/lrver 
{«tissue non-
specific}
Placenta!
Intestinal
Germ-ce!i
NTPDase 8
Figure 1.5 Predicted membrane topography of ectonucleotidases, E-NTPDases 1, 2. 3. 5. 
6 and 8, E-NPPs 1-3, alkaline phosphatases and ectonucleotidase-5,-nucleotidase. The 
dark blocks on the E-NTPDases represent ayyrase conserved regions that are involved 
in catalytic activity (modified from Zimmermann, 2001).
1.7.1 The E-NTPDase family
The E-NTPDase family are responsible for the sequential removal of the y- and P- 
phosphates of extracellular tri- and diphosphonucleotides (Gendron et al, 2002). 
Currently eight members of the family have been identified, cloned and characterised, E- 
NTPDase 1-8. All the E-NTPDase enzymes have five highly conserved sequence 
domains termed apyrase conserved regions (APCR) that are involved in catalytic activity 
(Robson et al, 2006).
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1.7.2 Surface membrane E-NTPDases
Of the eight subtypes, four are cell-surface located with an extracellular catalytic site; 
they are E-NTPDase 1, 2, 3 and 8. They are glycosylated enzymes with a molecular mass 
of around 70-80 kDa with a common membrane topography of two transmembrane 
domains which are near the N-and C-termini (Zimmermann, 2001; Knowles and Chang, 
2003). Their activity is dependent on millimolar concentrations of Ca2+ or Mg2+ ions. 
The four enzymes show different substrate specificity and hydrolysis rates for nucleoside 
diphosphates (Robson et al, 2006). E-NTPDase 1 hydrolyses ATP and ADP almost 
equally well (Heine et al, 1999), E-NTPDase 2 has a strong preference for ATP, about 
30-fold over ADP, whilst E-NTPDase 3 and 8 have a slight preference for ATP over 
ADP as a substrate (Zimmermann, 2001). ATP is rapidly hydrolysed to AMP by E- 
NTPDase 1 with minimal amounts of free ADP production preventing activation of P2Y 
receptors. However hydrolysis by E-NTPDase 2 results in ADP production which is 
slowly broken down to AMP creating agonists to P2Y receptors. Again E-NTPDase 3 
and 8 activity results in an intermediate product formation of ADP and then AMP 
(Vorhoff et al, 2005; Bigonnesse et al, 2004). E-NTPDases can form homo-oligomeric 
complexes which can increase their catalytic activity, E-NTPDase 1, 2 and 3 have been 
found as dimers or tetramers (Wang et al, 1998).
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1.7.3 Intracellular membrane E-NTPDases
E-NTPDase 4 has a similar general structure to E-NTPDase 1 to 3 and 8 but differs by 
alternative splicing (Biederbick et al, 2000). It is located entirely intracellulary, facing 
the lumen of cytoplasmic organelles, such as the Golgi apparatus (Wang and Guidotti, 
1998) and lysosomal/autophagic vacuoles (Biederbick et al, 1999). It hydrolyses 
nucleoside 5’-di- and triphosphates.
E-NTPDase 5 and 6 have a predicted N-terminal hydrophobic sequence but do not have 
the C-terminal transmembrane domain and are localised intracellularly. E-NTPDase 5 
has been located to the endoplasmic reticulum and E-NTPDase 6 to Golgi apparatus but 
both have also been identified as a secreted soluble form (Trombetta and Helenius, 1999; 
Braun et al, 2000). They have a strong preference for nucleoside diphosphates with E- 
NTPDase 5 hydrolysing UDP and GDP and E-NTPDase 6 GDP and IDP. It has been 
suggested that E-NTPDase 6 supports glycosylation reactions in the Golgi apparatus and 
then nucleotide hydrolysis following its release (Braun at al, 2000).
More recently discovered, E-NTPDase 7 is also located intracellularly, facing the lumen 
of organelles. This enzyme hydrolyses a number of nucleoside triphosphates including 
UTP, GTP and CTP but not ATP (Shi et al, 2001).
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As mentioned above ectonucleotidase activity has been implicated in the emergence of 
atropine-resistant contractions in some bladder pathologies. There is evidence to suggest 
they play a role in other pathologies such as the proliferation of cancer cells. They have 
however also been shown to play positive roles in other pathologies, especially those of 
the cardiovascular system particularly inflammatory responses (Gendron et al, 2002).
1.7.4 Soluble ectonucleotidases
Ectonucleotidases are normally located on the extracellular membrane surface of cells 
however some soluble forms have also been described. The soluble enzymes could be 
released from nerve vesicles or could arise from proteolytic cleavage of membrane- 
bound enzymes. Studies have not be carried out to determine if these enzymes are 
released from parasympathetic nerves of the detrusor and contribute to the breakdown of 
ATP in this neuromuscular junction. Soluble ectonucleotidases are released upon nerve 
stimulation of guinea-pig vas deferens. Superfusate from only stimulated tissue was able 
to degrade exogenous ATP, but the effect was abolished when the tissue was stimulated 
in the presence of TTX implying the enzymes were released from the nerves (Todorov et 
al, 1997). There are two released soluble enzymes which hydrolyse ATP: one to ADP 
and AMP; and the second to AMP and adenosine (Mihaykova-Todorova et al, 2002). 
The first shows some similarities to ENTPDases and is ARL 67156-sensitive, whilst the 
second has similarities to ectonucleotidase-5’-nucleotidse (Westfall et al, 2002).
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1.8 MEASUREMENT OF ATP
ATP is a ubiquitous substance with numerous functions within biological systems. 
Recently its role as an important transmitter has been begun to be established in both the 
central and peripheral nervous system, playing a role not only in the bladder, as discussed 
above, but in all systems and tissues. ATP has been identified as a neurotransmitter 
through electrophysiological, pharmacological and direct measurement studies. Silinsky 
and Redman (1996) used patch electrodes to measure activation of ATP-gated ion 
channels via stimulation of frog cutaneous pectoris nerve muscle preparations. The 
experiments suggested that ATP was synchronously released with Ach in response to 
nerve impulses. The use of agents such as atropine and ABMA has highlighted the role 
of ATP in detrusor contraction of the bladder of most mammalian species.
1.8.1 ATP measurement techniques
Various techniques have been employed to measure directly ATP release from tissues 
and nerves including the use of radio-labelled ATP, fluorescence detection HPLC and the 
luciferin-luciferase assay. Each method has associated advantages and drawbacks. A 
consideration when using radiolabelled purines is that they may not follow the uptake 
and release of endogenous ATP and it is difficult to distinguish ATP from other purines 
released by the tissue (Sperlagh and Vizi, 1996). The luciferin-luciferase assay is simple
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and has a high sensitivity, in the femptomolar range, whilst the use of HPLC enables 
ATP breakdown products to be also measured from the same sample. Superfusate 
samples taken at 10 second intervals during 60 second stimulation of guinea-pig vas 
deferens were analysed by HPLC-fluorescence detection to show co-transmitter ATP 
release with NA was likely to be from separate exocytotic vesicles (Todorov et al, 1996). 
The study used 2-chloroacetaldehyde to produce the fluorescent derivatives ethano (e)- 
ATP to enable the ATP and its breakdown products to be measured. The luciferin- 
luciferase assay was used to measure ATP release from human detrusor following 
varying degrees of stretch and electrical stimulation (Kumar et al, 2004). A sample of the 
solution surrounding the tissue in the organ bath was taken following intervention and 
measured and compared to a basal recording. Santos et al (2003), used the luciferin- 
luciferase assay to measure ATP release from the rat phrenic nerve: they showed that the 
release was frequency dependent over 1-5 Hz. As before the ATP measurement was 
made by taking samples of the bath solutions and comparing them to basal levels.
Although the techniques above provide useful and sensitive methods for measuring direct 
ATP release they are difficult to use in vivo and many rely on the measurement of ATP 
in samples taken from the solution surrounding the preparation. Superfusate sample 
collection means that there is a delay between ATP release and ATP measurement and 
this can lead to degradation of ATP and inaccurate measurements. ATP will also be 
broken down by any ATPases collected in the sample. Another major drawback of these 
techniques is that they are unable to measure ATP release in real-time during 
physiological activity. The recent development of microelectrode biosensors provides a
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novel way of measuring endogenous ATP release in real-time, allowing for the timing, 
dynamics and quantity of ATP release to be recorded (Llaudet et al, 2004; Dale et al, 
2005).
1.8.2 Microelectrode biosensors - characteristics
Biosensors are described as any sensor that uses a biological component to bind 
specifically to an analyte of interest and provide a physical signal that is a function of the 
amount of analyte (Dale et al, 2005). The initial microelectrode biosensors for purines 
were developed by Dale (1998) for the measurement of adenosine in frog embryos. The 
benefit of microelectrodes is that they give good temporal and spatial resolution and are 
minimally invasive, especially when compared to other methods. The adenosine and 
ATP electrodes are prepared in a similar way and work on the same principles. Enzymes 
are entrapped in a robust, highly porous biolayer which is thinly coated around a 
platinum microelectrode (Figure 1.6). The enzymes are entrapped so that they are not 
lost from the electrode and therefore it can be used repeatedly. With the ATP electrode 
the enzymes present are glycerol kinase and glycerol-3-phosphate oxidase. In the first 
step of the enzyme cascade glycerol kinase catalyses the transfer of a phosphate group 
from ATP to glycerol. Glycerol must therefore be present throughout the experiment for 
the electrode to be active. In the second step hydrogen peroxide is produced by the 
oxidation of glycerol-3-phosphate. The H2C>2 thus generated can be amperometrically 
detected when oxidised by the Pt electrode polarised to 500-700 mV relative to an 
Ag/AgCl reference.
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The ATP electrodes have a diameter of 50-100 pm, respond rapidly (10-90% rise time < 
10s) and display a linear response to ATP over the concentration range 200 nM to 50 pM 
(Llaudet et al, 2005). To account for any electroactive species in the environment or 
‘non-specific’ electroactive interferents that may contribute to the recordings a null 
electrode that lacks any enzymes is placed in close proximity to the active electrode and 
a differential recording is made (Gourine et al, 2005).
1.8.3 Microelectrode biosensors -  uses
Due to the recent development of the electrodes there is a limited experience of their use. 
The adenosine electrodes were first used to investigate the dynamics of adenosine 
production in the spinal cord during motor activity in the frog and its possible 
contribution to temporal motor patterns (Dale, 1998). The study showed when the 
electrode was optimally placed there was a rise, for up to a minute, of adenosine 
following the end of activity. They have also been used to measure adenosine from the 
dorsal surface of the brainstem and from with the nucleus tractus solitarii during the 
defence response caused by hypothalamic stimulation in the rat (Dale et al, 2002) and to 
study the role of adenosine release during hypoxia in rat hippocampal slices (Freguelli et 
al, 2003).
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The use of the ATP electrode so far includes measuring the release of ATP from the 
spinal cord of Xenopus embryos during swimming (Llaudett et al, 2004, 2005). The 
electrodes were placed in alignment with the ventral part of the spinal cord and transient 
ATP release was observed during the swimming episode. The role of ATP in control of 
respiratory activity has been investigated with ATP electrodes (Gourine et al, 2005). The 
group was able to show that hypoxia induced a marked increase in ATP and that the ATP 
is produced throughout the ventrolateral medulla in locations corresponding to the 
ventral respiratory column. In the most recent study to utilise the ATP electrode, Pearson 
et al (2005), showed that the retinal pigment epithelium (RPE) regulates proliferation in 
the neural retina via the release of ATP.
The experiments with adenosine and ATP electrodes have shown they have a wide 
application both in vivo and in vitro. In this thesis the ATP microelectrode biosensor will 
be used to try to measure ATP in real time under sensitive stimulation parameters of 
contraction of the detrusor smooth muscle.
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1.9 AIMS AND OBJECTIVES OF THESIS
Hypothesis:
Nerve-mediated ATP release plays a variable role in contractile activation in detrusor 
smooth muscle from animal and human bladders. This variable role is due to differential 
breakdown or release of extracellular ATP.
Aims of the thesis:
The aim of this project was to investigate the role of ATP signalling in the 
neuromuscular junction of guinea pig and human detrusor smooth muscle with particular 
emphasis on ATP breakdown by ectonucleotidases. The effects of ectonucleotidase 
modulators were investigated on the contractile activity of electrically field stimulated 
isolated detrusor preparations. Ectonucleotidase activity was determined by measuring 
ATP degradation in detrusor samples using a luciferin-luciferase assay. Real-time PCR 
was used to establish relative levels of ectonucleotidase enzymes in samples of human 
detrusor. Nerve mediated release of ATP in guinea pig detrusor strips was measured in 
real time using microelectrode biosensors.
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Objectives:
The following experimental objectives were addressed through the experiments 
performed in this study, to determine the role of ATP release and breakdown in detrusor.
i.) To determine the effect of altering ectonucleotidase activity on nerve-induced 
contractions in guinea-pig and human detrusor, and whether this differs 
between tissue from stable and overactive human bladders.
ii.) To determine the rate of ectonucleotidase activity in guinea-pig and human 
detrusor and whether this differs between detrusor samples from stable and 
overactive human bladders.
iii.) To determine if there are any differences in the expression of ectonucleotidase 
1, 2, 3 or 5 in detrusor samples from stable and overactive human bladders.
iv.) To establish if novel ATP sensitive microelectrode biosensors are suitable to 
measure ATP release in real time during nerve-stimulated contractions of 
guinea-pig detrusor.
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2.0 Materials and Methods
2.1 SOLUTIONS AND CHEMICALS
2.1.1 Physiological Solutions
The physiological saline solution used for experiments was a modified Tyrode’s solution 
buffered with either N-[2-hydroxyethyl]piperazine-N’-[2-ethaneesulfonic acid] (HEPES) 
or NaHCCh/CCh. The compositions of these solutions are shown in Tables 2.1 and 2.2. 
Fresh Tyrode’s was prepared daily using deionised water from a Purite reverse osmosis 
water filter (Purite Ltd, Thames, Oxon, UK). Stock solutions of 1 M KC1, MgCb, and 
NaH2PC>4 were prepared in deionised water and CaCL was purchased as a 1 M solution 
(BDH). All stock solutions were stored at 4°C. Glucose, Na pyruvate, NaCl, NaHCC>3 
and HEPES were added as solids. Solids were weighed on a Sartorius balance (Sartorius 
Ltd. Epsom, Surry) and liquids were measured using a measuring cylinder or variable 
volumetric pipettes.
NaHCOs/CCVbuffered solutions, used for experiments utilising ATP biosensors, were 
gassed with 95% O2 , 5% CO2 mixture to maintain a pH of 7.33 ± 0.02 at 37°C (see 
section 2.3). An aliquot of a 5 M glycerol stock was added to this modified Tyrode’s 
solution to give a final concentration of 2 mM. Glycerol was added as it was a co­
substrate required for the operation of the ATP biosensor (see section 2.8).
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The Tyrode's solution used in the tissue strip experiments was buffered with HEPES. The 
pH of the solution was adjusted to 7.3 using 1 M NaOH and a pH meter (Meter - Solex 
digital pH/MV meter, Taiwan R.O.C. Electrode -  BDH glass+). The solution 
temperature was maintained at 37°C during experiments.
Modifications were made to the HEPES-buffered Tyrode’s solution for use in the ATP 
degradation experiments measuring ecto-ATPase activity in detrusor. The modification 
made to the HEPES buffered Tyrode's was to remove all calcium and add 5 mM ethylene 
diamine tetra acetic acid (EDTA). The pH of the solution was adjusted to 7.8 as required 
for the luciferin-luciferase assay. This solution was used ice-cold to dilute samples and to 
terminate ATP degradation.
An ungassed, nominally Ca2+-free HEPES buffered Tyrode’s solution with the pH 
adjusted to 7.6 was used for transport and storage of human tissue samples. The 
composition is shown in Table 2.3. This solution was also used for the storage of guinea 
pig bladders.
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Table 2.1 Composition of Tvrode’s solution
Chemicals Concentration (mM)
NaCl 118.0
NaHC03 24.0
KC1 4.0
MgCl2.6H20 1.0
NaH2P04.2H20 0.4
CaCl26H20 1.8
Glucose 6.1
Na pyruvate 5.0
Table 2.2 Composition of HEPES Tvrode’s solution
Chemicals Concentration (mM)
NaCl 132.0
HEPES 10.0
KC1 4.0
MgCl26H20 1.0
NaH2P04.2H20 0.4
CaCl2.6H20 1.8
Glucose 6.1
Na pyruvate 5.0
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Table 2.3 Composition of Ca+2 -free HEPES Tvrode’s solution
Chemicals Concentration (mM)
NaCl 105.4
NaHC03 22.3
KC1 3.6
HEPES 19.5
MgCl2.6H20 0.9
NaH2P04.2H20 0.4
Glucose 5.4
Na pyruvate 4.5
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2.1.2 Chemicals and Drugs
The chemicals and drugs used as interventions during the experiments were added to the 
appropriate Tyrode’s solution to give the required concentration.
Atropine, 6-N,N-diethyl-P-y-dibromoetheylene-D-adenosine-5’-triphosphate trisodium 
(ARL), disodium-adenosine triphosphate (Na2ATP), a - f  -methyl ene-adeno si ne
triphosphate (ABMA), carbachol and tetrodotoxin (TTX) were added to the Tyrode’s 
solutions from 10 mM stocks. The stocks were prepared by dissolving the solid 
chemicals in deionised water and were stored at 4°C or in small aliquots at -20°C.
Nifedipine (10 mM) stock solution, prepared in dimethyl sulphoxide (DMSO), was made 
on a daily basis due to its instability in light.
High potassium chloride solutions, 120 mM, were prepared by addition of a 1 M stock 
solution to the glycerol-containing Tyrode’s solution.
Apyrase solid was dissolved in HEPES-Tyrode’s solution to give a stock concentration 
of 20 U.ml'1. The concentration was calculated by the enzyme activity of each batch. 
Aliquots of 500 pil were frozen at -20°C in eppendorf tubes. Once thawed, 500 pi of 
HEPES Tyrode’s was added to the aliquots to give a final concentration of 10 U.ml1.
77
Adenosine 5’-triphosphate bioluminescent assay kit, containing ATP assay mix; ATP 
assay mix dilution buffer; and ATP standard was purchased from Sigma. The assay mix 
was a lyophilized powder containing luciferase, luciferin, MgSC>4 , dichloro-diphenyl- 
trichloroethane (DDT), EDTA, bovine serum albumin (BSA) and tricine buffer salts. It 
was reconstituted using 5 ml deionised water. Any dilutions of the assay mix were made 
using the dilution buffer.
Chemicals were purchased from Sigma unless stated otherwise.
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2.2 TISSUE COLLECTION AND PATIENT GROUPS
2.2.1 Human detrusor
Human detrusor tissue samples were obtained from open surgery with local ethical 
committee approval from University College London Hospital Trust and informed 
patient or guardian consent.
Biopsies were dissected from the dome region in a posterior to anterior direction. 
Samples are immediately placed and transferred from the surgical theatre in Ca2+ -free 
HEPES buffered Tyrode’s solution. Samples were stored at 4°C and could be used for up 
to 48 hours.
Samples were divided into different groups depending on results of urodynamic tests or 
pathology:
i) ‘Control’ group consisting of stable bladders. Control samples were obtained 
from patients undergoing a cystectomy for bladder cancer or removal of a 
localised bladder tumour. Samples dissected from whole bladders removed by 
cystectomy were taken from sites unaffected by the tumours.
ii) ‘Overactive’ group. Patients in this group had urodynamically-proven 
bladder overactivity. The overactivity was associated with neurological 
disorders, bladder outflow obstruction or was idiopathic. These samples were
79
obtained, in the main, from ileocystoplasty procedures. Samples were 
obtained from patients with urodynamically proven bladder overactivity.
2.2.2 Guinea Pis detrusor
Male Dunkin-Hartley guinea pigs (400-600 g) were sacrificed by cervical dislocation 
according to United Kingdom Home Office specifications, under a personal and project 
licence to Professor CH Fry. The bladder was dissected out and immediately placed in 
Ca2+-free HEPES buffered Tyrode’s solution. The bladder was immediately used or was 
stored at 4°C for up to 48 hours before use.
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2.3 ISOMETRIC TENSION MEASUREMENT
2.3.1 Muscle strip preparation
Both human detrusor samples and whole guinea pig bladders were placed in dissection 
dishes containing Ca2+-free HEPES buffered Tyrode’s solution. Samples were held in 
position with fine gauge syringe needles.
The guinea pig bladder was opened and the urothelium was dissected away with fine 
dissection scissors. The detrusor layer contained densely packed muscle bundles which 
ran longitudinally from the base to the dome. The bundles were a greyish-white colour 
and are slightly translucent. Longitudinal strips were cut avoiding the trigone.
When present, the serosa was removed and the urothelium dissected away from human 
samples. Human detrusor bundles appeared in random orientation and were pearly-white 
in colour with a slight translucent quality. Longitudinal arrangements of muscle bundles 
dissected for strips were identified using a binocular microscope (Nikon AL5, Nikon 
Corporation, Tokyo, Japan).
A segment of the human samples was frozen and stored in liquid nitrogen (N2 ) for 
subsequent experiments.
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Where possible, strips were dissected to consist of discrete bundles of muscle however 
this was not always possible with human samples. The strips had approximately the 
following dimensions: diameter l-2mm, length 4-6mm. The strips were tied at either end 
with surgical suture thread (Persalls sutures, cornea silk, US7/0).
2.3.2 Tissue mounting and equipment set-up
Tissue strips were transferred to the trough of a horizontal organ bath. Warmed water to 
37°C flowed in channels either side of the trough to maintain the temperature of the 
tissue and solution within the trough. In the trough the tissue was fastened to a static 
hook using suture. The other end was attached, again with suture to an isometric force 
displacement transducer (Model FT.03, Grass instrument Co. USA). Using 
micromanipulators (Prior instruments Ltd., Bishop’s Stortford, Hertfordshire, UK) the 
position of the tissue was adjusted to ensure it did not touch either the sides or the bottom 
of the trough and that the tissue was completely immersed in solution.
The tissue was superfused with HEPES-buffered Tyrode’s solution which was 
maintained at 37°C in a water bath. The superfusate flowed, under gravity, through a 
water-jacketed system to the trough at rate of 5 ml.min'1. The volume of the organ bath 
was approximately 0.064 cm3.
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The organ bath was attached to a heavy metal table and stage. The stage was placed in 
sand tubs in order to minimise mechanical interference to the recordings by external 
vibrations.
The force displacement transducer was connected to a bridge amplifier with variable gain 
(TB4M Transbridge, World Precision Instruments, US). The amplifier was then 
connected to a chart recorder with a low-pass filter of comer frequency 10 Hz (Multitrace 
2; ORMED Ltd, Hertfordshire, UK). The tissue was stimulated by pulse trains from a 
constant-current source via platinum (Pt) electrodes in the walls of the trough. The pulses 
were generated by a stimulator (Stimulator Model 200, Palmer Bioscience, Sheemess, 
Kent) and gated by a programmer (Model 150, Palmer Bioscience, Sheemess, Kent). The 
stimulation was about 1.5 times threshold by adjusting output voltage (30-40 V). The 
protocol is described in section 2.3.1.
At the end of the experiment the dimensions of the muscle strip were measured to 
determine the cross-sectional area of the muscle in order to normalise force values (mN. 
mm'2).
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2.3.3. Calibration o f tension transducer
To calibrate the tension transducer a range of weights were hung vertically from the force 
transducer hook. The deflections, measured in mm, were plotted as a function of the 
force exerted by gravity. The force F in Newtons (N) being:
F = m*g
where m = mass of weight (kg), g = acceleration due to Earth’s gravity (9.81m.s'2)
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Figure 2.1 Calibration plot o f tension transducer.
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2.3.4 Apyrase protocol
The experimental protocols were the same for guinea pig and human detrusor tissue.
Once fastened in the organ bath, muscle strips were stretched using micromanipulators to 
approximately 1.5-times their relaxed length. This was to ensure maximum contraction 
tensions were obtained upon electrical stimulation.
Electrical field stimulation elicited TTX-sensitive phasic contractions of the tissue strip 
via the embedded motor nerves. The stimulation parameters were 3-second pulse trains 
(0.1 ms pulse width) every 90 seconds at varying frequencies.
Guinea pig and human muscle strips were stimulated at 8 Hz and 20 Hz respectively until 
the contraction size attained was stable. The time required to reach a stable response was 
between 30 minutes and 1 hour. The particular frequencies were selected to give a 
contraction of about half-maximal force. Force-frequency curves were generated by 
stimulating the strips at a range of frequencies between 1 and 40 Hz.
Due to the cost of apyrase it was not possible to allow the apyrase-containing superfusate 
to flow through the bath. Therefore during all apyrase interventions the superfusate flow 
was suspended (‘no flow’). For these interventions 1 ml of 10 U.ml'1 apyrase was 
warmed to 37°C and added to the bath via a syringe and a three-way tap attached to the 
tubing just before it entered the bath. As a result of apyrase interventions being 
performed in such a way an equivalent ‘no flow’ situation was performed with the tissue
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in HEPES Tyrode's without addition of apyrase. In both instances flow was returned 
when the intervention was completed. The maximum time for the flow to be suspended 
was 15 minutes. The ‘no flow’ situation would be considered as the control to which 
apyrase interventions should be compared.
The effect of apyrase on the force frequency curve and fixed-frequency contractions of 
guinea pig and human detrusor were investigated. The effect of apyrase in the presence 
of atropine (1 pM) was also studied.
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2.3.5 Data analysis
r m a x - / ”Empirical fits to force-frequency T = —“ —-  data was performed by least squares
Krf
analysis. Tmax is the estimated maximum effect, ki/2  is the half-maximal frequency to 
generate half-maximal response. /  is the frequency of stimulation, and n is a constant. 
For n = 1 the relationship would describe a rectangular hyperbola, for n > 1 the curve 
would assume an increasing degree of sigmoidicity. No physiological significance was 
associated with the value of n. It was used only to optimise the curve fit.
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2.4 TOTAL RNA ISOLATION
Before any experiment involving RNA or DNA was carried out the work-bench and all 
apparatus were cleaned with RNase Zap (RNase Zap, Ambion) to prevent contamination.
2.4. IP reparation o f RNeasy Fibrious Tissue Mini Kit
The kit purchased to isolate RNA from the human detrusor samples was RNeasy Fibrous 
Tissue Mini Kit, (QLAGEN Ltd, West Sussex). Buffers RLT, RPE, RDD and RW1, 
RNase free water and protein kinase-K were contained in the kit, whilst DNase-1 was 
purchased separately from Ambion Inc. The kit was prepared and used as described in 
the instruction handbook with some small alterations.
Initial Preparations
10 pi of p-mercaptoethanol (Sigma) was added to every 1 ml of Buffer RLT. 
Buffer RLT is a lysis buffer containing the highly denaturing guanidine 
isothiocyanate. This inactivates RNases to ensure isolation of intact RNA.
Buffer RPE was diluted to lin 4 with 96-100% ethanol to give a suitable working 
concentration
DNase 1 stock solution was prepared by dissolving the DNase-1 solid in 550 pi 
RNase free water. The solution was mixed but not vortexed. DNase-1 solution is 
used to digest any DNA present in the sample.
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2.4.2 Preparation of Tissue
To isolate RNA from each human detrusor tissue sample 10-30 mg of each frozen sample 
was rapidly cut and weighed. The frozen tissue sample pieces were then placed in 600 pi 
of Buffer RLT and homogenised using a rotor-stator homogeniser. Homogenisation 
continued until the sample was cloudy and uniformly homogeneous (usually 40-60 
seconds). The homogenate was transferred to a 2 ml eppendorf tube.
2.4.3 RNA Isoltaion
580 pi of RNase-free water was added to the homogenate followed by 20 pi of 
proteinase-K solution which was mixed by pipetting. Proteinase-K solution is added to 
digest proteases, it contains a subtilisin-type protease isolated from the saprophytic 
fungus Tritirachium Album. The solution was incubated for 10 minutes at 55°C in a 
heating block (Eppendorf Thermomixer 5436) and then centrifuged for 3 minutes at 
10,000 x g (Eppendorf Centrifuge 54151). The supernatant was pipetted into a new 1.5 
ml micro-centrifuge tube, avoiding the pellet of tissue debris. In some samples a thin 
layer or film was present on top of the supernatant and efforts were made to avoid 
transferring any of this layer with the supernatant. 600 pi of 100% ethanol was added and 
mixed to provide good binding conditions of the RNA to the column.
From this supernatant solution 700 pi was pipetted onto an RNeasy mini spin column 
(contains a silica gel membrane that binds RNA) which in turn was placed in a 2 ml
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collection tube. This was centrifuged for 15 seconds at 8000 x g. The remainder of the 
supernatant solution was pipetted onto the same column and centrifuged in the same 
way. The flow-through was discarded into a separate waste container. To wash the 
column 350 pil of Buffer RW1 was pipetted onto the column and centrifuged 15 seconds 
at 8000 x g: again the flow-through was discarded.
DNase-1 solution was prepared by adding 10 pi of DNase-1 stock solution to 70 pi of 
Buffer RDD and mixing gently (DNase-1 is very sensitive to physical denaturation). The 
80 pi of DNase-1 solution was pipetted onto the membrane of the RNeasy mini column, 
this was then incubated at room temperature for 15 minutes. Once digestion was 
complete 350 pi of Buffer RW1 was pipetted onto the column. Following centrifugation 
(15 seconds, 8000 x g) the flow-through and collection tube were discarded. The column 
was transferred to a clean 2 ml collection tube and 500 pi of Buffer RPE was pipetted 
onto it. To wash, the tube was closed, centrifuged (15 seconds, 8000 x g) and the flow­
through discarded. Another 500 pi of Buffer RPE was added to the column and 
centrifuged for 2 minutes at 8000 x g. In order to dry the membrane and reduce the 
possibility of buffer carry-over, the column was placed into a clean collection tube and 
centrifuged for a further 1 minute.
To elute the RNA, the column was again transferred to a new 1.5 ml collection tube and 
30 pi of RNase-free water was added to the column. This was centrifuged for 1 minute 
(8000 x g). The elute containing the RNA was stored at -20°C.
All discarded flow-through was mixed with 100% ethanol before being disposed.
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2.4.4 Determination o f RNA quality
To ensure the isolated RNA was of an acceptable quality to use for further studies the 
samples were analysed using an RNA 6000 Nano Labchip Kit (Agilent Technologies, 
UK) and the Agilent 21000 Bioanlyser (Agilent Technolgies, UK). The technique 
enables minimal samples to be analysed by “lab on a chip” technology. Samples are 
electrophoretically separated and detected by laser-induced fluorescence, and translated 
into gel-like images and electropherograms. The kit was prepared and used as described 
in the guide.
-  Preparing the gel
The reagents were left to stand at room temperature for 30 minutes to equilibrate. An 
aliquot (550 pi) of RNA 6000 Nano gel matrix was pipetted into the top receptacle of 
a spin filter. This was centrifuged for 10 minutes at 4000 rpm (Eppendorf Centrifuge 
54151) and then the spin filter was discarded. 65 pi aliquots of the filtered gel were 
placed into RNase-free microfuge tubes and stored at 4°C.
-  Preparing the gel-dye mix
Reagents were allowed to equilibrate to room temperature for about 30 minutes 
making sure the dye concentrate was protected from light. The RNA 6000 Nano dye 
concentrate was vortexed and then spun down. 1 pi of this dye was added to a 65 pi 
aliquot of filtered gel, vortex mixed and then centrifuged for 10 minutes at 14000 
rpm (Eppendorf Centrifuge 54151).
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-  Loading the gel-dye mix
A new Nano chip was opened and placed on the chip priming station of the 
bioanalyser. 9 pi of the gel-dye mix was pipetted into the well labelled The chip 
priming station was then closed and the plunger pressed down and held for 30 
seconds. The plunger was then slowly released and the priming station opened. 9 pi 
of the gel-dye mix was pipetted into the two wells marked G.
-  Loading the RNA 6000 Nano marker
5 pi of the RNA 6000 Nano marker was pipetted into the well marked with the 
symbol of a ladder and into each of the twelve sample wells.
-  Loading the ladder and sample
RNA 6000 ladder (Ambion Inc) was pipetted into an RNase-free microcentrifuge 
tube and heat denatured at 70°C for 2 minutes. 1 pi of the ladder was pipetted into the 
well marked with the ladder symbol and 1 pi of each RNA sample was pipetted into 
the sample wells. Wells that were not used to analyse a sample had 1 pi of RNA 
Nano maker added. The chip was placed in the vortex mixer and vortexed at 2400 
rpm for 1 minute.
-  Setting up the bioanalyzer
Before the chip was placed in the bioanalyzer (Aligent 2100) the electrodes were 
cleaned using RNaseZAP and RNase-free water in the electrode-cleaning chip. The 
electrodes were then allowed to air dry before the sample chip was inserted and the
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lid closed. The computer software, 2100 Expert, was used to select the appropriate 
assay (electrophoresis, RNA, Eukaryote Total RNA Nano) and start the bioanalyzer. 
Once the run was complete the chip was removed and discarded and the electrodes 
cleaned as before.
2.4.5 Determination of RNA concentration
The concentration of each human detrusor RNA sample to be used in expression studies 
was determined by using a Genequant RNA/DNA calculator (Geneguant Pro, Amersham 
Biosciences). The instrument was set to measure the absorbance at 260 nm and 280 nm 
to determine the RNA concentration. All samples were defrosted but kept on ice whilst 
the measurements were taken.
Small glass capillary tubes with a volume of 7 [a1 were dipped into the sample solution 
and held until the solution filled the tube. One end of the tube was then sealed using 
plastercine. The capillary tube was then carefully placed in the Genequant and the 
absorbance taken and recorded. The capillary tube was then removed and discarded. 
Before the samples were measured a capillary filled with RNase-free water was 
measured in order to set a background reading.
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2.5 REVERSE TRANSCRIPTION
RNA is very unstable and will degrade easily. Reverse transcription to cDNA gives an 
identical population that is stable at high temperatures and therefore samples are able to 
undergo the polymerase chain reaction (PCR). In the reaction RNA is denatured by heat 
and then cooled in the presence of random hexamers (short random repeats of six to ten 
nucleotides) which bind to complimentary sequences on RNA. Addition of a mixture of 
deoxyribonucleotides (dNTP) and a DNA polymerase enzyme in the presence of a 
suitable buffer initiates the polymerisation reaction.
2.5.1 Reaeents
5 x PCR Buffer II (contains MgC^ as the enzyme requires Mg2+ to function), 10 mM 
GeneAmp dNTP blend, MuLV (Moloney murine leukaemia virus) Reverse 
Transcriptase, RNase Inhibitor and random hexamers were purchased from Applied 
Biosystems (USA). All reagents used were thawed on ice and then kept on ice whilst in 
use.
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2.5.2 Protocol
A mastermix of the reagents was prepared by adding them in the following proportions:
5 x PCR Buffer II lx (4pl per well)
lOmM dNTP blend 1 mM each dNTP (2pl per well)
RNase inhibitor lU.pl'1 (1 pi per well)
Random hexamers 2.5 pM (1 pi per well)
The mastermix was pipetted into the required wells of a 96-well plate (MicroAmp® 
Optical 96-well Reaction Plates, Applied Biosystems). To each well an appropriate 
volume of sample was added to give a concentration of between 100 ng and 1 pg of 
RNA. The final solution volume of each well was 20 pi, the remainder of this volume 
was made up with RNase/DNase free water. Each sample was prepared in triplicate as + 
reverse transcriptase reactions. A negative (-) reverse transcriptase reaction was also 
prepared and was used as a control for DNA contamination, if there was no reverse 
transcriptase present no cDNA could be made. On each plate four water controls were 
included, this is to check the reliability of the reagents. The plate was incubated for 10 
minutes at room temperature to allow the extension of hexamers. Then to the + reverse 
transcripatase reaction wells 1 pi of MuLV reverse transcriptase was added. To the -  
reverse transcriptase reaction wells and the water controls 1 pi of water was added. Caps 
(MicroAmp® Optical Caps, Applied Biosystems) were placed on the plate and pushed 
down to seal. The plate was then gently mixed.
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The plate was placed in a thermal cycler (Peltier Thermal Cycler, DNA Engine DYAP™ 
MJ Research). The reverse transcription protocol was as follows:
42°C 15 min reverse transcribe
99°C 5 min denature
5°C 5 min cool
Once the reaction was complete and the cDNA made the plate was stored at -20°C for 
the samples to be used in further studies.
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2.6 RELATIVE EXPRESSION OF TAQMAN® RT-PCR
TaqMan® enables real-time measurements of accumulating polymerase chain reaction 
(PCR) products using a dual-labelled TaqMan fluorogenic probe system (Medhurst et al, 
2000). The technique utilises Taq DNA polymerase (from Thermus aquaticus) which is 
complexed with an antibody and called Taq Gold. Taq has a 5 prime to 3 prime (5’-3’) 
DNA polymerase activity (adds nucleotides to the 3’ hydroxyl group of oligonucleotide 
primers). It has exonuclease activity, also 5’-3 \ which removes nucleotide from the 5’ 
end of any oligonucleotide that is bound to the template strand down-stream of the 
annealed primer. In the Taqman reaction is a third oligonucleotide, a reporter and 
quencher labelled probe. The probe anneals downstream (towards the 3’ end) of the 
forward primer. The reporter and quencher are covalently attached fluorophores with the 
reporter dye at the 5’ end and the quencher dye at the 3’ end. The reporter dye fluoresces 
(achieved by Forster Resonance Energy Transfer, FRET) when illuminated by laser light, 
but is quenched (fluorescence reduced) when the quencher dye is in close proximity. 
When the probe anneals downstream of the primer the Taq exonuclease cleaves the probe 
into individual nucleotides and thus releases the reporter from the quencher. The 
fluorescence of the reporter can then be detected and increases as each probe is cleaved. 
The increase in fluorescence is directly related to the amount of cDNA at the start of the 
reaction. For the different bladder samples tested a relative change in gene expression 
can be calculated by normalising for the amount of 18S rRNA and generating an 
arbitrary copy number.
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2.6.1 Reagents
The TaqMan® 2x Jump Start Mastermix, Taqman ribosomal RNA control reagent [18s 
forward primer, 18s reverse primer, 18s probe (VIC reporter dye labelled)], dual labelled 
oligonucleotide probe (FAM reporter dye labelled) and the Taqman® Gene Expression 
Assay kits for ENTPDase 1, 2, 3 and 5 were purchased from Applied Biosystems. 
DNase/RNase free water was purchased from Sigma. All reagents used were thawed and 
kept on ice during use.
2.6.2 Protocol
The samples to be tested were all of those obtained in the reverse transcription 
experiment. They were triplicates of each human detrusor sample and the -  reverse 
transcription reaction of each sample. Four non template controls (NTC) were also 
prepared as controls containing no sample.
A mastermix of the reagents was prepared, sufficient for the number of wells needed. 
The volumes and final concentrations of reagents per well were as follows:
2x Jump Start Mastermix 12.5 pi
Reference Dye 0.25 pi
rRNA primer and probe mix 1.25 pi
ENTPDase assay mix (20x) 1.25 pi
DNase/RNase free water 7.25 pi
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To each of the wells of the MicroAmp® Optical Reaction 96-well plate 22.5 p,l of the 
mastermix was added. To each of the sample wells 2.5 pi of the sample cDNA was 
added and to each of the controls 2.5 pi of DNase/RNae free water was added. The 
mastermix and samples were added quickly and carefully to minimise contamination. 
MicroAmp® Optical caps were placed securely on the wells of the plate. The plate was 
then centrifuged (Eppendorf Centrifuge 581 OR) for 1 min to ensure the small volume of 
solution was at the bottom of each well with no bubbles.
2.6.3 TaaMan® RT-PCR
The TaqMan® (ABIprism™ 7700 Sequence Detector) and computer were switched on in 
that order. The computer program used was SDS 1.9.1. The default settings were 
checked to ensure they were ‘Plate type: single reporter, Instrument: 7700, Sequence 
detection and Run: real time’. The FAM option was selected on the dye layer and the 
plate layout set up using ‘sample type’. Each well to contain a sample was designated as 
unknown, those with no sample but water were designated as no template control. They 
dye layer was then changed to VIC and again the wells were designated with the 
appropriate sample type. This was to ensure the machine read both the probe for the gene 
of interest (FAM dye labelled) and the probe for the ribosomal control (VIC dye 
labelled). The instrument exposure time was set to 25 seconds. The thermal cycler 
conditions were set at 10 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C 
and 1 minute at 60°C. The sample volume was set to 25pl and then the run could be
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started. Once the run was completed the plate was removed from the instrument and 
discarded in a biohazard bin.
2.6.4 Data analysis
The linear plot of the raw fluorescent data for the FAM dye label from the run was 
selected. The baseline was moved so that it crossed the first curve just as it began to rise. 
The ordinate was set to a logarithmic scale to ensure the baseline was within the 
exponential part of the plot, i.e. the plot appeared linear. The procedure was repeated for 
data from the VIC dye label run. The plate layout was then shown with the brightness of 
the wells indicating the final amount of PCR product generated in the particular well. 
The wells containing samples should have been bright whilst the no template control 
should be dark. The raw numerical data was exported from the computer. The data was 
in the form of threshold cycle (Ct) which is the time point expressed in the number of 
PCR cycles at which the fluorescence signal generated by probe cleavage reaches a 
detectable threshold. The relative quantity of the gene of interest (FAM) was expressed 
as a percentage of the house keeping gene (VIC). This was calculated in the following 
way; for each sample the value of FAM Ct subtracted from VIC Ct was calculated (the 
number of additional cycles required for FAM to reach the threshold level compared to 
VIC). The value of 2 to the power of this difference was calculated (every cycle will 
double the amount of DNA, therefore this represents the fraction of the gene of interest 
compared to the housekeeping gene), this value was expressed as a percentage of the 
housekeeping gene.
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2.7 ECTONUCLEOTIDASE ACTIVITY
2.7.1 Preparation of ATP assay kit
The ATP assay kit (Sigma) was prepared as described in the instructions. The assay kit 
contains luciferin and luciferase. Following the addition of the assay kit to a sample 
containing ATP the following reactions occur, the first is catalysed by luciferase; 
luciferin + ATP ► luciferyl adenylate + PPi 
luciferyl adenylate + O2 ^ oxyluciferin + AMP + light
The light intensity produced can be measured by a photomultiplier and is proportional to 
the ATP concentration of the sample.
The assay mix was dissolved in 5 ml of sterile water and frozen at -20°C in 100 pi 
aliquots. The assay mix dilution buffer was dissolved in 50 ml of sterile water and store 
at 4°C. The ATP assay mix was diluted 25-fold with the assay mix dilution buffer when 
used for determining the ATP standard curve and in sample analysis. The diluted mixed 
was prepared daily.
2.7.2 Preparation o f Tissue
Guinea pig bladder strips of approximately 20 mg (dimensions -  3 mm diameter x 4 mm 
length) were cut and the urothelium was removed. Each strip was cut into two before 
being incubated to increase the surface area of the tissue sample, in order to aid diffusion
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of the ATP into the tissue. Tissue samples were placed in plastic test tubes containing 3 
ml of HEPES-buffered Tyrode's solution.
Human detrusor samples were cut to give four pieces, each sample weighing 
approximately 20-40 mg, and frozen. The frozen samples were then thawed at room 
temperature in 3 ml of HEPES-buffered Tyrode's solution, in a plastic test tube, prior to 
the experiment.
2.7.3 Luminometer
The luminometer used was a Lumistar Galaxy (BMG Labtech Ltd, Aylesbury, UK). The 
Lumistar was connected to a computer with the corresponding dedicated acquisition 
software written and configured by BMG Labtech Ltd. Samples were measured in 96- 
well plates (Optiplate, Packard). The luminometer was set to inject 100 pi of the ATP 
assay mix into each well that contained a sample or standard just prior to the 
measurement being taken. Each well that contained a sample or standard was measured 
for ten seconds. To ensure adequate mixing of the sample and ATP assay mix the plate 
was shaken throughout measurement. The parameters for shaking were set for orbital 
shaking with a diameter of 3 mm.
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2.7.4 ATP standards
A standard curve was performed every day prior to samples being tested. The gain was 
determined for each set of standards and samples by using the instruments internal gain 
adjustment. The instrument measures the well containing the standard with the highest 
ATP concentration several times and sets a gain accordingly.
The standards were prepared by performing a serial dilution of a 10 mM ATP stock 
solution. Tyrode's solution containing 5 mM EDTA and no added calcium was used for 
dilution. The standards’ concentration range was 0.01 pM to 30 pM.
Relative Light Units
2 10'
1.5 10'
1 10'
5 10'
0 10'
0 5 10 15 20 25 30
pM ATP
Fisure 2.2 Calibration plot o f ATP standards. (n - 3 ) Mean ±  s.d
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2.7.5 Experimental protocol
Two of the four pieces of detrusor cut from each sample of human or guinea pig bladder 
were used as controls and the other two were used to test the effect of the 
ectonucleotidase inhibitor ARL 67516.
Both control and test tissue samples were placed in plastic test tubes containing 3 ml of 
warmed Tyrode’s solution. The test tubes were placed in a shaking water bath (Grant 
SS40-2, Grant Instruments, Cambridge) heated to 37°C and left to equilibrate for 
approximately 30 minutes. Following equilibration the tissue samples were transferred 
carefully using tweezers to a tube containing 950-990 pi of either Tyrode's, (control) or 
Tyrode’s with 100 pM ARL 67156, (test). Both solutions had been warmed to 37°C in 
the water bath. Samples were left for 10-15 minutes shaking in the water bath prior to the 
addition of one of five concentrations of ATP, in order to measure the rate of ATP 
breakdown.
At time zero 10, 20 or 50 pi of a stock ATP solution (10 mM or 100 mM) was added to 
each of the control and test samples to give a final ATP concentration of either 200 pM, 
500 pM, 1 mM, 2 mM or 5 mM and in each case a final volume of 1 ml. The samples 
were left in the heated water bath shaking for 30 minutes. At set time points (0, 5, 10, 20, 
30 minutes) 10 pi aliquots of each sample were taken. When investigating the 
degradation of 200 pM and 500 pM the 10 pi aliquots taken were immediately placed in 
eppendorf tubes containing 990 pi of chilled calcium-free Tyrode's solution containing
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5m M EDTA. During 1, 2 and 5mM ATP degradation two 10 |xl aliquots were taken at 
each of the five time points and placed in separate eppendorf tubes containing 1.99ml of 
chilled calcium-free Tyrode's containing 5mM EDTA. Following addition of the 10 pi 
aliquots to the eppendorf tubes the samples were vortex-mixed (Genie 2, Scientific 
Industries) and stored in the fridge for same-day anaylsis.
Each tissue sample was used to assay the rate of ATP breakdown over the entire range of 
ATP concentrations, starting with the lowest concentration. In between each ATP 
concentration the tissue sample was washed in 3.5 ml of fresh warmed Tyrode's solution, 
in a test tube placed in the shaking water bath for 15 minutes. Following washing, the 
tissue samples were transferred to 950-990 pi (depending on the concentration of ATP to 
be tested) of Tyrode's solution or 100 pM ARL 67156 Tyrode's solution and incubated 
for 10 minutes in the water bath prior to the addition of the next ATP concentration to be 
tested. Once all ATP concentrations had been studied each tissue sample was weighed.
2.7.6 Measurement o f ATP.
To determine the rate of degradation of each ATP concentration the diluted aliquots 
taken from each time-point, at the five ATP concentrations, were assayed for ATP using 
the luciferin-luciferase assay.
From each of the diluted sample aliquots 100 pi was pipetted into wells of a white 96- 
well plate (White 96-well Optiplate, Perkinelmer). The samples were spaced out on the
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plate, in order to limit the effect of cross-over between wells affecting the recorded 
measurement.
2.8 AMPEROMETRIC ATP DETECTION
2.8.1 Experimental set up - tissue
Guinea pig bladder was the tissue used in experiments measuring the release of ATP 
from detrusor. The bladder strips were prepared following the same method as those in 
the tension experiments (see section 2.3). The one difference was the size of the strip. As 
larger strips were required they were cut slightly wider and ran the whole length of the 
bladder, from base to dome. The strips were approximately 2 mm wide and between 7-10 
mm in length.
The strips were secured into the horizontal organ bath and superfused with Tyrode’s 
solution containing 2 mM glycerol and was constantly gassed with 95% O2 , 5% CO2  
mixture and warmed to 37°C. The flow rate of the superfusate was 2 ml.min'1. The strips 
were lengthened using micromanipulators until a maximal contraction was achieved 
whilst ensuring minimal tissue movement.
All solutions used for interventions were warmed to 37°C in the water bath and gassed 
with a 95% O2 , 5% CO2 mixture. All solutions were prepared with Tyrode's solution 
containing 2 mM glycerol.
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2.8.2 Experimental set up - biosensors
The ATP biosensor (Sarrisaprobe™-ATP, Sarrisa Biomedical Ltd, Coventry, UK) 
electrode is a needle shaped microelectrode constructed of Pt/Ir wire that is coated at the 
end with a polymer containing specific enzymes. The electrode specifications are shown 
in Table 2.4. In the presence of glycerol ATP is ulilised by the enzymes to give a final 
product of H2 O2 which can be detected amperometrically by the electrodes. The null 
electrode (SA10002, Sarrisa Biomedical Ltd, Coventry, UK) is essentially the same as 
the ATP biosensor except that the polymer coat lacks any enzymes.
Table 2.4 ATP Biosensor specifications
Sensor length (tip) 2 mm x 50 pm (diameter)
Response time 10-90% rise time <10 seconds
Linear range 0.5 pM to 50 pM
Sensitivity 0.5 nA per pM
Both ATP and null electrodes were purchased dehydrated and were stored at 4°C. 
Rehydration required the electrode tip to be immersed in Tyrode’s solution containing 2 
mM glycerol for approximately 10 minutes. Once hydrated it was important to minimise
107
exposure of the electrodes to air. Hydrated electrodes could be stored in Tyrode’s 
solution at 4°C and used for up to 5 days. Due to reduction in electrode sensitivity the 
electrodes were discarded after two sets of experiments.
Prior to rehydration, the electrodes were carefully bent 80° to enable them to lie across 
the top of the tissue. They were bent at the point where the Pt/Ir wire becomes visible and 
the enzyme-containing plastic coating ends.
The ATP and null biosensors were connected to a potentiostat (MicroC low-noise carbon 
fibre potentiostat, World Precision Instruments Ltd, Aston, UK) via Triax shielded 
cables. The potentiostat specifications are listed in Table 2.5.
A Ag/AgCl reference electrode was placed in a 3 M-KC1 salt bridge, the tip of which was 
immersed in the superfusate solution in the bath. The reference electrode was connected 
to the two potentiostats to act as a reference for both the ATP and null biosensors. This 
electrode was at the same ground potential for the bath and measuring equipment.
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Table 2.5 Potentiostat specifications
Electrode polarisation 
voltage 0.65 V (adjustable from 0 to 2 pA)
Current ranges 2000 pA, 20 nA, 200 nA, 2 pA
Current/voltage 
conversion factor From 1 pA.mV'1 to 1 nA.mV'1
Rise time 1 millisecond
Micromanipulators were situated on the table next to the bath and were positioned 
appropriately prior to mounting the sensors so as to reduce the risk of air exposure and 
damage. Once the ATP and null biosensors were inserted into the holders they were 
quickly lowered into the bath so that they were submerged in the superfusate. With the 
use of a binocular microscope the biosensors were positioned side-by-side in the 
superfusate above the tissue as far from the embedded platinum stimulating electrodes as 
possible. This was to minimize the effect of a stimulation artefact on the recording.
109
Isometric force 
transducer
Reference
electrode
Superfusate filled 
organ bath
Guinea pig detrusor 
strip
Pt electrode-
ATP biosensor Null biosensor
Static hook
Figure 2.3 Diagram showing the positioning o f guinea pig detrusor muscle and 
biosensors used for measuring the release of ATP.
When the biosensors were in a satisfactory position the potentiostats were switched on 
and the sensors began polarizing. It could take up to 10 minutes for polarization to take 
place. The polarization potential was set at 500 mV.
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2.8.3 Experimental set-up -  recording
The signals produced by the sensors and measured by the potentiostats were recorded on 
a computer. The potentiostats were connected to the computer via an analogue-to-digital 
converter. The software program used was Clampex (pClamp Axon Instruments), which 
enabled the two biosensors signals and the tissue tension to be recorded along with a 
differential measurement. This differential measurement, which is the actual ATP signal, 
was attained using a home-made DC differential amplifier that subtracts the null signal 
from the ATP signal. The amplifier had a common mode rejection ratio of 1 in 10,000.
2.8.4 Biosensor calibration
Calibration of the electrode was performed at the beginning and end of each experiment 
and at least once during the experiment to ensure electrode sensitivity was satisfactory. 
The calibration was performed in situ when 10 pM ATP in 2 mM glycerol Tyrode’s 
solution was gassed with 95% O2 5% CO2 and superfused to the tissue and sensors, a 
sample is shown in Figure 2.4. The electrodes display a linear response to ATP over the 
concentration range 200 nM to 50 pM (Llaudet et al, 2005) and therefore a one point 
calibration is recommended by the manufacturers.
I l l
V50 s
Fieure 2.4 Sample calibration recording for 10 uM ATP
2.8.5 Experimental protocol
Before the sensors were positioned the tissue was stimulated at 8 Hz until isometric 
phasic tension reached a steady level. The stimulation parameters were the same as those 
described for the tension experiments (see section 2.3) except the interval between 
stimulation trains was 110 seconds. An optically-isolated constant-voltage stimulator 
(DS2 Digitimer, Hertfordshire, UK) to minimise pick-up of stimulation artefacts was 
connected between the stimulator and platinum electrodes in the bath. The output voltage 
was adjusted to achieve a satisfactory steady level contraction of the tissue and minimal 
stimulation artefact on the sensor recordings. The stimulator was switched off whilst the 
sensors were being placed on the preparation and subsequently polarized.
Following polarization a 10 pM ATP calibration was performed. If successful the 
experiment continued with a set of controls whereby the electrodes remained in the 
superfusate, off the tissue. The first control was the generation of a force-frequency curve 
by stimulating the strips at a range of frequencies, between 1 and 24 Hz. The other
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controls consisted of generating contractures using 3 pM carbachol and 120mM KC1. 
This was to determine the extent of ATP release from contraction of the muscle itself. 
Before the sensors were placed on the tissue a further 10 pM ATP calibration was carried 
out. Following the controls and calibrations, using the micromanipulators, and aided by a 
binocular dissection microscope, the sensors were placed on the tissue. The best results 
were obtained when the sensors were lowered sufficiently so that they were slightly 
embedded in the tissue and no longer visible. The electrodes were often repositioned a 
number of times in order to obtain a response that was not effected by movement of the 
muscle. The sensors were placed as far from the Pt stimulating electrodes were 
positioned close together to reduce interference.
With the sensors in place a force-frequency curve was generated to measure release of 
ATP at the various stimulation frequencies (1-24 Hz) and the 3 pM carbachol and 120 
mM KC1 contractures were repeated. The effect of 100 pM atropine, ABM A and 
nifedipine, individually or combined, on the ATP released during the force-frequency 
curve or at fixed frequencies was examined. A force-frequency curve in the presence of 
TTX was always generated at the end of each experiment, followed by a final 10 pM 
ATP calibration.
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Scheme 2.1 Block diaeram o f the set-up for measuring ATP release from guinea pis 
detrusor strips.
2.9 DATA PRESENTATION AND STATISTICAL ANALYSES
Data sets are presented at means ± standard deviations, unless otherwise stated. Data 
from the RT-PCR measurements are expressed as medians and 25%, 75% interquartiles 
because these are derived from logarithmic transformations of the primary 
measurements. To test for significance between data sets, paired or unpaired Student’s t- 
tests were used for mean data sets. For median data sets a Mann-Whitney U-test was 
used. The null hypothesis was rejected when p>0.05.
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3.0 Results
3.1 TENSION EXPERIMENTS
3.1.1 Nerve mediated contractions
The muscle strips of both guinea pig and human detrusor were allowed to equilibrate at a 
stimulation frequency of 8 Hz and 20 Hz respectively for up to 1 hour. The stimulation 
frequencies were chosen as they have previously been determined to generate half- 
maximal tension.
The mean maximum nerve-mediated force estimated from force-frequency curves by 
guinea pig from the force-frequency was 27.7 ± 17.4 mN.mm'2 (n=57). The mean tension 
at 8 Hz (11.9 ± 7.2 mN.mm'2) was 43 ± 19.5% of the maximum force. The mean half 
maximal frequency (fy2) for guinea pig strips was 9.5 ± 3.5 Hz.
For the stable human detrusor strips the estimated mean maximum force generated 
during the force frequency was 27.2 ± 20.4 mN.mm'2 (n=25). The mean tension at 20 Hz 
was 11.7± 5.4 mN.mm' . For this group of samples the mean fVi was 15.9 ± 7.0 Hz.
For the combined overactive human detrusor group (n=28) the estimated mean maximum 
force generated was 24.3 ± 15.4 mN.mm'2 with a mean Wi of 19.9 ±11.2 mN/mm2. In 
this group the mean tension at 20 Hz was 14.6 ± 13.2 mN.mm'2.
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The estimated maximum force values, fi/ 2  values and mean tension achieved at 20 Hz 
were not significantly different between the stable and overactive human groups.
% max force
1 0 0  -i
80-
60-
40-
2 0 -
0 5010 20 30 40
Frequency (Hz)
Fieure 3.1 Force frequency curves for guinea pis and human stable and overactive 
detrusor strips as percentage o f estimated maximal tension: Guinea pis, circles: stable 
human, diamonds: overactive, squares. Mean values ±s.d.
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3.1.2 Atropine resistance
At the end of the tension experiments guinea pig and human tissue was stimulated at 8  
Hz and 20 Hz respectively in the presence of the muscarinic antagonist atropine (1 pM). 
This was followed by the addition of tetrodotoxin (TTX) which blocks the release of 
neurotransmitters from the nerve. In the presence of TTX contractions were abolished 
indicating there was no direct muscle stimulated component of contraction. The atropine 
resistant component was calculated as the TTX-sensitive contraction after the addition of 
atropine.
In guinea pigs, two neurotransmitters initiate contraction, acetylcholine (Ach) and ATP 
(Bayliss et al, 1999). Atropine blocks the Ach-dependent component. Force-frequency 
curves were generated in the presence of atropine and the mean maximum force was 
reduced to 41.9% of that in control conditions (12.9 ± 6.95 mN.mm'2). The mean P/ 2  
value, 14.06 ± 11.84 Hz, was not significantly different from that in the presence of 
atropine. The mean tension generated at 8 Hz was also reduced to 5.03 ± 3.26 mN.mm'2.
When atropine was added to the stable human preparations the contractions were 
completely abolished in all but three of the 25 strips. The lack of atropine resistant 
contractions in human stable bladder samples agrees with previous observations. With 
the three preparations where atropine resistance was observed the donor patients did not 
have urodynamic assessments prior to operation and for the reason categorised as stable.
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In contrast to samples from stable human bladders, atropine-resistant contractions have 
been demonstrated in some bladder pathologies (Bayliss et al, 1999). This nerve- 
mediated atropine resistance could be eliminated by desensitising the P2X receptors with 
ABM A, implying the contraction was activated by ATP. In the combined over-active 
human group 11 of the 28 samples showed some atropine resistance. In the presence of 
atropine the median maximum force generated was reduced to 13.8% of that in control 
conditions. The mean Wi was 13.8 ± 6.4 Hz, as shown in Figure 3.4 was significantly 
reduced in the presence of atropine. The percentages of atropine resistance for the 
samples of each group are shown in Figure 3.2 and force frequency curves in guinea-pig 
and overactive human detrusor samples in the presence of atropine are shown in Figure 
3.3.
% atropine resistance
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Figure 3.2 Percentage o f atropine resistance for each guinea-pig. stable and overactive
human detrusor samples (circles). Median and 25th and 75m auartiles (squares).
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Fisure 3.3 Force-frequency plot for guinea p is and over active detrusor strips in the 
presence o f 1 uM atropine as percentage o f estimated maximal tension in control 
conditions: Guinea pis, circles: overactive, squares. Mean values ±s.d.
f (Hz)
1/2V '
Fieure 3.4. Estimated fm values for overactive human detrusor in the presence (white) 
and absence (black) o f  1 uM atropine: n = l l ,  mean values ±s.d.
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3.1.3 Apyrase experiments
The role of ectonucleotidases has been implicated in atropine resistance therefore the 
affect of the enzyme apyrase on each of the tissue groups was investigated. Apyrase 
hydrolyses ATP and ADP to AMP and thus, should increase the rate of ATP breakdown. 
All solutions were prepared in HEPES-buffered Tyrode's solution. When apyrase was 
added to the preparations the superfusion system was switched off because of the 
expense of the compound. The flow was stopped for a period of 15minutes. 
Consequently control experiments were performed to ensure that cessation of the flow 
did not have an effect on the contractile parameters.
Force frequency curves were constructed in flow and no-flow conditions (n=19). Figure
3.5 shows that the force frequency relationships were not significantly different. With 
superfusate the mean maximal force was 34.2 ±15.6 mN.mm 2 and with no flow it was 
29.7 ± 13.5 mN.mm' . When guinea pig and human tissue preparations were stimulated 
at fixed frequencies in a no-flow condition for 15 minutes there was very little change in 
the force of contractions compared to when the superfusate was flowing (Figure 3.6). 
However, all apyrase interventions were compared to the control no-flow intervention. 
To ensure changes in tension could be observed in the no-flow situation the calcium 
concentration of the HEPES solution added during a no-flow episode was raised from 1. 8  
mM to 3.6 mM and 7.2 mM. The augmentation of tension seen with increasing calcium 
concentration when the solution was flowing, was the same as when the flow was 
stopped. Therefore, the cessation of flow for a brief interval did not per se affect the
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contractile properties of the preparation or their ability to respond to inotropic 
intervention.
Tension (mN.mm2) 
50 n
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Figure 3.5 Force-frequency curves o f guinea pig detrusor preparations in superfusate 
flow (circles) and no-flow (squares) conditions. mean values ± s.d.
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3 min
No Flow
Figure 3.6 Sample trace o f guinea pig detrusor preparation during a no-flow condition 
for a 15 minute period. Tissue was stimulated at 8 Hz.
3.1.4 Apyrase experiments -guinea pig detrusor
Apyrase (10 U .m l1) reduced significantly tension elicited at 16 Hz stimulation when 
compared to control. This effect of apyrase was completely and rapidly reversed on 
return to control solution (see Figure 3.7). In 21 experiments the tension was reduced to
81.5 ±1 4.5 % of control. Ayprase also caused similar significant reductions of tension 
when the frequency was fixed at 2, 4 and 8 Hz when compared to control. These results 
are summarised in table 3.1.
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Apyrase 10 U.ml
Figure 3.7 Sample trace showing the effect o f apyrase on 16 Hz. nerve-mediated 
contraction o f guinea pig detrusor. Apyrase was present for 15 minutes.
3.1.5 Apyrase experiments -human detrusor; stable bladders
Apyrase had no significant effect on the contraction elicited by 24 Hz stimulation (n=12), 
Figure 3.8. The mean tension achieved at 24 Hz stimulation in apyrase was 103 ± 16 % 
of that in control. Preparations were stimulated at 24 Hz as this frequency is just above 
the estimated i\n  for this tissue.
The lack of effect of apyrase is consistent with the hypothesis that there is no ATP 
component of contraction in human detrusor from stable bladders.
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3 min
Apyrase 10 U.ml'1
Figure 3.8 Sample trace showing the effect o f apyrase on 24 Hz. nerve-mediated 
contraction o f stable human detrusor
3.1.6 Apyrase experiments -human detrusor: overactive bladders
The human preparations from overactive bladders were stimulated at 24 Hz in the 
presence of apyrase for 15 minutes. The result was a significant reduction in the tension 
generated, Figure 3.9. The mean tension was decreased to 87.5 ± 7.5 % compared to 
control (n=14). When the frequency was fixed at 4, 8, 16 and 20 Hz apyrase caused a 
reduction in the tension generated however the reductions were not significant. This may 
be due to the low sample numbers. In all experiments where there was a reduction, 
contractions returned to pre-apyrase tension upon return to HEPES solution.
As with the guinea pig preparations the reduction caused by apyrase in the overactive 
strips indicates that a proportion of the nerve-mediated contraction is initiated by ATP 
and that by increasing its hydrolysis the contraction tension can be reduced.
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Apyrase (10 U.ml'1
Figure 1 9  trace showing the effect of 10 U.ml'1 Apyrase on 24 Hz nerve
mediated contraction o f human detrusor from overactive bladders
Table 3.1 Summary o f results o f effect o f apyrase in guinea pis and over active human 
detrusor at various fixed frequencies. * indicates significant difference from control.
p<0.05 unpaired Student’s t-test
Fixed Frequency (Hz) % reduced to by 
apyrase -  guinea pig
% reducted to by 
apyrase -  over active
2 80.1 ±8.3* 
(n=6)
-
4 78.7 ± 11.2* 
(n=8 )
97.4 ±13.6 
(n=2 )
8 79.9 ± 14.3* 
(n=l 1 )
95.7 ± .3 
(n=4)
16 81.5 ± 14.5* 
(n=2 1 )
95.3 ± 6.4 
(n=5)
2 0 - 90.1 ± 17.2 
(n=ll)
24 - 87.5 ±7.5* 
(n=14)
The percentage reductions caused by apyrase on fixed-frequency nerve-mediated 
contractions of guinea pig (16 Hz) and human detrusor (24 Hz) are summrised in Figure 
3.10a. Reduction in both guinea pig and overactive human detrusor groups were 
significant with a greater attenuation in the guinea pig samples. This is in concord with 
the larger ATP-dependent component of contraction in guinea pig compared to 
overactive human detrusor. Comparing Figure 3.10a and 3.10b (reprint of Figure 3.2 for 
comparison with Figure 3.10a) shows that atropine and apyrase have the greatest effect in 
guinea-pig detrusor, little or no effect in detrusor from stable bladders and an 
intermediate effect in detrusor from overactive human bladders.
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Fieure 3.10a Effect o f apyrase on fixed frequency nerve-mediated contractions in 
detrusor from guinea p is  (16 HzMblue) and overactive (red) or stable (sreen) human 
bladders (24 Hz). Mean ± standard deviation (squares). * indicates significant difference 
from control. p<0.05 unpaired student’s t-Test
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Figure 3.10b (reprint o f Figure 3.2 for comparison with Figure 3.10a) Percentage of 
atropine resistance for each guinea-pig, stable and overactive human detrusor samvles
(circles). Median and 25th and 75th auartiles (squares).
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3.1.7 ARL 67156 effects on guinea pig detrusor
An alternative way of manipulating ectonucleotidase activity in detrusor samples was to 
inhibit activity using the ectonucleotidase specific inhibitor ARL 67156 (100 pM). A 
concentration of 100 pM was used as this concentration was used previously to inhibit 
ATP action whilst not effecting P2X receptors (Crack et al, 1995; Westfall et al, 1997). 
The trace in Figure 3.11 shows the effect of 100 pM ARL 67156 on a guinea pig strip 
stimulated at 16 Hz. The inhibitor caused a rapid increase of tension which was 
completely reversible upon return to Tyrode's solution.
In a number of experiments (n=6) 100 pM ARL 67156 caused a significant average 
increase in tension of 28.6 ± 20.3 % compared to control as shown in Figure 3.12. With 
the inhibition of ectonucleotidase activity and therefore a reduced breakdown of ATP 
there is an increase in contraction.
2
ARL 67156
Figure 3.11. Sample trace showing the effect o f 100 uM ARL 67156 on 16 Hz nerve 
mediated contraction o f guinea pig detrusor
4 mN.mm
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Fisure 3.12 Effect o f 100 uM  ARL 67156 on fixed frequency (16 Hz.) nerve-mediated 
contractions o f suinea pis detrusor. * p<0.05 unpaired Student's t-test
The effect of ARL 67156 in the presence of atropine was recorded in four samples to 
observe the effect of the inhibitor on the ATP component of contraction only. In Figure 
3.13 the control bar is the contraction in the presence of atropine alone. When ARL 
67156 was added mean tension significantly increased by 19.0 ± 6 . 8  %. This further
Control ARL 67156
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implied that the increase of tension was due to an increase of the ATP component of 
contractile activation.
% force
Control ARL 67156
Fisure 3.13 Effect o f 100 uM ARL 67156 on fixed frequency (16Hz) nerve-mediated 
contractions in the presence o f atropine in guinea pig detrusor. Control: black, ARL 
67156: white. .* p<0.05 unpaired Student's t-test
3.1.8 Summary o f results
In guinea-pig and human detrusor from overactive bladders increasing addition of 
apyrase, and thus increasing ATP breakdown, reduced the force of contraction. This was
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unlike in detrusor from stable human bladders where apyrase was without effect. The 
lack of atropine resistance and effect of apyrase in human samples from stable bladders is 
consistent with the hypothesis that breakdown of ATP released due nerve stimulation is 
complete. Atropine resistance and an apyrase effect in samples from overactive human 
bladders indicate an incomplete degradation following nerve stimulated release. 
Inhibition of ectonucleotidase in guinea-pig detrusor by ARL 67156 resulted in an 
increase in contraction force. These results show that modulating ectonucleotidase 
activity, and therefore ATP breakdown, can alter the force of nerve mediated contraction 
in detrusor smooth muscle when there is an atropine resistant component to contraction.
132
3.2 TOTAL RNA ISOLATION
3.2.1 Extraction and assessment
After extraction of RNA from human detrusor samples using the RNAeasy kit the RNA 
samples were analysed to determine if they were suitable for use in further gene 
expression studies. Preparation of RNA can result in its degradation and introduce 
contaminants, therefore the condition of the RNA has to be established. This was 
achieved using the Aligent 2100 Bioanalyser and the RNA 6000 Labchip kit which 
checked for both integrity and purity. The technique used electrophoresis to separate the 
RNA transcripts according to their mass and an intercalating dye to detect the RNA. All 
data were recorded by computer.
On each chip a standard ladder was run with fragments of 0.2, 0.5, 1, 2, 4 and 6  kbases. 
The gel-like image of the ladder can be seen in lane one of each of the gels in Figures 
3.15 to 3.17. An example of the electropherogram for the ladders is shown in Figure 
3.14. The ladder should appear as six discrete bands on the gel-like images and six peaks 
on the electropherogram. A successful sample should appear as two discrete bands, one 
for each of the ribosomal 18s and 28s. The sample electropherogram should show two 
separated peaks. Each ladder and sample also contains a marker which appears as the 
bottom band on the gel and the first peak on the electropherogram to indicate that a 
sample was loaded. The experimental group (i.e. from stable or overactive bladders) of 
the different sample numbers is shown in Table 3.2 at the end of this section.
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Fisure 3.14 Electropherogram showing an RNA 6000 standard ladder which has 
fragments o f 0.2, 0.5, 1, 2. 4 and 6 kbases eluted over time (seconds). The gel-like image 
of the ladder is shown on the right hand side.
The gel-like image for each of the samples can be seen in Figure 3.15 to 3.17. The gel in 
Figure 3.15 shows the results for samples A, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11. All 
samples except 8 and 9 in lanes 4 and 2 respectively showed discrete ribosomal 18s and 
28s bands. Sample 8 showed very faint bands whilst no band could be observed for 
sample 9.
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Samples 13 to 24 are shown on the gel-like image in Figure 3.16 with only samples 13, 
15 and 24 showing only two discrete bands. Samples 17, 19, 20, 21 and 22 showed faint 
bands or no bands at all. Although sample 16 in lane 4 showed the ribosomal 18s and 28s 
bands there was a third band indicating contamination. Lanes 2, 6  and 11 show samples 
14, 18 and 23 as smeared bands indicating degradation of the sample.
The gel-like image in Figure 3.17 shows samples 25 to 31 in lanes 6  to 12. The two 
ribosomal bands were present in samples 25, 26, 27 and 28 however no bands could be 
seen in samples 29, 30 and 31.
Some samples were prepared and run a second time due to their equivocal appearance on 
the first run. These samples were 8 , 14, 16, 19 and 20 and are shown in lanes 1 to 5 in 
Figure 3.17. Of the repeated samples only sample 19 showed two discrete bands.
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Figure 3.15 Gel like image o f total RNA extracted from human detrusor samples. Lane L 
(far left) shows the RNA 6000 ladder. lanes 1 to 12 show detrusor samples A to 11.
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Figure 3.16 Gel-like image o f total RNA extracted from human detrusor samples. Lane L 
shows the RNA 6000 ladder, lanes 1 to 12 show detrusor samples 13 to 24.
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Fieure 3.17 Gel-like image o f total RNA extracted from human detrusor samples. Lane L 
shows the RNA 6000 ladder. lanes 6 to 12 show detrusor samples 25 to 31 and lanes 1 to 
5 show repeats o f samples 8, 14, 16, 19 and 20.
The decision to include or exclude an RNA sample in further studies was determined by 
the appearance on the gel and the resolution of the two ribosomal, 18s and 28s, 
fluorescent peaks. Figure 3.18 shows electropherogram examples of: i) a non-degraded 
sample with no contamination; ii) a degraded sample; iii) a sample with a contaminate.
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Figure 3.18 Electropherograms showing examples of: A. a non-degraded sample with no 
contamination; B, a degraded sample; and C. a contaminated sample of human detrusor 
RNA.
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The samples to be used in gene expression studies that were not degraded and did not 
contain impurities were samples are shown in Table 3.2. The samples were separated into 
two groups, stable and overactive human detrusor, also shown in Table 3.2.
Table 3.2 Stable and overactive human detrusor samples that were to be included or 
excluded in further studies
Included Excluded
Human -  stable A, 2, 5, 6 , 7, 10, 11, 
13,24
8 , 12, 16, 17, 18, 
2 0 , 2 2
Human - overactive 1,3,4, 15, 19, 25, 
26, 27, 28,
9, 14, 21, 23, 29, 
30,31
3.2.2 RNA Concentration
For the samples to be used in gene expression analysis the RNA concentration was 
determined using the Genequant calculator spectrophotometer. The equipment had an 
internal calibration which enabled the sample concentrations to be determined. The 
absorbance at 260 and 280 nm was measured. The purity of the samples was measured 
by the Genequant as the A260/A280 ratio. A ratio of approximately two indicates good 
purity (Genequant website). The concentrations and ratios of the samples are shown in 
Table 3.3. The ratios obtained are close to the preferred value of two implying the 
samples are pure which concurs with the gel images and electropherogram results.
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Table 3.3. RNA sample concentration and A260/A280 ratio
Sample
group
Sample Concentration
pg/pl
260/280 ratio
A 0.028 1.84
2 0.107 2
5 0.087 1.92
6 0.107 1.95
Stable 7 0.016 1.97
1 0 0.038 1.96
1 1 0.064 1.96
13 0.067 2 . 1 1
24 0.033 1.94
1 0.063 1.98
3 0.026 2.133
4 0.050 1 . 8 8
Overactive 15 0.052 2 . 1 0
19 0.137 2 . 1 0
25 0.091 2.16
26 0.079 1.97
27 0.061 1.92
28 0.062 1.95
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3.3 RELATIVE EXPRESSION OF ENTPDASE 1, 2 ,3 , AND 5 GENES
After determination of the RNA concentration of each of the human detrusor samples 
they were reverse transcribed to cDNA. This enabled TaqMan RT-PCR to be performed 
on each of the samples to investigate the expression of ENTPDase 1, 2, 3, and 5 genes in 
human bladder. E-NTPDase 1, 2 and 3 were investigated because they are surface bound 
enzymes that could degrade nerve-mediated released ATP in the neuromuscular junction 
and may therefore influence contractile function. E-NTPDase 5 was selected from the 
intracellular membrane bound ectonucleotidases as a control to compare relative 
expression levels and any differences between the two sample groups.
In the TaqMan RT-PCR as amplification of the gene of interest and the endogenous 
control continues with each cycle with a threshold cycle ( C t )  is reached. This is the time- 
point expressed in the number of PCR cycles, at which the fluorescence signal generated 
by probe cleavage reaches a detectable threshold. FAM was the reporter dye for the gene 
of interest probe and VIC for the 18s endogenous control. The lower the Ct number the 
greater the amount of gene present in the original detrusor sample.
3.3.1 ENTPDase 1
Each of the samples was prepared and measured in triplicate, the CT numbers for the 
triplicates were averaged to give a Ct number for ENTPDase 1 gene in each sample. The
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18s control CT average of all the samples taken as the average of the triplicate averages, 
was 16.02 ± 0.73 and the Ct average for ENTPDase 1 was 27.67 ± 0.88.
The detrusor samples were then separated into two groups, stable and overactive, to 
determine if there was any difference in the expression of ENTPdase 1 gene between 
them (Figure 3.19). The average Ct numbers for the 18s control were not different 
between the two groups (values). However, there was a significant difference between 
the two groups in the expression of ENTPdase 1 gene. Average Ct for the stable samples 
was 27.22 ± 0.5 and the overactive group was 28.1 ± 1.0, indicating reduced RNA levels 
in the overactive group.
Further analysis of the data was carried out to incorporate the internal control data in the 
results. The proportion of transcript of the gene of interest present compared to that of 
control (18s) was determined for each sample. A comparison of the medians (25th and 
75th quartiles) of the relative quantity of ENTPDase 1 between stable and overactive 
detrusor is shown in Figure 3.20. The median relative quantity of ENTPDase 1 in stable 
detrusor was 0.0336 (quartiles 0.0291 and 0.0371) compared to 0.0276 (quartiles 0.0216 
and 0.0307) in overactive detrusor. When compared, using a Mann Whitney U-rank test, 
the relative quantity of ENTPDase 1 was significantly less in the overactive detrusor 
samples compared to the stable samples.
These results suggest that there is less ENTPdase 1 cDNA present in overactive detrusor 
samples compared to samples from stable bladders.
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Cycle Number 
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Figure 3.19 Comparison of threshold cycle number for VIC labelled control gene (18s) 
(grey) and FAM labelled ENTPDase 1 gene (white) between stable and overactive 
detrusor samples. Mean ± standard deviation. * n<0.05 paired Student's t- test
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Figure 3.20 Comparison o f relative quantity o f ENTPDase 1 gene compared to control 
gene in stable (grey) and overactive (white) detrusor samples. Median. 25th and 75th 
quartiles. *o> 0.05 Mann Whitney U-test.
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3.3.2 ENTPDase 3
The triplicate threshold cycle numbers obtained from the ENTPDase 3 assay were 
analysed in the same way as ENTPDase 1. The control gene Ct value was 15.4 ± 0.8. 
The average Ct value for ENTPDase 3 in all the detrusor samples was 33.8 ± 1.9.
When the samples were separated into the groups of stable and overactive, Figure 3.21, 
there was no significant difference between the either the expression of control or 
ENTPDase 3. The Ct values for stable and overactive samples were 33.8 ±1.5 and 34.5 
± 2 . 1  respectively.
However when the proportion of ENTPDase 3 present compared to that of the 18s 
control was determined there was a difference between the stable and overactive groups. 
The relative median quantity for stable, 0.000362 (quartiles 0.000227 and 00061), was 
significantly greater compared to overactive, 0.00204 (quartiles 0.000311 and 0.000226), 
as shown in Figure 3.22.
When the internal control of each sample was taken into account in the analysis of 
ENTPDase 3, the data showed that there was less ENTPDase 3 cDNA present in 
overactive detrusor samples compared to those which were from stable bladders. 
However, the relative quantity of ENTPDase 3 compared to ENTPDase 1 was only about 
1% and so represented a minor component of overall ENTPDase expression.
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Figure 3.21 Comparison o f threshold cycle number for VIC labelled control gene (18s) 
(grev) and FAM labelled ENTPDase 3 gene (white) between stable and over active 
detrusor samples. Mean ± standard deviation.
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Figure 3.22 Comparison o f relative quantity o f ENTPDase 3 eene compared to control 
gene in stable (grey) and overactive (white) detrusor samples. Median. 25th and 75th 
quartiles. *p<0.05 Mann Whitney - test.
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3.3.3 ENTPDase 2
The triplicate threshold cycle numbers obtained from the ENTPDase 2 assay were 
analysed in the same way as ENTPDase 1. The average control Ct value was 16.9 ± 0.8. 
The average Ct value for ENTPDase 2 in all the detrusor samples was 34.7 ±1 .6  
indicating that ENTPDase 2 was present in the detrusor samples.
When the samples were separated into the groups of stable and overactive, Figure 3.23 
panel A, there was no significant difference between the either the expression of control 
or ENTPDase 2. The Ct value for stable was 34.2 ±1.1 and was 35.1 ±1.9  for the 
overactive samples.
There was also no significant difference in the median relative quantity of ENTPDase 2 
between stable and overactive detrusor samples (Figure 3.23, panel B). Stable detrusor 
samples had a median relative quantity of 0.000417 (quartiles 0.000239 and 0.000808) 
and overactive detrusor samples was 0.000512 (quartiles 0.000304 and 0.000705).
These results suggest that there was no difference in the amount of ENTPDase 2 gene 
present in stable and overactive detrusor samples.
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Figure 3.23 Comparison o f expression o f ENTPDase 2 between stable and overactive 
detrusor samples. A. comparison o f threshold cycle number for VIC labelled control 
gene (grey) and FAM labelled ENTPDase 2 (white), mean ± standard deviation. B, 
comparison of relative quantity, stable (grev), overacvtive (white), median and 25th and
th75 quartiles.
3.3.4 ENTPDase 5
The average cycle threshold number for the internal control gene in all the detrusor 
samples in the ENTPDase 5 assay was 19.1 ±3.2. The Ct value for the ENTPDase gene 
was 33.8 ±1.0 thus indicating the presence of ENTPDase 5 in the detrusor samples.
When the detrusor samples were separated into stable and over-active groups there was 
no significant difference in the mean control and ENTPDase 5 gene Ct values between
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the two groups as shown in Figure 3.24 panel A. The mean control Ct values for the 
stable and overactive groups were 19.4 ± 3.4 and 18.8 ± 3.2 respectively and 33.7 ± 0.7 
and 33.9 ±1.2 for the ENTPDase 5 gene.
When the relative quantity of ENTPDase 5 compared to control was compared between 
the two groups, Figure 3.24 panel B, there was no significant difference. The median 
relative quantity of ENTPDase 5 in stable detrusor was 0.00545 (quartiles 0.000796 and 
0.03873) and 0.003123 (quartiles 0.000486 and 0.005828) in overactive detrusor 
samples.
The results show that there was no significant difference in the amount of ENTPDase 5 
in stable detrusor compared with over-active human detrusor.
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Figure 3.24 Comparison o f  expression o f  ENTPDase 5 between stable and overactive 
detrusor samples. A. comparison o f threshold cycle number for VIC labelled control 
gene (grey) and FAM labelled ENTPDase 5 (white), mean ± standard deviation. B, 
comparison o f relative quantity. stable (grey), overacvtive (white), median and 25th and
t h75 auartiles.
3.3.5 Relative quantities o f ENTPDase 1. 2 and 3 expression
When comparing the relative quantity of E-NTPDase 1, 2, and 3 gene expression 
compared to the control gene, E-NTPDase 1 was much greater in both stable and 
overactive human detrusor samples, Figure 3.25.
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Figure 3.25 Comparison of relative quantity o f E-NTPDase 1. 2, and 3 series compared 
to control sene in A ) stable and B) overactive human detrusor samples. median and 25th 
and 75th auartiles.
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The results show that all four ectonucleotidase are present in detrusor from human 
bladders although E-NTPDase 1 expression was significantly greater than E-NTPDase 2, 
3 and 5. Expression of E-NTPDase 1 and 3 was significantly greater in detrusor samples 
from stable bladders compared to those from overactive bladders. Some overactive 
bladders have an ATP component to nerve-mediated contraction which could be a result 
of decreased breakdown of ATP as a consequence of reduced ectonucleotidase 
expression particularly as the highly expressed E-NTPDase 1 is reduced in detrusor 
samples from overactive bladders.
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3.4 ATP DEGRADATION RATE
3.4.1 Guinea pis detrusor
The rate of degradation of five concentrations of ATP by guinea pig detrusor was 
measured over a period of 30 minutes to investigate the activity of ectonucleotidases. The 
measurements of the ATP concentration in the solution surrounding a detrusor strip were 
taken at time points of 0, 5, 10, 20 and 30 minutes. Light units measured by the 
luminometer were converted to ATP concentrations using the ATP calibration curve. 
Figure 3.26 shows an example of the degradation of the five ATP concentrations over the 
thirty minutes. The initial concentrations of ATP plotted in Figure 3.26 and then used to 
determine degradation rates were those measured in the time zero aliquots; ie 
immediately following addition of stock ATP and mixing of the solution containing the 
detrusor sample. The breakdown of ATP followed an approximately linear pattern from 
which the rate of degradation at each concentration was determined. Detrusor samples 
were weighed and therefore rates for each of the detrusor samples could be normalised. 
The calculated rates in this experiment for each concentration are plotted in Figure 3.27 
for total ATPase activity to determine the maximum rate of breakdown (Vmax) and the 
ATP concentration required to produce half the maximum rate (Km).
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Figure 3.26 Example o f ATP degradation over time by guinea pig detrusor. Initial 
concentrations o f ATP were 0.2, 0.5, 1, 2. and 5 mM.
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Fisure 3.27 Plot o f ATP degradation rates at varying ATP concentrations for the 
experiment illustrated in figure 3.26.
155
In eight guinea pig preparations the average ATP degradation rates at each of the five 
ATP concentrations were plotted as shown in figure 3.28. The data from individual 
experiments give an average estimated Vmax of 3.7 ± 2.3 nmol.s^.mg"1 and a Km of 4.32 ± 
2.41 mM for the total ATPase enzyme activity in guinea pig detrusor.
ATP degradation rate 
(nmol.s“1.m g 1)
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Figure 3.28 Average ATP degradation rate in guinea pig detrusor. Mean ± standard 
deviation.
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In order to determine the ectonucleotidase-dependent rate of ATP degradation the 
inhibitor ARL 67156 was used. Figure 3.29 shows an example of the rates of degradation 
achieved at 1 and 5 mM ATP in the presence and absence of 100 pM ARL 67156. ARL 
67156 caused the ATP breakdown rate in the example to be reduced by 11.7% and 
47.3% for 1 and 5 mM respectively in this example. The ARL 67156- sensitive fraction 
of the ATP breakdown rate was taken as the ectonucleotidase rate.
ATP degradation rate 
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2 0 1
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0 .5 -  
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Figure 3.29 Example o f ATP degradation rates at 1 and 5 mM ATP in the absence and
presence o f 100 uM ARL 67156. Control, black: ARL 67156, white.
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In the presence of the ectonucleotidase inhibitor ARL 67156 the average breakdown of 
ATP in the eight guinea pig detrusor preparations was reduced by 19.6 ± 28.8 % with 1 
mM ATP and by 39.1 ± 29.0 % with 5mM ATP (Figure 3.30). In the latter case the 
reduction of activity was significant. A paired Student’s t-test was used to compare the 
rates of degradation of ATP in the presence and absence of ARL 67156. When the initial 
concentration of ATP was 5mM the ectonucleotidase sensitive component rate of 
breakdown was 0.62 ± 0.54 nmol.s'1 .mg'1.
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Figure 3.30 guinea pig - average ATP degradation rate at 1 and 5 mM ATP in the 
presence o f ARL 67156. Control: black, ARL 67156: white. Mean ± standard deviation. * 
p<0.05 paired Student's t-test.
An alternative formulation of the ARL-67156-sensitive component was to calculate the 
Vmax value from the rate vs [ATP] plot in the absence and presence of the inhibitor. The 
difference between the two Vmax values was the desired variable. Figure 3.31 shows the 
average breakdown rates in the absence and presence of 100 pM ARL 67156 over the
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full range of ATP concentrations. The estimated Vmax was significantly reduced from 3.7 
± 2.3 to 2.2 ±1.3 nmol.s^.mg"1. However, the Km was unaltered; 4.32 ± 2.41 vs 3.58 ±
2.33 [aM , respectively.
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Figure 3.31 Average ATP degradation rates at vary ins ATP concentrations in the 
presence (squares) and absence (circles) o f ARL 67156. Mean ± standard deviation. * 
p<0.05 paired Student’s t-test.
To ascertain the rates of the ectonucleotidase activity only, the rates obtained at each 
ATP concentration in the presence of 100 pM ARL 67156 were subtracted from those in
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control conditions. The subtracted rates were plotted (Figure 3.32) to yield an average 
Vmax of 1.1 ± 1.4 nmol.s"1 .mg' 1 and a Km of 1.47 ± 0.99 mM for ectonucleotidase activity 
in guinea pig detrusor.
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Figure 3.32 ARL 67156 sensitive average ATP degradation rates at varying ATP 
concentrations Mean ± standard deviation
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Figure 3.33 shows each of the components of ATP breakdown, total ATPase, ARL 
67156 resistant ATPase and ARL 67156 sensitive ATPase , ectonucleotidase, activity 
over the full range of ATP concentrations tested.
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Fizure 3.33 ATP degradation over a ram e o f  ATP concentrations by suinea vie  
detrusor. Control: circles, ARL 67156 insensitive: squares, ARL 67156 sensitive: 
diamonds. Mean ± standard deviation.
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3.4.2 Human detrusor -  stable bladders
Ectonucleotidase activity was also measured in sample pieces of human detrusor from 
stable bladders. As with guinea-pig samples, the degradation rates with five initial 
concentrations of ATP (0.2, 0.5, 1, 2, and 5 mM) were measured over 30 minutes. Figure 
3.34 shows an example where the concentration of ATP declined at all concentrations 
over this period. The rate of decline was greater as the initial concentration of ATP 
increased, as shown in the plot of Figure 3.35 for this experiment.
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Fisure 3.34 Example o f ATP desradation over time by human detrusor from a stable 
bladder. Initial concentrations o f ATP were 0.2. 0.5, 1, 2. and 5 mM.
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Fisure 3.35 Human detrusor from a stable bladder -ATP degradation rates at varying 
ATP concentrations from the data shown in figure 3.34.
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The average degradation rates in control conditions as a function of the initial ATP 
concentrations are shown in Figure 3.36. The average estimated Vmax for total ATPase 
activity in stable human detrusor (n=13) was 2.4 ± 0.9 nmol.s'1 .mg"1. The average 
estimated Km was 4.47 ± 2.48 mM.
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Fisure 3.36 Average ATP degradation rates in human detrusor from stable bladders. 
Mean ± standard deviation
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When the experiment was performed in the presence of ARL 67156 the rates of ATP 
breakdown at each of the five ATP concentrations were reduced significantly when 
compared to those in control conditions. The bar chart in Figure 3.37 illustrates this at 
two particular concentrations of initial ATP, 1 and 5 mM. The rate at each concentration 
was reduced by a similar amount: 35.5% with 1 mM ATP and 36.4% with 5 mM ATP. 
At 5mM the ectonucleotidase activity resulted in an ATP breakdown rate of 0.51 ± 0.43 
nmol.s'1.mg'1.
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ATP degradation rate
(nm ol.s1.mg'1)
2 . 0 -
1.5-
1 . 0 -  
0 .5 -
o.oJ
1mM 5mM
Intial ATP concentration
Fisure 337  Human detrusor: stable bladders- mean ATP degradation rate at 1 and 5 
mM ATP in the presence (black bars) and absence (whit bars) o f 100 uM ARL 67156 
Mean ± standard deviation. * p<0.05 paired Student’s t-test.
Assuming ARL 67156 is completely effective at inhibiting ectonucleotidase activity the 
breakdown of ATP observed in the presence of ARL 67156 is the result of all ATPase 
activity, except ectonucleotidase activity. The average rates of breakdowns over the ATP 
concentration range in the presence of the inhibitor are shown along with control rates in 
Figure 3.38. The estimated Vmax was significantly reduced with ARL 67156 from 2.4 ±
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0.9 to 1.6 ± 0.7 nmol.s'1 .mg'1; the Km values were similar in the two conditions: 4.47 ± 
2.48 vs 3.46 ± 1.74 mM, respectively.
ATP degradation rate 
(nmol.s'1.mg'1)
2.5
2.0
0.5
0.0
ATP (mM)
Fisure 3.38 Human detrusor: stable bladders - average ATP desradation rates at 
varying ATP concentrations in the presence (circle) and absence (square) o f 100 uM  
ARL 67156. Mean ± standard deviation.
The rate of ectonucleotidase activity was determined by plotting the ARL 67156 
sensitive fraction. This was calculated, as with the guinea pig samples, by subtracting the 
rates obtained at each ATP concentration in the presence of ARL 67156 from those 
obtained in control condition. The average ARL 67156 sensitive rates are plotted in
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Figure 3.39. The Vmax estimated from the plot was 1.1 ±0.4  nmol.s'1 .mg' 1 and the Km 
was 4.45 ± 2.62 mM.
ATP degradation rate 
(nmol.s'1 .mg'1)
0.8
0.6
0 .4 -
0 . 2 -
0.0
ATP (mM)
Fisure 3.39 Human detrusor: stable bladders-ARL 67156 sensitive average ATP 
degradation rates at varying ATP concentrations Mean ± standard deviation.
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ATP deradation rate
(nmol.s'1 .mg'1)
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Fisure 3.40 ATP degradation over a range o f ATP concentrations in human detrusor 
from stable bladders. Control: circles. ARL 67156 insensitive: squares, ARL 67156 
sensitive: diamonds. Mean ± standard deviation.
Figure 3.40 illustrates ATP breakdown over a range of ATP concentrations by total 
ATPase and ARL 67156 resistant ATPase activity and ARL 67156 sensitive, taken to be 
ectonucleotidase activity.
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3.4.3 Human detrusor -  overactive bladders
The same experiments were performed on samples of detrusor from overactive human 
bladders (n=ll). In the control experiments degradation of the five initial concentrations 
of ATP over the 30 minute period followed the same linear pattern of decline as with the 
samples from stable bladders. The amount of breakdown varied with the different initial 
ATP concentrations with increasing breakdown rates at greater concentrations of initial 
ATP. Breakdown rates were calculated for each ATP concentration for each sample. The 
graph in Figure 3.41 shows the average rates of breakdown of ATP in the overactive 
detrusor samples. The estimated Vmax for these samples was 2.0 ± 1 . 0  nmol.s' 1 .mg' 1 and 
the Km was 3.33 ± 1.74 mM.
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ATP degradation rate
(nmol.s’1.mg'1)
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Fisure 3.41 Human detrusor: stable bladders - average ATP degradation rates at 
varying ATP concentrations. Mean ± standard deviation
When the experiments were carried out with the addition of ARL 67156 the degradation 
rates calculated were reduced when compared to control. Figure 3.42 shows that with 
initial concentrations of ATP of 1 and 5 mM the presence of the ectonucleotidase 
inhibitor the breakdown rates were significantly reduced by an average of 35.7 and 
46.8% respectively. The ARL 67156 sensitive component of activity with an intitial ATP 
concentration of 5 mM degraded ATP at a rate of 0.59 ± 0.36 nmol.s' 1 .mg'1.
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ATP degradation rate 
(nmol.s'1.mg'1)
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1.5-
1 . 0 -  
0 .5 -  
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Initial ATP concentration
Fisure 3.42 Human detrusor: overactive bladders - average ATP degradation rate at 1 
and 5 mM ATP in the presence o f 100 uM  ARL 67156. Control: black bars, ARL 67156: 
white bars. Mean ± standard deviation, * p<0.05 paired Student's t-test.
When all the average rates obtained with ARL 67156 were plotted (shown in Figure 
3.43) the estimated Vmax of ATPase activity excluding ectonucleotidases was 
significantly reduced to 1.1 ± 0.4 nmol.s1 .mg' 1 compared to control and whilst the Km at 
3.06 ± 1.43 mM was similar to control.
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ATP degradation rate
(nmol.s'1.mg"1)
2.0
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Fisure 3.43 Human detrusor: overactive bladders - average ATP degradation rates at 
varying ATP concentrations in the presence (squares) and absence (circles) o f 100 uM  
ARL 67156. Mean ± standard deviation.
In a similar way to data from human samples from stable bladders the activity of the 
ARL 67156 sensitive fraction was plotted (Figure 3.44). The average estimated Vmax, 
estimated from individual ARL 67156 sensitive curves was 1.2 ± 0.9 nmol.s'1 .mg" 1 and 
was significantly smaller compared to Vmax of total ATPase activity. The average Km,
3.33 ± 2.48 pM, was not different when compared that for total activity.
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ATP degradation rate
(nmol.s'1.m g 1)
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Figure 3.44. Human detrusor: overactive bladders -  ARL 67156 sensitive average ATP 
degradation rates at varying ATP concentrations. Mean ± standard deviation.
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The components of ATP breakdown measured, total ATPase, ARL 67156 resistant 
ATPase and ARL 67156 sensitive ATPase activity, are shown in Figure 3.45.
ATP degratdatio rate 
(nm ol.s'1.mg‘1)
2.0
0.5-
0.0
0 1 62 3 4 5
ATP (mM)
Fisure 3.45 ATP degradation over a range o f ATP concentrations in human detrusor 
from overactive bladders. Control: circles. ARL 67156 insensitive: squares, ARL 67156 
sensitive: diamonds. Mean ± standard deviation.
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3.4.4 Comparison o f data from stable and overactive human bladder samples
The aim of these experiments was to determine if there are any differences in the ATPase 
activity of stable and overactive human detrusor, in particular the ectonucleodiase 
activity.
When total ATPase activity was compared, Figure 3.46, there was no significant 
difference in the estimated Vmax or Km values between the stable and overactive samples,
2.4 ± 0.9 nmol.s'1 .mg'1, 4.47 ± 2.48 pM and 2.0 ± 1.0 nmol.s1 .mg'1, 3.33 ± 1.74 mM, 
respectively. There was also no difference in the rate of ATP breakdown with 5 mM 
ATP.
However when comparing the V m a x  values between groups in the presence of ARL 
67156 there was a significant difference with a higher V m a x  in stable detrusor, 1.59 ± 0 . 6 6  
nmol.s'1 .mg' 1 compared to overactive samples 1.1 ± 0.4 nmol.s'1 .mg' 1 (Figure 3.47). The 
rate of 5 mM ATP breakdown was significantly greater in the stable group compared to 
the overactive group. There was no difference in the Km values between the groups.
Figure 3.48 illustrates the estimated ARL 67156 sensitive fraction of ATPase activity in 
both stable and overactive human detrusor. There was no significant difference in the 
estimated V m a x  or rate of breakdown of 5 mM ATP between the two groups.
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ATP degradation rate
(nmol.s'1.mg'1)
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Figure 3.46 Comparison o f total ATPase activity in stable (circles) and overactive 
(squares) human detrusor. Mean ± standard deviation.
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ATP degradation rate
(nmol. s-1. mg'1)
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Fieure 3.47 Comparison o f ARL 67156 resistant ATPase activity in stable (circles) and 
overactive (overactive) human detrusor. Mean ± standard deviation.
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Figure 3.48 Comparison o f ARL 67156 sensitive ATPase activity in stable (circle) and 
overactive (square) human detrusor. Mean ± standard deviation.
3.4.5 Summary o f results.
There was an ARL 67156 sensitive component of activity in all three detrusor groups 
indicating ectonucleotidase activity can be estimated by this method. The ARL 67156 
sensitive component depends upon separate measurements in the presence and absence 
of ARL 67156. Therefore there will be error in the estimation of the ARL 67156 
sensitive component which will be a function of the errors inherent in theses two
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experiments. ATPase acitivy has been presented in two ways, firstly through an 
estimation of vmax from the rate vs ATP concentration curves and secondly, by 
presentation of data obtained at one starting concentration, 5 mM ATP. Both approaches 
have inherent problems the Vmax data are only estimations whilst the fixed concentration 
data represent only one sampling point. Table 3.2 shows the Vmax and km values for total 
ATPase, ARL 67156 resistant and ARL 67156 sensitive values for each of the three 
detrusor groups. Table 3.3 shows the rates for the 5 mM ATP data. Similar conclusions 
were drawn from both tables. Table 3.2 shows here was no significant difference 
between the km values in any of the tissue groups for the three fractions of ATPase 
activity. With respect to the absolute values of total ATPase activity, that measured in 
guinea-pig was significantly greater than in both groups of human samples; there was no 
difference between the two human groups. This difference was partially reflected in the 
ARL 67156 insensitive fraction where guinea-pig rates were significantly greater than 
those in samples from overactive bladders. It was also noted that the ARL 67156 
insensitive rates were significantly greater in the stable bladder group compared to the 
overactive group. However with respect to the ARL 67156 sensitive fraction the rates 
were similar in all three groups irrespective of whether this was estimated from the Vmax 
data or those obtained using the 5 mM ATP data set.
This would imply that the variation in proportion of atropine resistance between the three 
groups is not a result of different ectonucleotidase activity and ATP breakdown. Guinea- 
pig detrusor has the greatest ATP component of contraction and yet a similar 
ectonucleotidase activity as human detrusor which shows either much less or no atropine
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resistance. An hypothesis is that more ATP is released from the nerves in the guinea-pig 
to initiate contraction.
Table 3.4 Summary o f ATP degradation by suinea pig and stable and over-active human 
detrusor-Vmnr and km data. Mean ± standard deviation. Student's t-test *(human vs 
guinea-pig). A(stable vs overactive) v<0.05
Total ARL 6 7 1 5 6  
insensitive
ARL 6 7 15 6  sensitive
V m a x
nmol.s'1. 
mg' 1
Km
mM
V m a x
nmol.s'1.
mg' 1
Km
mM
V m ax
nmol.s"1.
mg' 1
Km
mM
Guinea pig 3 . 7  ± 2 . 3 4 . 3 2  ±  
2 . 4 1
2 . 1  ±  1 . 3 3 . 5 8  ±  
2 . 3 3
1 . 1  ±  1 . 4 1 . 4 8  ±  
1 . 0
Human - stable 2 . 4  ±  
0 . 9 *
4 . 4 7  ±  
2 . 4 8
1 . 6  ± 0 . 7 3 . 4 6  ±  
1 . 7 4
1 . 1  ± 0 . 4 4 . 4 5  ±  
2 . 6 2
Human - overactive 2 . 0  ± 
1 .0 *
3 . 3 3  ±  
1 . 7 4
1 . 1  ± 
0 . 4 * A
3 . 0 6  ±  
1 . 4 3
1 . 2  ± 0 . 9 3 . 3 3  ±  
2 . 4 8
Table 3.5 Summary o f ATP degradation by guinea pig and stable and over-active human 
detrusor-degradation rates with initial ATP concentration 5 mM. Mean ± standard 
deviation. Student's t-test *(human vs guinea-pig). A(stable vs overactive) p<0.05
Total ARL 67156 
insensitive
ARL 67156 67156 
67156 sensitive
Guinea pig 1.88 ±0.67 1 . 2 2  ± 0 . 6 6 0.62 ± 0.54
Human - stable 1.43 ±0.58 0.91 ± 0.28 0.51 ±0.43
Human - overactive 1.23 ±0.48* 0.66 ±0.15 *A 0.59 ± 0.36
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3.5 REAL TIME MEASUREMENT OF ATP RELEASE
Novel ATP biosensors were used to measure for the first time the real time release of 
ATP from detrusor smooth muscle. The emergence of atropine resistant contractions in 
detrusor from overactive bladders could result from altered nerve-mediated release of 
ATP. The electrodes provide a useful technique to determine if there is any difference in 
release between the two human groups. It was not, however, possible within the time­
frame of this thesis to measure the release from human samples. Guinea-pig detrusor 
preparations were used to establish the use of the electrodes for measuring ATP during 
nerve-mediated contractions. Strips were electrically field-stimulated to initiate 
contractions and the consequent ATP release from the preparation was measured. The 
aim of the experiments was to measure ATP released from nerves in the preparation 
during electrical stimulation.
3.5.1 Calibration
Calibration of each ATP biosensor was performed in situ with 10 pM ATP solution. The 
signal obtained on the null sensor was subtracted from the signal on the ATP sensor to 
give the differential signal. The average voltage recorded by the ATP sensor during 
calibration was 4.01 ± 1.95 V. Figure 3.49 shows an example of the differential ATP 
calibration signal.
183
50 s
10 pM ATP
Figure 3.49 Example o f ATP sensor calibration signal
3.5.2 Control contractures
To estimate the extent to which ATP released from the muscle itself, during contraction, 
contributes to the ATP electrode signal, the muscle strips were contracted independently 
of nerve mediated activation with 3 pM carbachol and by raising the extracellular 
potassium concentration. The concentrations of carbachol and KC1 were chosen to give 
comparable contraction magnitudes to those generated by nerve stimulation.
Figure 3.50 and 3.51 show examples of the tension and ATP sensor traces recorded when 
the detrusor strip was contracted with 3 pM carbachol and 120 mM KC1. Both figures 
show that while substantial contractures were achieved the increase in voltage from the 
ATP sensor was only small, compared to that measured during nerve-mediated 
stimulation (see below).
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rigure j .ju example or s /\ i r  signal ana di coniraciure rrom guinea-pig aetrusor strip 
following addition o f 3 uM carbachol. Solid bar indicates presence o f carbachol.
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Figure 3.51 Example o f A) ATP signal and B) contracture from guinea-pig detrusor strip
following an increase o f extracellular fKCll to 120 mM. Solid bar indicates presence of
high KCl.
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3.5.3 ATP release during nerve-mediated stimulation - Initial experiments
The tissue preparations were stimulated over the frequency range 1-20 Hz, firstly with 
the ATP sensitive electrode off the tissue and in the bath solution, and secondly in 
position on the tissue.
During the initial experiments, when the tissue was stimulated a large signal was 
recorded. However, as shown in Figure 3.52 panel A a signal was also recorded when the 
sensor was not on the tissue implying that at least part of the ATP electrode signal was a 
stimulation artefact. Panel B shows how the initial phase of the (ATP -  null) signal is 
oscillatory and also falls below the baseline. The stimulation artefact was greater at 
higher stimulation frequencies. Thus this initial phase may represent artefact from the 
electrical stimulus. However, a difference between the off-tissue and on-tissue ATP 
signal was the shoulder which appeared after the stimulation artefact. To try and improve 
ATP-null signal record to estimate ATP release the data set was digitally smoothed as a 
5:1 running average (Figure 3.52, panel C).
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Figure 3.52 Example o f ATP electrode signals during 8 Hz. EFS of a guinea pig detrusor 
strip. A) ATP - null signal with the ATP and null electrodes off the tissue, B) ATP - null 
signal with electrodes on the tissue, C) ATP - null signal from part B digitally smoothed.
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Once the data were smoothed they were analysed to estimate ATP release over the 
stimulation frequency range. The peak ATP signal that occurred during the stimulation 
period could not be used as a variable as it appeared this was affected by the stimulation 
artefact. Therefore the signal was integrated between the initiation of stimulation and 
then for various durations up to 30 seconds. The longest integration interval was chosen 
as this would encompass most of the ATP signal when the electrodes were on the tissue 
(Figure 3.52B).
The integration of the ATP signal at each of the stimulation frequencies is shown in 
Figure 3.53 A. The integral increases as the stimulation frequency is successively raised, 
but between zero and about 7 seconds the integral curves are unreliable, especially at 
higher frequencies, presumably due to stimulation artefact contamination.
Figure 3.53B shows progressive intervals over the range 3 to 30 seconds after the 
beginning of stimulation A lapse of three seconds was chosen as this was the duration of 
stimulation. The integration curves were improved but still showed some effect of the 
artefact. Also this analysis missed integration of the ATP signal at the time when tension 
was at its peak and when it might be anticipated that ATP release would be occurring.
To include the early part of the signal, but avoid the major effects of the stimulation 
artefact, the signal was integrated from time zero, but the signal during the artefact was 
not included (Figure 3.53 C). The latter was estimated from the null electrode signal -
i.e the end of the negative-going signal as in Figure 3.52A. This ATP signal in volts was
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converted to ATP concentration using the 10pM ATP calibration, the integration of 
which is showed in figure 3.53D.
Although the data could be analysed and a frequency-dependence was observed in the 
integrated ATP signal, as shown in panel D, it was not ideal to have such a large 
stimulation artefact in the data or not to include a section of the data in analysis. 
Therefore changes to the experimental set up were made. Efforts were made to improve 
the experimental system to minimise the stimulation artefact.
3.5.4 Improved experimental set u p
To minimise the stimulation artefact an optically-isolated constant voltage stimulator was 
interposed between the stimulator and the stimulating electrodes. This dramatically 
improved the ATP and null sensor signals as shown in Figure 3.54. Unlike previously 
there was no stimulation artefact when the electrode was on or off of the tissue. There 
was also no artefact present on the null sensor signal and when this signal was subtracted 
from the ATP electrode signal the consequent ATP-related signal was more evident.
As the detrusor strip was electrically field stimulated over a range of frequencies the 
tension and signals from the ATP sensitive and null sensor were recorded. The difference 
between the ATP and null sensor signals was recorded simultaneously. Figure 3.55 
shows an example of raw data obtained over the frequency range 1 to 24 Hz and
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demonstrates how the ATP and null signals were improved, with a lack of a stimulation
artefact.
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Figure 3.53 Example o f intesration o f smoothed ATP sienals following EFS of guinea 
pig detrusor over the frequency range 1 - 2 0  Hz. A) Integration from time o f stimulation 
up to 30 seconds. B) Integration from 3 seconds after time o f stimulation up to 30 
seconds. C) Integration from time o f stimulation up to 30 seconds but not including the 
signal during the stimulation artefact. D) Integration as C expressed as ATP 
concentration.
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Figure 3.54 Examples o f electrode signals before and after the inclusion o f an optically - 
isolated constant voltage stimulator. A)Electrodes off-tissue signal. B) Null electrodes 
signal. C) ATP-electrode signal D) ATP electrode -  null electrode signal. All traces 
obtained at 24 Hz. stimulation rate
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5 mN.mm-2
200 s
JL J lu.
1 2 4 8  12 16 20 24Hz
ATP Luij I ^  _ 1.93 V
Null □ 0.18 V
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200 s
2 V
Figure 3.55 Example o f raw signals obtained from null and ATP sensors, the difference 
of the signals and the tension recorded when a guinea-pig detrusor strip was electrically
field stimulated over the frequency range 1 to 24 Hz.
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3.5.5 Carbachol and KCl contractures
Several experiments were performed to estimate the proportion of ATP released by 
muscle contraction itself. Figure 3.56 panel A shows equivalent mean peak tension 
contractions evoked by 8  Hz electrical field stimulation, 21.7 ± 7.2 mN.mm' , and 3 pM 
carbachol, 24.4 ± 14.3 mN.mm'2. Panel B of Figure 3.51 shows the mean ATP signal at 
the time if peak tension, 6.5 ± 3.9 nmol.l"1 following 8  Hz EFS and 3.0 ± 3.0 nmol. 1 
following 3pM carbachol. The EFS signal is significantly greater than the carbachol 
signal.
When the tissue was contracted by raising the extracellular K concentration the peak 
tension achieved was equivalent to that of 16 Hz EFS. Figure 3.57 panel A shows the 
mean peak tension for 16 Hz EFS, 38.2 ± 13.8 mN.mm'2, and for increased KCl, 36.9 ±
13.4 mN.mm'2. Panel B Figure 3.52 shows that the mean ATP signal at the time of peak 
tension is significantly greater when contraction was evoked by 16Hz EFS compared to 
increased KCl. The mean ATP signal by 16 Hz EFS was 6 . 8  ±1.9 nmol.l1 and was 1.6 ±
1.2 nmol.l1 by increased KCl.
EFS contractions and nerve-independent contractures had equivalent mean peak tensions 
the ATP signal was significantly greater for the EFS evoked contraction. These results 
indicate that at worst less than half of the ATP signal can be attributed to the contraction 
of the muscle itself.
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Figure 3.56 Estimation o f the proportion o f ATP released by the contraction of guinea 
pig detrusor muscle itself A) Equivalent mean peak tension contractions evoked bv 8 Hz 
EFS (grey) and 3uM carbachol (white). B) ATP signal at time of peak tension of 8Hz 
EFS (grey) and 3uM carbachol (white). Mean ± standard deviation. Student’s t-test 
p<0.05.
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Figure 3.57 Estimation o f the proportion o f ATP released by the contraction of guinea 
pig detrusor muscle itself. A) Equivalent mean peak tension contractions evoked by 16 
Hz EFS (grey) and increased extracellular potassium levels (white). B) ATP signal at 
time o f peak tension o f 8Hz. EFS (grey) and increased extracellular potassium level
(white). Mean ± standard deviation. Student's t-test p<0.05.
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3.3.6 Frequency-dependent ATP release
The difference signal (ATP -  null electrode signal) for each frequency was again 
integrated from time of stimulation up to 30 seconds. The average integration at each 
frequency is plotted in Figure 3.58. The graph shows that as the frequency increased 
from 1 to 12 Hz there was a large increase in the ATP integral. Further increases in 
stimulation frequency did not result in any further increases in the ATP integral. In fact 
the integral became slightly smaller at 20 Hz and then much smaller at 24 Hz.
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Figure 3.58 Average integration o f ATP release from time o f stimulation up to 30 
seconds following EFS o f guinea pig detrusor strips over frequency range 1 - 2 0  Hz.
Standard deviations not plotted for clarity.
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The frequency-dependence of the contractile response and the ATP electrode signal are 
illustrated in Figure 3.59. Average tension and the ATP integral over the first five 
seconds following stimulation are shown over the frequency range 1 to 24 Hz. Each 
curve has been normalised as a proportion of the maximal response. The ATP integral 
reaches a maximal response at a lower frequency compared to tension. This is confirmed 
by estimating the frequency required to produce half the maximal response for each 
variable, the fr/2  value Figure 3.60. The ATP integral fi/2 , 4.4 ±3.0 Hz, was significantly 
smaller than the tension fi/2 , 12.0 ± 2.6 Hz. This would suggest that ATP is preferentially 
released at lower frequencies of stimulation.
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Figure 3.59 Average ATP integral and tension as a percentage o f maximal response over 
frequency range 1 to 24 Hz. ATP signal was integrated for five seconds from time of 
stimulation. ATP integral: squares, tension: circles. Mean ± standard deviation.
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Figure 3.60 The estimated frequency required to produce half the maximal response of 
tension and ATP signal integrated over five seconds from time of stimulation. Tension: 
grev. ATP integral: white. Mean ± standard deviation. p<0.05 Student's paired t-test.
3.3.7 ATP release in the presence o f atropine
In the presence of lpM  atropine the integration of the ATP signal from the time of 
stimulation up to 30 seconds over the frequency range 1 to 24 Hz followed a similar 
pattern to those in control conditions. The ATP integral increased as the stimulation 
frequency increased from 1 to 12 Hz and then fell as the frequency increased up to 24 
Hz, Figure 3.61.
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Figure 3.61 Averase integration o f ATP release from time of stimulation up to 30 
seconds following EFS o f guinea pis detrusor strips over frequency range 1 -  20 Hz. in 
the presence o f luM  atropine. Standard deviations not plotted for clarity.
Figure 3.62 illustrates the frequency-dependence of the ATP release and tension in the 
presence of lpM  atropine. The average tension and five second ATP integral over the 
frequency range 1 to 24 Hz are shown. In the presence of lpM  atropine the frequency 
dependence of the ATP signal and tension were comparable. The maximum response 
reached by each variable is achieved at an equivalent frequency.
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The average estimated frequencies required to produce half maximal tension and for the 
five second ATP integral were not significantly different 7.3 ± 3.5 Hz and 3.1 ± 1.6 Hz 
respectively, (Figure 3.62). This is contrast to the situation when total nerve-mediated 
tension was compared to the frequency-dependence of ATP release.
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Figure 3.62 Average ATP integral and tension as a percentage o f maximal response over 
frequency range 1 to 24 Hz. in the presence o f 1 uM atropine. ATP signal was integrated 
for five seconds from time o f stimulation. ATP integral: squares, tension: circles. Mean ± 
standard deviation.
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In summary, atropine caused a shift in the tension force-frequency curve to the left 
compared to control. The tension i\n was significanlty smaller in the presence of 
atropine. However there was no variation between the ATP signal fm  in the two 
conditions and the values were not significantly different from the tension force- 
frequency f 1 /2 in the presence of atropine., Figure 3.63.
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1 6 q
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Figure 3.63 Average estimated frequency required to produce half the maximal tension 
and five seconds ATP integral in the presence and absence o f 1 uM  atropine, tension: 
black, ATP: white. Mean ± standard deviation, *A v<0.05.
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Figure 3.64 demonstrates that the relationship between tension generated and ATP 
released is not linear, with ATP signal reaching a maximum before tension.
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Figure 3.64 Sample plot o f tension (mN.mm ) against peak ATP (uM) obtained with 
electrical field stimulation over the frequency range 1 to 24Hz.
In the presence of 1 pM TTX nerve-mediated contractions and the ATP electrode signals 
at all frequencies were abolished.
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3.5.8 Summary o f results
These results show that the novel ATP sensitive microelectrode biosensors provide a 
useful technique to measure real-time release of ATP during nerve-mediated contraction 
in detrusor smooth muscle. When ATP integrals from equivalent contractions evoked by 
direct muscle stimulation using carbachol and 8 Hz electrical field stimulation were 
compared the 8 Hz integral was significantly greater than the carbachol. This indicates 
that a proportion of the ATP measured is released from stimulated nerves. The release of 
ATP was frequency dependent with a preferential release of ATP at low stimulation 
frequencies. The electrodes could now be used to determine any differences in ATP 
release in detrusor from stable and overactive human bladders that may contribute to 
atropine resistance and symptoms of overactivity.
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4.0 Discussion
4.1 EXPERIMENTAL LIMITATIONS
In this thesis a number of techniques were used to investigate the role of extracellular 
ATP in signalling pathways concerned with neurally-mediated activation of detrusor 
smooth muscle. These included the measurement of isometric tension experiments with 
muscle strips, estimation of ectonucleotidase activity through ATP degradation, 
molecular studies of gene expression and measurement of ATP release using 
microelectrode biosensors.
4.1.1 Isometric tension experiments
Tension experiments, used to look at the effect of apyrase and ARL 67156, used small 
tissue preparations of approximately 1 mm in width and 4-6 mm in length. Using small 
strips allows for adequate superfusion of the tissue by solutions, and the fluid exchange 
time through the organ bath was sufficient to prevent hypoxia within the tissue. One 
limitation of some of these experiments was due to the expense of apyrase, such that 
experiments using this agent were carried out when preparations were not superfused. 
Instead superfusate flow was stopped and 1ml apyrase containing Tyrode’s solution was 
added directly to the bath. When the superfusate was suspended for the addition of 
apyrase the duration was limited to prevent impairment of the tissue. Force-frequency
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curves were comparable in flow and no-flow conditions and upon restoration of flow, 
indicating the tissue did not suffer any negative effects during these interventions.
There is also a possibility that the contractile response may be distorted by the amount of 
connective tissue in the sample muscle strip, with little or no contractile response in some 
samples from overactive human bladders. It was observed by microscopy that the 
connective tissue content varied between species and sample groups with greater 
amounts in human compared to guinea-pig. In some overactive human bladder strips 
there may also have been some denervation as the response to electrical field stimulation 
was poor compared to stable human and guinea-pig samples. In these instances the 
stimulation strength had to be increased. Any changes to the stimulation parameters may 
have increased the amount of direct muscle stimulation however in the majority of 
samples it was found that 1 pM TTX abolished contractions so that direct muscle 
stimulation was generally negligible.
4.1.2 Molecular experiments
Molecular studies were used to extract RNA from human detrusor samples which were 
then used to determine if specific ectonucleotidase genes were expressed. Human bladder 
samples were limited and often small. However the sensitive techniques used require 
only small amounts of starting material; 30 mg of each bladder sample was used. RNA 
extraction was simplified by using purchased RNA extraction kits from Sigma. The kit
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enables rapid extraction of RNA which is important to prevent RNA degradation that 
occurs once the sample is defrosted. The other consideration when preparing RNA 
samples is contamination. To determine the extent of degradation and contamination 
each sample was analysed using the Aligent 2100 bioanalyser. This enabled the samples 
to be visualized on a gel-like image and any samples which were degraded or contained a 
contaminant could be eliminated, and so reduce any inaccuracies in analysis. An 
additional benefit of this approach was that very small quantities, 1 pi, of sample were 
required. Unfortunately a number of samples had to be eliminated at this stage from 
further investigation due to degradation. It is important to freeze rapidly samples of tissue 
in liquid nitrogen once they are removed from the bladder during the surgical procedure 
to prevent degradation of the RNA. However due to the location of some of the operating 
theatres it was not always practical or possible to freeze samples immediately.
Pre-designed and pre-optimised probe and primer sets for quantitative gene expression 
analysis of human genes were used to obtain the best results. Even so a number of 
measures were taken to ensure accuracy, including all samples being prepared in 
triplicate and an internal control was included in each sample. As a sample of known 
ectonucleotidase 1, 2, 3 and 5 expression was not included in the analysis, comparisons 
in expression level was made between the stable and overactive sample groups.
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4.1.3 ATP degradation experiments
Experiments measuring the rate of ATP degradation by human detrusor samples were 
carried out to measure the activity of ectonucleotidases in the tissue. The original 
intention was to perform measurements on each sample before and after addition of the 
ectonucleotidase inhibitor ARL 67156. However due to time restraints the addition of 
ARL 67156 could not be performed on exactly the same piece of tissue as the control but 
on an adjacent piece of tissue from the same sample. This will have increased the error 
in calculating the ARL 67156-sensitive component of ATPase activity by the detrusor 
sample.
There were a number of initial problems with obtaining reproducible results from the 
spectrophotometer used to measure ATP-degradation products. There appeared to be 
cross-over between different wells of the reader-plate, particularly with samples 
containing higher concentrations of ATP. A number of steps were taken to reduce this 
error and improve the accuracy of the measurements. When the initial ATP concentration 
was 1, 2 or 5 mM two aliquots were taken at each time point to increase the accuracy of 
the measurements, and the samples were spread out as much as possible on the plates. 
Also an ATP standard curve was measured at the beginning of each experiment.
The km and Vmax values for total ATPase and ectonucleotidase activity in the stable and 
overactive bladder groups were used as the derived experimental variables, and were 
calculated from an estimated curve fit of ATPase degradation rate as a function of initial
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ATP concentration. There were a number of calculations from the raw data to the final 
estimations, increasing experimental errors, and it was not always possible to fit a curve 
of ATP degradation rate against increasing ATP concentration to obtain Vmax or km 
estimates for individual tissue samples. The ATPase activity due to ectonucleotidases 
was derived by subtracting the activity measured in the presence of ARL 67156 from the 
total ATPase activity of the tissue, as described above. Therefore there will be an error in 
the estimation of the ARL 67156-sensitive component which will be a function of the 
errors inherent in these two separate series of measurements. At lower initial 
concentrations of ATP the proportion of the ARL 67156-sensitive activity was small 
compared to the total ATPase activity, although they were significantly different. As the 
Vmax and km were estimates an alternative way of comparing the ATPsase activity in the 
two groups of tissue samples was used. This was to compare rates of ATP breakdown at 
a fixed initial concentration of ATP, 5 mM. As there were no differences in the km 
between the two groups the use of a single fixed concentration to estimate ATPase rates 
was justified. The results and conclusions were similar with either method of analysis.
The above method was used in this study to compare ectonucleotidase activity within 
different experimental groups as the luciferin-luciferase assay is sensitive. However 
some problems with the protocol have resulted in reservations about the accuracy of the 
results, due to the inherent errors. If this experiment was to be repeated it is proposed that 
alternative methods, such as HPLC analysis, might also be used for comparison. HPLC 
would also enable the measurement of the particular ATP degradation products from the 
same samples to be measured.
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4.1.4 Microelectrode biosensor experiments
The electrode used to measure ATP release from guinea-pig detrusor strips had not 
previously been used on electrically field-stimulated smooth muscle preparations. The 
experimental parameters and protocol were therefore unknown and had to be determined 
and optimised. However the benefits of the electrode over the other, more established 
methods of measuring ATP (described in the introduction) were significant, especially 
measuring ATP release in real-time. Calibration of the electrodes was performed in situ 
and needed to be carried out at the beginning, end and once during each experiment to 
account for decreasing sensitivity due to wear-and-tear of the electrode during the 
experiment. The effect of any interference or noise in the system was reduced by using a 
null electrode alongside the active electrode.
4.2 RESULTS OVERVIEW
The aim of this thesis was to study the role of extracellular ATP signalling in the 
neuromuscular junction of detrusor smooth muscle contractile function. The role that 
ectonucleotidases may have in variable ATP breakdown associated with bladder 
overactivity was investigated.
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4.2.1 Isometric tension experiments
The contribution of attenuated ectonucleotidase activity on altering isometric tension in 
detrusor from some experimental groups was tested by increasing nerve-derived ATP 
breakdown with the addition of apyrase, a relatively non-specific ATP and ADPase. This 
would indicate any change in contraction that may result from changes in the activity of 
endogenous ectonucleotidases. The addition of apyrase resulted in a reduction of nerve- 
mediated force using detrusor from both human patients with overactive bladders and 
guinea-pig. This was in contrast to contractions elicited in human detrusor where there 
was no significant effect of apyrase and so no ATP component of contraction.
Upon addition of ARL 67156, an ectonucleotidase inhibitor, to guinea-pig detrusor 
preparations there was a reversible and significant increase in the force of nerve- 
medaited contraction compared to control. This again indicates that ATP is released 
during nerve-mediated stimulation. An additional experiment would have been to test the 
effects of ARL 67156 on nerve-mediated contractions in both the human detrusor sample 
groups however this was not possible due to the expense and lack of availability of the 
inhibitor.
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4.2.2 Ectonucleotidase expression
Although it is believed that the breakdown of ATP in the neuromuscular junction in 
detrusor is by ectonucleotidases there was no previous demonstration of their gene 
expression in this tissue. Therefore molecular studies were performed to identify 
ENTPDase 1, 2, 3 and 5 expression and to determine if there were any differences in 
expression levels. RNA was extracted from samples of detrusor from patients with stable 
and overactive bladders. Following reverse transcription to cDNA, Taqman RT-PCR was 
performed on the samples to determine a threshold cycle number for each of the genes of 
interest. The results showed that mRNA to all four enzymes was present in both sample 
groups. There were however some differences between the groups with higher levels of 
ENTPDase 1 and 3 in stable compared to overactive bladders. There was also a 
difference in the relative levels of expression, with a significantly higher level of 
ENTPDase 1 compared to the other three.
4.2.3 Ectonucleotidase activity
ATP degradation was measured to estimate directly any variation of ATPase activity in 
the different experimental groups. A preliminary study, with small numbers of 
preparations, indicated that there was a reduction of ectonucleotidase activity in detrusor 
samples from overactive bladders compared to those from stable bladders (Harvey et al, 
2002). Degradation of five concentrations of ATP by detrusor samples over a period of
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30 minutes was measured in the presence and absence of ARL 67156. ATP 
concentrations of aliquots taken at specific time points were measured using a luciferin- 
luciferase assay. The rate of degradation of ATP increased with greater initial 
concentrations of ATP in both sample groups and the presence of ARL 67156 reduced all 
rates of degradation. There were no significant differences in total ATPase activity 
between detrusor samples from the stable and overactive bladder groups in the rate of 
ATP breakdown with an initial concentration of 5 mM, or the km or Vmax values. . The 
ARL 67156-resistant fraction of activity was significantly greater in detrusor from stable 
bladders compared to overactive bladders. However there was no difference in the ARL 
67156-sensitive activity. Thus no evidence was found for a difference in unit 
ectonucleotidase activity in detrusor samples from patients with stable or overactive 
bladders.
4.2.4 Real time ATP release
To try to measure the real-time release of ATP from stimulated nerves in detrusor smooth 
muscle novel ATP microelectrode biosensors were used. An experimental set-up and 
protocol was designed to determine the utility of the novel electrodes in this tissue. It was 
possible to record extracellular ATP signals following direct muscle stimulation with 
carbachol and electrical field stimulation. All nerve-mediated signals were abolished in 
the presence of TTX and reduced by atropine although to a lesser extent than the force of 
contraction. The relationship between ATP release and stimulation frequency was
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investigated. The ATP signal reached a maximal response at a lower frequency compared 
to tension. Comparing the ATP integral obtained from equivalent mean peak tension 
contractions evoked by electrical field stimulation and 3 pM carbachol it was shown that 
a proportion of the ATP signal can be attributed to ATP released from nerves following 
stimulation.
4.3 ATP AND NERVE-MEDIATED CONTRACTIONS IN DETRUSOR SMOOTH 
MUSCLE
Nerve-mediated contractions and force-frequency relationships of human and guinea-pig 
detrusor smooth muscle were assessed and the effect of altering ATP degradation on 
contractions was investigated.
4.3.1 Contractile properties of human and guinea-pig detrusor to electrical field 
stimulation
The magnitude of force generated when normalised per unit cross-section of preparation 
from nervemediated contractions of detrusor preparations from human, both stable and 
overactive, and guinea-pig bladders was similar at their half-maximum stimulation 
frequencies, 20 and 8  Hz respectively. This implies the contractility of the detrusor
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muscle using this method of stimulation is similar between the two species and between 
control and pathological sources of human tissue. There was however a difference in the 
force-frequency relationship between the two species as there was a difference in the half 
maximal stimulation-frequency (fi/2 ). Human detrusor required a higher stimulation 
frequency, with the fi/2 for stable bladder samples being 15.9 ± 7.0 Hz, and overactive 
bladder samples were not significantly different from stable bladders with an fi/2  of 19.9 
± 11.2 Hz. However guinea-pig detrusor had a value of 9.5 ± 3.5 Hz. These results were 
comparable to those of previous studies (Ikeda, 2006; Harvey et al, 2002; Bayliss et al, 
1999). This variation may be due to a difference in the neurotransmitters released by the 
two species. Guinea-pig detrusor has two significant components to contraction, ATP 
and acetylcholine, compared to just acetylcholine in human (see Introduction -  section 
1.4). This was also evident by the significant atropine-resistance observed in guinea-pig 
preparations. This difference in f \n  value between the two species is compatible with the 
hypothesis that ATP is released at lower stimulations frequencies than is Ach (See 
Discussion -  section 4.8). There was no significant difference in the maximum force or 
f 1/2 frequencies of nerve-mediated contractions in the detrusor samples from stable and 
overactive bladders. However it may be argued that if there is some atropine-resistance in 
detrusor from overactive human bladders that this group should have an intermediate f\n 
between guinea-pig and stable human samples. In this study overactive human bladder 
samples are contained within one sample group however not all samples showed atropine 
resistance, 1 1  of the 28 tested, which may explain the similar fi/2  of this group compared 
to stable samples.
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It has been shown in a number of other species that two phases to nerve mediated 
contraction can be seen, for example in rabbit bladder (Zhao et al, 1993) and rat bladder 
(Yu et al 1996). The initial phase was due to ATP activating rapid opening of P2Xi 
ligand-gated receptors which resulted in an influx of Ca2+. The second, later phase was 
dependent on acetylcholine stimulating M3 receptors activating slower, second 
messenger pathways to release intracellular Ca2+. This bi-phasic response was not often 
observed in human and guinea-pig preparations, perhaps because the wave-form was 
dampened by the visco-elastic properties of the extracellular matrix which in human 
samples in particular is a significant proportion of the tissue mass.
4.3.2 Effect of altered ATP breakdown on nerve-mediated contractions
In detrusor muscle strips from guinea-pig and overactive human bladders 10 TJ.ml' 1 
apyrase caused a significant and reversible reduction in the magnitude of nerve-mediated 
contractions elicited at 16 Hz and 24 Hz respectively. Apyrase (10 U.ml'1) was also 
shown to significantly reduce EFS contractions in rat tail arteries to a similar extent to 
that seen in guinea-pig detrusor (Fukumitsu et al, 1999). In contrast to guinea-pig and 
overactive human bladder samples apyrase had no effect on preparations from stable 
human bladders.
Apyrase is a non specific ATP and ADPase that would, along with endogenous 
ectonucleotidases degrade ATP in the neuromuscular junction. This would support there
214
being an ATP component of contraction in both guinea-pig and overactive human 
bladder as addition of apyrase would increase breakdown and limit the amount of ATP 
able to activate P2X receptors on the muscle membrane to initiate a purinergic 
component of contraction. This is corroborated by the lack of apyrase effect in stable 
bladder samples and implies there is no ATP component to contraction. This lack of 
action of apyrase in the stable human bladder samples is not due to an inability of the 
muscle to respond to purinergic agonists as ATP and ABMA added to the superfusate 
have been shown to elicit contractions. (Bayliss et al, 1999). ATP released by motor 
nerves must therefore be hydrolysed completely by ectonucleotidases and explain the 
lack of effect of apyrase in this sample group.
There was also a positive correlation between apyrase-induced reduction of contraction 
and the proportion of atropine resistance. As atropine resistance increased so did the 
extent of reduction of contraction by apyrase. If ectonucleotidase activity was reduced in 
the overactive bladder, increasing ATP breakdown by addition of extra ATPase activity 
should reduce the atropine-resistant component of contraction observed in overactive but 
not stable human bladders.
The effect of enzyme activity was also investigated through the addition of the 
ectonucleotidase inhibitor ARL 67156. ARL 67156 inhibits ectonucleotidase activity 
with a PIC5 0  of 4.62 in human blood cells (Crack et al, 1995) and 5.1 in the rat vas 
deferens (Khakh et al, 1995). In this study 100 \iM ARL 67156 significantly potentiated 
nerve-mediated contractions in guinea-pig detrusor strips. Higher concentrations of ARL
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67156 were not used as it is also a weak antagonist at P2X receptors (Crack et al, 1995) 
which would tend to reduce the force of contraction and thus confound the experimental 
data. By inhibiting the breakdown of ATP released from the motor nerves, more ATP 
was able to activate contraction. This hypothesis was further supported by the significant 
increase in contraction by ARL 67156 in the presence of atropine. The effect of ARL 
67156 in this thesis is comparable to another study investigating the effect of the 
inhibitor in guinea-pig bladder (Westfall et al, 1997). In this study ARL 67156 was also 
shown to enhance contractions by exogenous ATP but not those to the non-hydrolysable 
ATP analogue, ABMA. This is consistent with ARL 67156 inhibiting breakdown of 
ATP, and not affecting directly smooth muscle contractile function.
It would be of interest to determine the effect of ARL 67156 in stable and overactive 
human detrusor. Inhibition of ectonucleotidase activity in stable detrusor samples should 
produce an increase of tension of nerve-mediated contractions as a result of a reduction 
of ATPase activity. This would provide support for the hypothesis of a reduced 
ectonucleotidase activity to generate atropine-resistance in some overactive bladders. If 
tension were increased when ARL 67156 was applied to bladder preparations from stable 
and overactive, this would provide further evidence that ATP is released on nerve- 
stimulation in human detrusor.
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4.3.3 Atropine-resistant nerve-mediated contractions
Atropine-resistant contractions are evoked by non-cholinergic neurotransmitters and it 
has been established that in the bladder this neurotransmitter is ATP (Bumstock et al, 
1978). This atropine-resistance is seen in detrusor from most animal species with the 
exception of humans and old world monkeys, where acetylcholine is the sole 
neurotransmitter (Kinder and Mundy, 1985). Atropine-resistance was observed in all 
guinea-pig detrusor samples, atropine reduced contractions by 41.9 % which is similar to 
other studies (Creed et al, 1991). Also consistent with previous work was the lack of 
atropine-resistance observed in all but three of the 25 stable bladders samples (Sjogren et 
al, 1982).
There were atropine-resistant contractions in a number of the detrusor samples from 
overactive human bladders. Greatest atropine-resistance in overactive bladders has 
previously been observed in detrusor samples from those with concomitant obstruction 
(Ikeda, 2006; Bayliss et al 1999). The overactive group in this thesis did not contain any 
obstructed bladder samples and so the extent of atropine-resistance would have been 
smaller than observed in other studies. Atropine-resistance has been observed in other 
bladder pathologies including interstitial cystitis (Palea et al, 1993), although the 
mechanism for the phenomenon has not been investigated in this group.
Reasons for the emergence of atropine-resistance in some disease states, as discussed in 
the Introduction, could include alterations in neurotransmitter release, sensitivity of the
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smooth muscle receptors and reduced ectonucleotidase activity. A reduced breakdown of 
ATP has been proposed (Harvey et al, 2002) where there was decreased ectonucleotidase 
activity in overactive bladder. There has been evidence of change in receptor expression 
in some pathologies including interstitial cystitis (Birder et al 2004), urge incontinence 
(Moore et al, 2001) and an increase in P2X receptors was observed in men with outlet 
obstruction compared to control patients (O’Reilly et al., 2001). It is unlikely that 
atropine-resistance is due to a change in the sensitivity of the smooth muscle to ATP or 
Ach, as demonstrated by Wu et al (1999). It has also been suggested that atropine 
resistance increases naturally with ageing (Yoshida et al, 2001), but the reason for this is 
unknown.
4.4 E-NTPDase 1,2 ,3  AND 5 EXPRESSION
Nerve-stimulated ATP release from motor nerves in detrusor smooth muscle is degraded 
by ectonucleotidases bound to the surfaces of cells within the neuromuscular junction. 
The specific ectonucleotidase enzymes involved in human detrusor have not been 
identified. Gene expression assays were used to investigate the presence of E-NTPDase 
1, 2, 3 and 5 in 18 human detrusor samples, comprising samples from both stable and 
overactive bladders.
The data showed that all four of the E-NTPDase were present in all human detrusor 
samples. The human samples were divided into stable and overactive bladder groups to
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compare the relative quantity of each enzyme. There were no differences between the 
samples groups in the levels of E-NTPDase 2 and 5. However there was a significant 
reduction in overactive bladder samples compared to stable ones in the level of both E- 
NTPDase 1 and 3. When comparing the levels of the E-NTPDases to each other the 
relative quantity of E-NTPDase 1 was considerably greater than the other three. Thus any 
reduction in E-NTPDase 1 will be the significant one in terms of overall E-NTPDase 
expression.
E-NTPDase 2 has the greatest preference for ATP, over other nucleotides, whilst E- 
NTPDase 3 has only a slight preference for the nucleotide (Zimmermann, 2001). 
However the levels of these two enzymes were significantly lower than those of E- 
NTPDase 1 which hydrolyses ATP and ADP equally well. It is possible that the levels of 
E-NTPDase 1 are higher because it rapidly degrades ATP to AMP compared to E- 
NTPDase 2 and 3 which produce the intermediate product of ADP which is then slowly 
degraded to AMP (Vorhoff et al, 2005). ADP is an agonist for some purinergic, P2, 
receptors present in the neuromuscular junction, therefore greater levels of E-NTPDase 1 
would prevent activation of P2 receptors by ADP and any effect this may have on 
detrusor contraction. As E-NTPDase 5 in bound to intracellular membranes and has a 
preference for nucleoside diphosphates it is unlikely that it would have any effect on 
breakdown of nerve-mediated released ATP.
A reduction in the relative quantity of the E-NTPDase 1 and 3 gene expression in the 
overactive bladder compared to stable bladder may have an implication in the breakdown
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of the ATP released from motor nerves during contraction particularly as there was a 
reduction in the most abundant enzyme, E-NTPDase 1. With lower levels of enzymes 
there may not be sufficient hydrolysis of ATP to prevent it initiating contraction. It is in 
overactive bladders where the reduced E-NTPDase levels were observed that a 
purinergic component of contraction is implicated.
E-NTPDase 8  is also located on the cell surface with an extracellular facing catalytic site 
(Robson et al 2006) and hydrolyses ATP and ADP. The cloned human E-NTPDase 8  
exhibits a preference for ATP, hydrolysing ADP poorly (Knowles and Li, 2006). 
Therefore this enzyme may be involved in the breakdown of ATP released from nerves 
in the detrusor. The levels of E-NTPDase 8  were not investigated in this thesis as a pre­
optimised expression kit was not available for this enzyme. Therefore it is not known if it 
is present in detrusor or if there is any difference in its expression between the two 
bladder groups.
It should be taken into account that although the data shows a reduction in E-NTPDase 1 
and 3 this is only at the gene level. The amount of enzyme at the protein level and the 
activity levels of the enzymes must be considered when drawing firm conclusion about 
the impact of these changes on ATP breakdown in physiological conditions.
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4.5 ECTONUCLEOTIDASE ACTIVITY
In contrast to stable human bladder detrusor, samples from patients with overactive 
bladders have a purinergic component to nerve-mediated contraction shown by atropine- 
resistance. Experiments in this thesis tested the hypothesis that this was due to a reduced 
ectonucleotidase activity in overactive bladder. This would provide evidence to indicate 
changes in ATP breakdown were responsible for atropine-resistance in some bladder 
pathologies.
The data was presented in two ways: Vmax and km estimates of ATPase activity; and 
breakdown rates obtained with an initial starting concentration of 5 mM ATP. As the 
two representations gave equivalent results only Vmax and km data is discussed.
Total ATPase activity was significantly greater in detrusor from guinea-pig compared to 
that from humans, whilst the activity in stable and overactive bladders was comparable. 
The addition of ARL 67156 did not alter the km values for each group, but did 
significantly reduce the estimated Vmax for all groups. This indicates the presence of 
ectonucleotidases in both guinea-pig and human detrusor smooth muscle. The estimated 
ARL 67156 resistant Vmax for overactive bladders was significantly lower than that for 
the stable bladders and guinea-pig groups which were similar. However the ARL 67156 
sensitive fraction of the ATP breakdown rate which was taken to be the ectonucleotidase 
rate only was not significantly different between any of the three detrusor groups.
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This is in contrast to the previous study where the ARL 67156-sensitive fraction was 
smaller in samples from overactive bladders compared to those from stable bladders 
(Harvey et al, 2002). Comparing the results of the two studies the Vmax estimates for 
total, ARL 67156 resistant and ARL 67156 sensitive ATPase activities were very similar 
in the stable groups.
There was a varying proportion of atropine-resistance in detrusor from guinea-pig, and 
stable and overactive human bladders but an equivalent ectonucleotidase activity. This 
would indicate that reduced ATP breakdown is not responsible for atropine-resistance. 
The greatest degree of atropine-resistance was observed in guinea-pig detrusor, with 
much less resistance in overactive bladders and none in stable bladders. It may be 
hypothesised that the ATP component of contraction in guinea-pig is due to an increased 
release of ATP following nerve stimulation. If this is so the emergence of an ATP 
component of contraction in detrusor from overactive bladders may be the result of 
altered nerve-mediated ATP release, with an increase in release compared to stable 
bladders.
The proportion of atropine-resistance in human samples used for this set of experiments 
was not determined due to their relatively small size which would have precluded both 
sets of measurements being carried out on the same biopsy sample, and this would be of 
advantage in any future experiments of this type.
222
The experiments in this thesis measured the activity of membrane-bound 
ectonucleotidases within the detrusor. ATP breakdown following release from stimulated 
motor nerves may not be due to these enzymes alone. There is evidence to show that in 
the vas deferens of guinea pig a soluble ectonucleotidase is released upon nerve 
stimulation (Todorov et al, 1997). It may therefore be necessary to also stimulate the 
tissue when measuring degradation of ATP to include the contribution from this possible 
source also.
4.6 ALTERED ECTONUCLEOTIDASE ACTIVITY
Although results from this study show that there was no significant difference between 
ectonucleotidase activity in stable and overactive bladder, gene analysis showed there 
was a reduction in the levels of some E-NTPDases in overactive bladder which may 
effect ATP breakdown. It is important to consider what could alter the activity of 
ectonucleotidases in physiological conditions. The activity could be affected by 
conditions in the extracellular space, by expression of a less active form of the enzyme or 
a reduced production.
Maximal activity of E-NTPDases 1, 2, 3 and 8  are dependent on Ca2+ and Mg2+ ions in 
the millimolar range and they are inactive in their absence (Robson et al, 2006). However 
it is unlikely that these ions would differ between stable and overactive bladders. Activity 
is also greater at alkaline pH values (Zimmermann, 2001) and may therefore be reduced
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by acidosis. Blood flow to the detrusor can be reduced during filling and spontaneous 
contractions particularly when there is detrusor hypertrophy such as in obstructed 
bladders (Azadzoi et al, 1996; Batista et al, 1996) In these conditions reduced blood flow 
can cause a decrease in tissue partial oxygen pressure and acidosis (Lin et al, 1995; 
Nielsen, 1995). Furthermore, acidosis by raising extracellular PCO2 content increases the 
force of contraction (Liston et al, 1991) which may in part be due to a reduced 
ectonucleotidase activity. However it is not known if these effects would persist in 
isolated tissue.
Potential splice variants for E-NTPDase 1 and 2 have been isolated (Zimmermann, 
2001). Any alteration of structure may modify the substrate specificity and activity of the 
enzymes particularly if the pyrase-conserved regions are effected. Glycosylation and 
surface location of the enzymes has also been shown to be crucial to activity (Zhong et 
al, 2 0 0 1 ).
The cause of altered expression of ectonucleotidases in detrusor is unknown but has been 
noted in other situations. The enhanced expression of E-NTPDase 1 in endothelial and 
mesangial cells is downregulated by glucocorticosteroids (Kapojos et al, 2004) and 
altered expression has also been observed human melanomas (Dzhandzhugazyan et al, 
1998).
Altered ectonucleotidase activity will not only effect the concentration of ATP within the 
neuromuscular junction and its ability to initiate contraction, but also the generation of its
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breakdown products such as ADP, AMP and adenosine. This is important because any of 
these products can act on pre or post-junctional receptors to modulate contraction. P2Y 
receptors can be activated by ADP to initiate relaxation, reduced ATPase activity may 
lead to a transient increase in ADP and reduced contractile activity. Adenosine has been 
shown to auto-regulate neurotransmitter release through activation of pre-junctional PI 
receptors. Adenosine and an A1 selective receptor agonist, CPA reduced the overflow of 
stimulated ATP release in the guinea-pig vas deferens (Driessen et al, 1994). Adenosine 
has also been shown reduce the strength of nerve-mediated contractions in both guinea- 
pig and human detrusor (Ikeda et al, 2003).
4.7 ECTONUCLEOTIDASE INHIBITION
There has always been a problem with inhibiting ectonucleotidase activity due to a lack 
of potent and selective inhibitors that do not have an effect on purinergic receptors. ARL 
67156 is thought to be the only selective inhibitor with minimal effect at P2X receptors. 
However a recent study has shown that ARL 67156 inhibits E-NTPDase 1 and 3 but not 
E-NTPDase 2 (Iqbal et al, 2005). This means that if E-NTPDase 1, 2 and 3 are present in 
detrusor it cannot be concluded that all ectonucleotidase activity is inhibited. The 
implications for this study are that there will possibly remain some ATP breakdown in 
the presence of ARL 67156 in tension experiments. Also the ARL 67156 sensitive 
fraction in ATP degradation studies will not give a rate for complete ectonucleotidase 
activity. This is particularly true as it is E-NTPDase 2 that has the highest preference for
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hydrolysing ATP. However as gene expression analysis showed in this thesis the most 
abundant E-NTPDase present in the detrusor samples was E-NTPDase 1 and therefore 
any continued activity of total E-NTPDase activity in the experiments is likely to be 
small.
Any future work may consider the use of new inhibitors that have recently been 
described for E-NTPDase 1, 2 and 3 termed polyoxometalates (Muller et al, 2006). They 
are significantly more potent than ARL 67156. The polyoxometalates are anionic 
complexes containing transition metal ions that are stable in aqueous solutions at 
biological pH values. The inhibitors vary in their selectivity for E-NTPDase 1, 2, or 3 
and thus it may be possible to inhibit E-NTPDase 2 and 3 but not the highly expressed E- 
NTPDase 1 (Muller et al 2006). The affinity for these inhibitors for purinergic receptors 
is limited to P2 Yi2 studies and although only moderate binding was observed the 
usefulness of these inhibitors in contractile experiments is unknown.
4.8 NERVE-MEDIATED ATP RELEASE
Atropine-resistance in overactive bladder has been observed in this thesis and by a 
number of other authors (Sjogren et al, 1982; Bayliss et al, 1999). One possibility for the 
emergence of this resistance is an alteration in the release of ATP following stimulation 
of nerves within the detrusor. As there is a purinergic component of detrusor contraction
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in guinea-pig it was used as a suitable model to optimise the use of a novel ATP 
microelectrode biosensor that is a sensitive technique to measure real-time release of 
ATP. Future studies may then be able to use the electrodes to investigate the theory of 
altered ATP release in overactive bladder.
When guinea-pig detrusor muscle strips were electrically field-stimulated at a frequency 
range of between 1 and 20 Hz it was possible to record an ATP signal from the electrode. 
When the signals were integrated over 5 seconds the amount of ATP released increased 
with increasing frequency of stimulation. Other studies that have investigated the release 
of ATP from rabbit (Ferguson et al, 1997) and human and porcine (Kumar et al, 2004) 
bladder using the luciferin-luciferase assay have shown that the predominant release of 
ATP is from the urothelium. In this thesis the urothelium was removed from all guinea 
pig strips studied. Another potential source of ATP release other than nerves is from the 
activated smooth muscle cells. Stimulation-dependent release of ATP in the mouse 
phrenic nerve-hemidiaphragm preparation was partly postsynaptic (Vizi et al, 2000) and 
in the same preparation in the rat it was estimated that over 60% of released ATP is 
derived from muscle fibres (Santos et al, 2003). ATP is released from the smooth muscle 
of guinea-pig vas deferens following activation of ai-adreoceptor stimulation by 
noradrenaline released from sympathetic axon terminals (Vizi et al, 1992). To determine 
the extent of ATP release from the detrusor muscle the ATP integral obtained from 
equivalent mean peak tension contractions evoked by electrical field stimulation and 3 
fxM carbachol was compared. The ATP intergral for EFS was significantly greater than
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that for carbachol indicating that not all of the ATP signal could be attributed to the 
contraction of the muscle itself.
In the presence of 1 pM atropine an ATP signal was recorded at all frequencies tested in 
a similar pattern to those of control. The addition of atropine reduced the EFS stimulated 
contractions and also the ATP integral. However atropine reduced the ATP signal to 
significantly lesser extent than tension. The reduction in ATP integral is probably due to 
a reduction in contraction and therefore a reduced ATP release from the activated 
muscle.
Following the addition of TTX no tension or ATP signal was recorded indicating that 
any ATP signal recorded is directly or indirectly related to neurotransmitter release from 
embedded nerves; from the nerve itself or from contraction of the muscle following 
neurotransmitter stimulation of appropriate receptors. The results indicate that a 
proportion of the ATP signal recorded during nerve-mediated stimulation is derived from 
the nerves.
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4.9 FREQUENCY DEPENDENCE OF NEUROTRANSMITTER RELEASE
The measurement of ATP signals following nerve-stimulation of detrusor smooth muscle 
from guinea-pig was used to investigate the frequency-dependence of neurotransmitter 
release, and in particular to determine if there was a preferential release of ATP at low 
stimulation frequencies.
The first evidence of frequency-dependent release were the 30 second integrals of ATP 
signals following nerve-stimulation over the frequency range 1- 24  Hz. There were large 
increases in the integral with frequency from 1 to 12 Hz but any further increases in 
frequencies resulted in no additional increases in the integral. When the frequency 
required to produce half the maximal response (fi/2 ) of tension and ATP integral were 
compared the ATP signal f\n was significantly less.
The ATP integrals followed a similar pattern in the presence of atropine with a f\a 
comparable to those in control conditions. This shows that the reduced contraction did 
not significantly affect the ATP signal and that a major proportion of the signal is due to 
constant levels of ATP released following stimulation of the nerves. Atropine did cause a 
shift in the i\a of tension with atropine having a significantly greater effect at higher 
stimulation frequencies, indicting a greater importance of acetylcholine at these 
frequencies. In the presence of atropine when contraction is mediated by ATP only the 
tension and ATP integral followed a similar pattern of frequency dependence. They both 
reached a maximal response at equivalent frequency and there was no significant
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difference in their im  value showing a direct relationship between release of ATP and 
contraction.
These combined results indicate that there is differential release of neurotransmitters 
during stimulation at various frequencies of the motor nerve in the detrusor smooth 
muscle. It is proposed that there is a preferential release of ATP at lower frequencies and 
acetylcholine at higher frequencies and this can be corroborated by previous studies with 
bladder tissue. In contrast to the atropine results in this study ABMA, the non- 
hydrolysable ATP analogue, caused a greater reduction of force at lower stimulation 
frequencies (Ikeda, 2006), again implying that a greater proportion of contraction is 
mediated by ATP at low frequencies. Similar findings using Ach and ABMA were made 
by Brading and Williams (1990). Also adenosine, NECA (a general Al/A2-agonist) and 
CPA (an A 1-specific agonist) reduced the force of nerve-mediated contractions 
particularly at lower frequencies (Ikeda et al, 2006). As their effects may be due to 
altering transmitter release via A 1-receptors, which preferentially reduces ATP release, 
this is consistent with preferential release of ATP at low frequencies of stimulation. 
Differential frequency-dependent release of neurotransmitters has also been described for 
other tissues (Todorov et al, 1999; Silinsky and Redman, 1996), as has the release of 
ATP at lower stimulation frequencies compared to its co-transmitter, NA (Kennedy et al 
1986) and Ach (Vizi et al 1997). However this study provides direct evidence of 
preferential release of ATP at lower that has not previously been shown.
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Although control experiments using direct muscle stimulation were used to estimate the 
proportion of ATP released from nerves and muscle it would be useful try to inhibit 
muscle contraction to rule out completely addition of ATP released from the muscle 
itself to the ATP signal measured. When the release of ATP from rat innervated 
hemidiaphragm was investigated at different frequencies of stimulation nicotinic receptor 
blockers D-tubocurarine and a-bungarotoxin were used to block nerve evoked 
contractions (Santos et al, 2003). The study showed this blockade inhibited over 60% of 
ATP released.
4.10 OVERALL CONCLUSIONS
ATP release following nerve stimulation acts as a co-transmitter with Ach to initiate 
contraction in detrusor smooth muscle in guinea-pig and some overactive but not stable 
detrusor from human bladders. There are three main factors that may account for the 
emergence of atropine resistant contractions in detrusor from overactive bladders; 
increased ATP release, reduced ATP breakdown and increased smooth muscle 
sensitivity. The latter option has previously been investigated and ruled out.
Tension experiments showed examples of how modulation of the activity of the 
ectonucleotidases can impact on the force of nerve-mediated contractions. Increased
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ATP breakdown resulted in a reduction in force whilst decreasing activity augments
force.
Gene expression studies revealed relative levels of E-NTPDase 1, 2, 3 and 5 in detrusor 
smooth muscle from stable and overactive human bladder samples. All four enzymes 
were expressed in both sample groups but the relative expression level of E-NTPDase 1 
was substantially greater than the other three. These results indicate that alteration in 
ATP breakdown due to differences in enzyme expression could contribute to atropine 
resistance and hence overactivity. The cause for altered expression remains unknown.
Measuring ATP degradation rates showed that there was no difference in 
ectonucleotidase activity between detrusor from stable and overactive bladders. However 
experiments also showed that human bladder ectonucleotidase activity was similar to that 
of guinea-pig. Guinea-pig has the greatest ATP component of contraction compared to 
the human groups which have little or no atropine resistance, it is therefore hypothesised 
that more ATP is released from nerves in the guinea-pig to initiate contraction.
Experiments showed that a proportion of the signal measured with ATP sensitive 
electrodes was ATP released from stimulated nerves in the guinea-pig detrusor. ATP 
measured was dependent on frequency in the presence and absence of atropine. The 
purinergic component of contraction closely followed the integral of measured ATP, with 
maximal responses at equivalent frequencies and comparable fi/2  values. The real-time 
measurement of ATP release with microelectrode biosensors provided evidence to
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support frequency dependent release of neurotransmitters with preferential release of 
ATP at lower frequencies of stimulation.
Overall this thesis provides evidence for two of the hypothesis proposed to explain the 
emergence of atropine-resistant contractions in human bladder overactivity. Firstly 
expression levels of some ectonucleotidases were reduced which may lead to reduced 
breakdown of ATP in bladder pathology, particularly so as the highly expressed E- 
NTPDase 1 was reduced in overactive bladders. Secondly ATP degradation studies 
showed equivalent breakdown rates for ATP by ectonucleotidases in the three groups of 
tissues which had varying ATP components of contraction. It is possible therefore that 
atropine-resistance in overactive bladder is due to an increase in ATP released by nerve 
stimulation.
4.10 FURTHER RESEARCH
The role of ATP and its breakdown in detrusor contraction is important and may 
contribute to bladder overactivity. This study showed that by inhibiting ATP breakdown 
in guinea-pig contractile force can be increased. It would be interesting to investigate the 
effect of inhibiting ectonucleotidase activity in stable and overactive bladder samples and 
possibly to use new more selective inhibitors of these enzymes to establish the effects of 
the individual subtypes and if there were difference between human groups.
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Although this study determined the relative expression levels of E-NTPDase 1, 2, 3 and 5 
this does not give any indication of the level of protein actually present. Further 
molecular studies, including western blots, would provide further information on 
enzymes present and any possible differences between pathological groups. As would 
immuno-histochemical studies to investigate the localisation of the enzymes within the 
samples.
This study provided the first measurement of real-time release of ATP from guine-pig- 
detrusor smooth muscle with the use of novel ATP sensitive microelectrode biosensors. 
The protocol developed proved effective and could be applied to other tissues 
particularly human detrusor from stable and overactive bladders to establish if altered 
release of ATP from nerves contributes to atropine resistance in some overactive 
samples. The electrodes could also be useful in investigating the effect of pre-junctional 
modulators of ATP release including adenosine.
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